ALLR18  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 Amendment 3.0, dated 03 -19-2018. Resubmitted to IRB 6 -12-2018(IRB approved: 6 -13-2018)  St. Jude  
 
Initial version, dated: 11 -22-2011, Resubmitted to CT -SRC 01 -18-2012 and 02 -16-2012,  
Resubmitted to IRB 03 -28-2012 and 04 -12-2012. (IRB approved: April 19, 2012).  
Amendment 1.0, dated 06 -14-2012. Resubmitted to IRB 08 -20-2012 (IRB approved: 09 -05-2012).  
Revision 1.1, dated 09 -18-2012. IRB Approved: 10 -18-2012. Activation date: 10 -19-12 
Amendment 2.0, dated 12 -02-2014. Resubmitted to IRB 02 -12-2015. IRB approved: 02 -24-2015.  
Revision 2.1, dated 03 -10-2015. Resubmitted to I RB 04 -20-2015 (IRB approved: 04 -24-2015)  
Activated: 06 -22-2015  
 
 
 
 
 
 
A PHASE II STUDY OF THERAPY FOR PEDIATRIC RELAPSED OR REFRACTORY 
PRECURSOR B -CELL ACUTE LYMPHOBLASTIC LEUKEMIA  AND LYMPHOMA  
 
IDE 11,533 ( CliniMACSTM System ) 
 
Principal Investigator 
Sima Jeha, M.D. 
Department of Oncology  
 
Co-Investigators  
 
Patrick Campbell, M.D., Ph.D.1 Brandon Triplett, M.D.6 
Cheng Cheng, Ph.D.3 Monika Metzger, M.D.1 
John K. Choi, M.D., PhD.4 Charles G. Mullighan, MBBS (Hons), MSc, M.D.4 
Kristine R. Crews, Pharm.D., BCPS2 Jennifer L. Pauley, Pharm.D.2 
William E. Evans, Pharm.D.2 Ching -Hon Pui, M.D.1 
Aditya H. Gaur, M.D.5 Mary V. Relling, Pharm.D.2 
Charles Gawad, MD, PhD1 
Terrence Geiger, M.D.4 
Tanja A. Gruber, M.D., Ph.D.1 Raul C. Ribeiro, M.D.1 
Jeffrey E. Rubnitz, M.D., Ph.D.1 
Hiroto Inaba. M.D., Ph.D.1 John T. Sandlund, M.D.1 
 Jun J. Yang, Ph.D.2 
 
 
St. Jude Children's Research Hospital 
262 Danny Thomas Place  
Memphis, Tennessee 38105 -3678  
Telephone: (901) 595 -3300  
 
 
Departments of Oncology1, Pharmaceutical Sciences2, Biostatistics, 3 Pathology4, Infectious 
Diseases5, and Bone Marrow Transplantation & Cellular Therapy6 
 
 
Contents of this document may not be extracted without permission from the Principal Investigator.  CM1, dated 8 -3-18 (IRB Approved: 8 -7-18) Activated: 6 -25-2018  CTG# - [STUDY_ID_REMOVED]  ALLR18  
ALLR18  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 Collaborating Investigators/Institutions  
 
Deborah Schiff, MD  
Pediatric Hematology/Oncology/Blood and Marrow Transplant 
Children's Hospital San Diego/UCSD  
3020 Children's Way 
San Diego, CA 92123 
Phone:  
Fax: 
 
 
Kenneth M. Heym, MD  
Cook Children’s Medical Center 
Hematology and Oncology Center 
901 Seventh Ave., Ste. 220  
Ft. Worth, TX 78104 
Phone:  
 
 
External Collaborating Scientists/Institutions  
 
Dario Campana, MD, PhD 
Elaine Coustan -Smith, MSc 
National University of Singapore 
21 Lower Kent Ridge Road 
Singapore  119077  
St. Jude  
IRB NUMBER:  Pro12817  
IRB APPROVAL DATE: 03/18/2019   
  
 
 
August 3, 2018 
To: IRB 
From: Sima Jeha, MD  
 
RE: ALLR18, A Phase II Study of Therapy for Pediatric Relapsed or  Refractory 
Precursor B -Cell Acute Lymphoblastic Leukemia and  Lymphoma.  
 
Clarification Memo  
 
Due to the unavailability of the drug Teniposide (VM -26), etoposide (VP -16) will be substituted 
for the remaining doses for patients currently on this study. The protocol Section 5.1.3 allows 
this substitution . Participants will be informed of the substitu tion verbally, and this will be 
documented in the medical record. The substitution of VP -16 will continue until 46 participants 
are enrolled to ensure that 40 evaluable patients are enrolled.  
 
1. During Interim Continuation (Section 5.3), Week 3 teniposide wi ll be substituted with 
Etoposide 300 mg/m2 on Day  1 
 
Week  Agent  Dosage and 
route  # Doses  Schedule  
1 VP16  
(etoposide)  300 mg/m2 IV 1 Day 1  
CYCLO  
(cyclophosphamide)  300 mg/m2 IV 1 Day 1  
2 MTX  
(methotrexate)  40 mg/m2 IV 1 Day 1  
6MP  
(mercaptopurine)  75 mg/m2 PO 7 Days 1 -7 
3 VP16  
(etoposide)  300 mg/m2 IV 1 Day 1  
ARA -C 
(cytarabine)  300 mg/m2 IV 1 Day 1  
4 DEX  
(dexamethasone)  12 mg/m2 PO 15 Days 1 -5 TID  
VINBLAST  
(vinblastine)  6 mg/m2 IV 1 Day 1  

St. Jude  
IRB NUMBER:  Pro22817  
IRB APPROVAL DATE: 03/18/2019   
 2. During Continuation Treatment (Sections 5.5.1 and 5.5.2), Weeks 3 and 7 teniposide will 
be substituted with etoposide 300 mg/m2 on Day  1. 
 
 
Week  Agents  
1 MTX + 6MP  
2 MTX + 6MP  
3 VP16 + ARA -C 
4 DEX + VCR  
5 MTX + 6MP  
6 MTX + 6MP  
7 VP16 + ARA -C 
8 DEX + VINBLAST  
 
5.5.2  Drug dosages, schedules and routes – Continuation  treatment  
 
MTX (methotrexate) 
6MP  (mercaptopurine) 
VP16  (etoposide)  
VCR  (vincristine)  40 mg/m2 
75 mg/m2 
300 mg/m2 
2 mg/m2 1 dose, IV* day 1 (weeks 1, 2, 5 & 6)  
days 1 -7, PO (weeks 1, 2, 5 & 6)  
1 dose, IV day 1 (weeks 3 & 7)  
(max 2 mg), 1 dose, IV push day 1 (week 4)  
ARA -C (cytarabine)  300 mg/m2 1 dose, IV day 1 (weeks 3 & 7)  
DEX (dexamethasone)  12 mg/m2 15 doses, PO day 1 -5 TID (weeks 4 & 8)  
VINBLAST (vinblastine)  6 mg/m2 1 dose, IV day 1 (week 8)  
ALLR18  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
  
 
Protocol and Title: ALLR18, A PHASE II STUDY OF THERAPY FOR PEDIATRIC 
RELAPSED OR REFRACTORY PRECURSOR B -CELL ACUTE LYMPHOBLASTIC 
LEUKEMIA AND LYMPHOMA  
Principal Investigator: Sima Jeha, M.D.  
IDE holder: St. Jude Children’s Research Hospital, IDE 11,533 (CliniMACS system)  
Brief overview: This phase II trial is studying risk -directed therapy (standard and high risk 
participants will receive different therapy) for precursor B -cell acute lymphoblastic leukemia or 
lymphoma in first relapse.  
Interventions:  
Biologicals : rituximab, Interleukin -2 
Drugs : vincristine, dexamethasone, clofarabine, cyclophosphamide, etoposide, PEG - 
asparaginase, Erwinia asparaginase, methotrexate, mercaptopurine, leucovorin, cytarabine, 
mitoxantrone, teniposide, vinblastine, imatinib, dasatinib, nilotinib  
Device : Clini MACS™ System  
Procedure : Intrathecal chemotherapy (ITMHA), NK cell infusions, allogeneic hematopoietic 
stem cell transplant (HSCT)  
Other : CNS irradiation, testicular irradiation  
Brief outline of treatment plan: The general treatment plan will consist of chemotherapy for 
standard -risk participants and chemotherapy followed by HSCT for high risk participants in  first 
relapse of B -precursor ALL or lymphoblastic lymphoma. Remission induction for all 
participants cons ists of three blocks of therapy, wherein the first block is a novel 
immunotherapy regimen that includes cytotoxic chemotherapy, rituximab and infusion of 
haploidentical NK cells. Standard -risk patients will continue to receive chemotherapy for a total 
duration of approximately 2 years. High -risk patients will be candidates for HSCT and will 
proceed to transplant once a suitable donor is found and the patient achieves negative  MRD.  
Study design: Phase II multi -center, non -randomized trial. Primary outcome m easure is 3 - 
year survival rate.  
Sample size: 40 evaluable participants over 6 years.  
Data management: Data management and statistical analysis will be provided locally by  the 
Hematological Malignancies Program clinical research staff, Leukemia/Lymphoma Division 
and Biostatistics Department at St. Jude Children’s Research  Hospital.  
Human subjects: The primary risk to participants in this research study is toxicity from the 
multi -modality therapies. For patients with relapsed ALL, there is no salvage regimen that offers 
a good cure rate. The current standard of care is intensive chemotherapy using di fferent 
regimens, and allogeneic transplant for those who have a suitable donor. The primary objective 
of this study is to increase the 3 -year survival rate. Rituximab and NK cell therapy has been 
shown to be safe and effective in similar pediatric maligna ncies, but both are investigational 
therapies for ALL in first relapse. As such, an additional risk to patients participating in this trial 
may be that rituximab and NK cell therapy increase incidence of side effects. Potential benefits 
for patients who pa rticipate in this study include a possible increase in progression free survival. 
Since the standard of care is intensive chemotherapy and allogeneic transplant, participants will 
be receiving the standard of care.  
ALLR18  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 Table of Contents  
1.0 OBJECTIVES  ................................ ................................ ................................ .........  1 
1.1 Primary  Objective  ................................ ................................ ...............................  1 
1.2 Secondary  Objectives  ................................ ................................ ..........................  1 
1.3 Exploratory  Secondary  Objectives  ................................ ................................ ...... 1 
2.0 BACKGROUND  AND  RATIONALE  ................................ ................................ ... 2 
2.1 Remission  Induction  ................................ ................................ ...........................  2 
2.2 Re-Induction  ................................ ................................ ................................ ....... 8 
2.3 Continuation and  Interim  Continuation  ................................ ..............................  8 
2.4 MRD to Determine Indication and Timing  of HSCT  ................................ .........  8 
2.5 Background and Rationale for Biologic and  Ancillary  Studies  ..........................  9 
3.0 ELIGIBILITY CRITERIA AND  STUDY  ENROLLMENT  ...............................  13 
3.1 Inclusion Cr iteria  for Participant ................................ ................................ ....... 13 
3.2 Exclusion Criteria  for Participant  ................................ ................................ ..... 15 
3.3 Screening criteria for NK  cell donors  ................................ ...............................  15 
3.4 Inclusion criteria for Selected NK  cell donor  ................................ ...................  16 
3.5 Research Participant Recruitment  and Screening  ................................ .............  16 
3.6 Enrollment on Study at  St. Jude  ................................ ................................ ........  16 
3.7 Enrollment on Study at  Collaborating  Sites  ................................ ......................  16 
4.0 RISK  ASSIGNMENT  ................................ ................................ ...........................  17 
4.1 Standard  Risk ................................ ................................ ................................ .... 17 
4.2 High  Risk ................................ ................................ ................................ ..........  17 
5.0 TREATMENT  PLAN  ................................ ................................ ...........................  17 
5.1 General  Overview  ................................ ................................ .............................  17 
5.2 Remission  Induction  ................................ ................................ .........................  19 
5.3 Interim Continuation  (4 weeks)  ................................ ................................ ........  29 
5.4 Re-Induction  Therapy  ................................ ................................ .......................  30 
5.5 Continuation  Treatment  ................................ ................................ ....................  31 
5.6 Plan for HSCT ................................ ................................ ................................ ... 33 
5.7 Prophylaxis and Treatment for  CNS Disease  ................................ ...................  34 
5.8 Participation of St. Jude Collaborating Sites in the  Treatment Plan  .................  34 
5.9 Participation of St. Jude Affiliates the  Treatment  Plan ................................ ..... 34 
5.10 Summary of Intrathecal Therapy  on ALLR18  ................................ ..................  35 
6.0 TREATMENT  MODIFICATIONS  ................................ ................................ ...... 36 
6.1 Philadelphia Chromosome -Positive  (Ph+) ALL  ................................ ...............  36 
6.2 PEG -Asparaginase  Allergies/Hypersensitivity  ................................ .................  37 
6.3 Irradiation for Participants wit h CNS Disease  ................................ ..................  37 
6.4 Treatment for  Testicular Involvement  ................................ ..............................  38 
6.5 Obesity  ................................ ................................ ................................ ..............  38 
6.6 Infants  ................................ ................................ ................................ ...............  38 
6.7 Down  Syndrome  Participants  ................................ ................................ ...........  38 
6.8 Participants with  Renal Dysfunction  ................................ ................................  39 
6.9 Participants with  Hepatic  Dysfunction  ................................ .............................  39 
6.10 Cardiotoxicity  ................................ ................................ ................................ ... 40 
6.11 Vinca  Alkaloid Neurotoxicity  ................................ ................................ ...........  40 
6.12 Pancreatitis  ................................ ................................ ................................ ........  40 
6.13 TPMT Status and  Thiopurine  Dosage  ................................ ...............................  41 
ALLR18  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 7.0 SUPPORTIVE  CARE  GUIDELINES  ................................ ................................ .. 41 
7.1 Management of Tumor  Lysis  Syndrome  ................................ ..........................  41 
7.2 Management  of Hyperleukocytosis  ................................ ................................ .. 42 
7.3 Prophylaxis for Pneumocystis Jiroveci  Pneumonia  (REQUIRED)  .................  42 
7.4 Prophylaxis for Fungal  Infections  (REQUIRED  ................................ ..............  42 
7.5 Prophylaxis for Bacterial  Infections  (REQUIRED)  ................................ ..........  43 
7.6 Management of  Febrile  Neutropenia  ................................ ................................  44 
7.7 Growth  Factors  ................................ ................................ ................................ .. 44 
7.8 Management of Capillary Leak  Syndrome Related  to Clofarabine  ..................  44 
7.9 Etoposide  Reactions  ................................ ................................ ..........................  45 
7.10 Drug  Interactions  ................................ ................................ ..............................  46 
7.11 Cytokine Release Syndrome Related to Administration of IL -2 and NK cells 46  
8.0 DRUG/DEVICE/BIOLOGIC  AGENT  INFORMATION  ................................ .... 47 
9.0 REQUIRED EVALUATIONS, TESTS,  AND  OBSERVATIONS  .....................  48 
9.1 Response  Evaluations  ................................ ................................ .......................  50 
9.2 Suggested Long -Term  Follow -up Evaluations  ................................ .................  50 
10.0 EVALUATION  CRITERIA  ................................ ................................ .................  51 
10.1 Response Criteria  for Leukemia  ................................ ................................ ....... 51 
10.2 Response Criteria for  Lymphoblas tic Lymphoma  ................................ ............  51 
10.3 Toxicity  Evaluation Criteria  ................................ ................................ ..............  52 
10.4 Acceptable Percentage of Missed Doses for Commercially Available Drugs .  52 
11.0 OFF THERAPY AND OFF  STUDY  CRITERIA  ................................ ................  52 
11.1 Off-Study  Criteria  ................................ ................................ .............................  52 
11.2 Off-Treatment  Criteria  ................................ ................................ ......................  53 
12.0 SAFETY AND ADVERSE EVENT  REPORTING  REQUIREMENTS  .............  53 
12.1 Reporting Adverse Experiences (AEs) and Deaths  on Treatment  ....................  53 
12.2 Recording AEs  and SAEs  ................................ ................................ .................  56 
12.3 Reporting Requirements to  the FDA  ................................ ................................  56 
12.4 Reporting to St. Jude Regulatory Affairs  Office  (RAO)  ................................ .. 57 
12.5 Reporting AEs to and from St. Jude and  Collaborating  Sites/Affiliates  ...........  57 
13.0 DATA COLLECTION, MONITORING  AND  CONFIDENTIALITY  ...............  58 
13.1 Data  Collection  ................................ ................................ ................................ . 58 
13.2 Data Collection Instructions for  Collaborating  Sites  ................................ ........  58 
13.3 Study  Monitoring  ................................ ................................ ..............................  59 
13.4 Confidentiality  ................................ ................................ ................................ .. 60 
14.0 STATISTICAL  CONSIDERATIONS  ................................ ................................ .. 60 
14.1 Accrual  ................................ ................................ ................................ ..............  60 
14.2 Monitoring of Induction Toxicities and  Short -Term  Efficacy  ..........................  60 
14.3 Primary  Objective  ................................ ................................ .............................  61 
14.4 Seconda ry Objectives  ................................ ................................ ........................  63 
14.5 Exploratory  Objectives  ................................ ................................ .....................  64 
15.0 OBTAINING  INFORMED  CONSENT  ................................ ...............................  65 
15.1 Consent/Assent  at Enrollment  ................................ ................................ ...........  65 
15.2 Consent at Age  of Majority  ................................ ................................ ...............  66 
15.3 Consent When English is Not the  Primary  Language  ................................ ....... 66 
16.0 REFERENCES  ................................ ................................ ................................ ..... 67 
ALLR18  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 APPENDICES:  
 
Appendix I: Tests performed for good clinical care and for research 
Appendix II: Pediatric rituximab infusion guidelines  
Appendix III: Drug/device/biologic agent information 
Appendix IV: ALLR18 schema  
Appendix V: Treatment and evaluation calendars 
Appendix  VI: Definitions related to infectious diseases  
Appendix VII:  Common substrates, inhibitors and inducers of CYP3A4/3A5 
Appendix VIII: HDMTX administration and monitoring guidelines, Induction Block  II 
ALLR18  
Page 1 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
1.0 OBJECTIVES  
 
The overall objective of this protocol is to improve the cure rate of relap sed 
precursor B -cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.  
 
1.1 Primary  Objective  
 
To estimate the 3 -year survival rate of participants with first relapse or primary 
refractory precursor B -cell ALL and lymphoblastic lymphoma treated wi th risk - 
directed therapy.  
 
1.2 Secondary  Objectives  
 
1.2.1 To determine minimal residual disease (MRD) levels at the end of 
remission induction therapy for participants with relapsed precursor B -cell 
ALL and compare the results with those in  ALLR17.  
 
1.2.2 To estimate levels of CD20 expression at baseline, during treatment with 
dexamethasone -containing chemotherapy and following rituximab treatment 
in Block 1 of remission induction therapy for relapsed precursor B -cell ALL.  
 
1.3 Exploratory Secondary  Objectives  
 
1.3.1 To assess donor natural killer (NK) cell immunoglobulin -like receptor 
(KIR) repertoire and explore the efficacy of NK cell infusions followed  by 
rituximab in relapsed  ALL.  
 
1.3.2 To study whether pre -existing or emerging development of serum 
antibodies to aspar aginase is related to hypersensitivity reactions or 
exposure to asparaginase or to anti -leukemic or adverse effects of therapy, 
in participants with relapsed  ALL.  
 
1.3.3 To describe the effect of prophylactic antibiotics  on: 
 
a. The evolution of antibiotic resistan ce in peri -rectal swab isolates of 
Escherichia coli , Klebsiella pneumonia , Pseudomonas aeruginosa , 
Streptococcus mitis and enterococci.  
b. Resistance patterns of bacterial isolates from all sterile site  cultures.  
 
Completed with amendment 3.0  
 
1.3.4 To characterize global gene expression and copy number changes  in 
leukemic cells at relapse and to compare to initial diagnosis (when 
available) to improve knowledge of mechanisms of  relapse.  
ALLR18  
Page 2 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
1.3.5 To determine in vitro sensitivity of pretreatment relapsed leukemic cells to 
anti-leukemic agents and compare to in vitro sensitivity at diagnosis  (when 
available).  
 
1.3.6 To engraft freshly harvested relapsed ALL cells into murine models  of 
ALL to gain insights into therapy  resistance.  
 
1.3.7 To study the development of resistant clones during therapy for relapsed  ALL.  
 
2.0 BACKGROUND AND  RATIONALE  
 
Cure rates for newly diagnosed ALL  have improved dramatically over the past 50 
years. In the recent St Jude Total XV study, the estimated 5 -year event -free survival 
(EFS) and overall survival (OS) rates for all 498 patients were 85.6% and 93.5% 
respectively.1 On the other hand, for children who relapse outcome is generally poor 
despite intensified therapy.2 In particular, outcome for those who relapse while still 
on therapy is dismal across multiple co -operative group and single institution studies 
(5-year OS between 11% and 29%).3,4 Preliminary analyses of the St Jude ALLR16 
study, which utilized an upfront topotecan window treatment followed by intensive 
multi -agent c hemotherapy, demonstrated a 5 -year OS of 40% while in the subsequent 
ALLR17 study with an etoposide and teniposide based regimen 3 -year OS estimate is 
49% for all patients. Hence, there is a need for novel therapeutic approaches. The 
outcome for patients w ith primary induction failure is also poor .5 The 10 -year 
survival rate is estimated at 32%. Thus, these patients will be eligible for  ALLR18.  
An exception is children < 6 years of age with induction failure and favorable 
cytogenetics (hyperdiploidy or ETV6 -RUNX1). This group of patients has a higher 
survival rate of approximately 72% with chemotherapy alone and will be excluded 
from ALLR18.  
 
2.1 Rem ission Induction  
 
MRD is an excellent surrogate marker for relapse free survival .4 Interim analyses of 
ALLR17 revealed that 71% of participants continue to be MRD positive at the end 
of remission induction therapy and the out come of these participants is poor.  
Similar results have been reported by the Children’s Oncology Group.5 Thus, in 
ALLR18, we will attempt to decrease this rate of MRD positivity by utilizing a 
novel immunotherapy regimen of rituximab, cytotoxic chemotherapy and  
haploidentical NK cells. The hypotheses for the induction regimen in ALLR18 are:  
 
1) Immunotherapy with the anti -CD20 monoclonal antibody rituximab can 
be given safely in children with relapsed precursor B -cell ALL in 
combination with cytotoxic  chemotherapy.  
2) Pre-treatment with dexamethasone will cause up -regulation of CD20 
expression in relapsed ALL blasts leading to increased rituximab mediated 
cell kill. 
ALLR18  
Page 3 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
3) NK cell infusions from a haploidentical donor in addition to direct anti- 
leukemia effects  will enhance efficacy of  rituximab.  
4) Cytotoxic chemotherapy will be synergistic with rituximab and will also 
augment NK cell function by induction of  neutropenia.  
5) This strategy will lower MRD levels, improve complete remission (CR) 
rates and ultimately event free  survival.  
 
2.1.1 Rationale for ritu ximab  
 
The CD20 antigen is a B -cell specific marker which is expressed on the surface of 
B-lymphocytes from the pre B -cell stage through the memory cell stage.  
Rituximab, a chimeric anti -CD20 monoclonal antibody is approved by the FDA 
for the treatment of patients with non -Hodgkin lymphoma and chronic 
lymphocytic leukemia. In the pediatric setting, rituximab is shown to be safe and 
efficacious in immune mediated disorders and non -Hodgkin ly mphoma.6-8 Though 
all its mechanisms of action are not completely understood, rituximab’s anti -tumor 
effects are attributed to direct inhibition of signaling pathways, complement 
mediated cytotoxicity and antibody -dependent cellular cytotoxicity (ADCC) .9 
Studies  have also demonstrated synergy with cytotoxic chemotherapy.9 Rituximab 
has been extensively used for the treatment of lymphomas but its use in ALL is 
limited. Nevertheless, a recent study in adult patients with ALL incorpora ted 
rituximab in a backbone of multi -agent chemotherapy (HyperCVAD) and 
demonstrated a survival benefit in patients less than 60 years (3 -year overall 
survival rates of 75% versus 47% with standard HyperCVAD alone).10 The 
potential therapeutic role of rituximab in childhood ALL is not defined but interest 
in this agent was ignited by a study showing that pretreatment of leukemic blasts 
with steroids either in vitro or in vivo caused up -regulation of CD20 and increased 
their su sceptibility to rituximab in vitro .11 At diagnosis, 52% of patients expressed 
CD20 on their peripheral blood blasts while on Day 8 of therapy, CD20 expression 
was noted in 75% of patients. These finding, which we have confir med in 
preliminary results at St Jude, suggest that rituximab therapy could be  incorporated 
in the treatment of ALL and can potentially augment leukemic cell  kill. 
 
2.1.2 Rationale for the choice of chemotherapeutic agents in the first induction  block  
 
Cytotoxic chemotherapy will include clofarabine, a highly active nucleoside 
analog approved by the FDA for children with relapsed/refractory ALL.12,13 
Clofarabine was rationally designed as a hybrid molecule to improve the activity 
and overcome the toxicities associated with fludarabine and cladribine. The 
cytotoxic effects of clofarabine are due to its inhibition of DNA synthesis and 
repair, induction of apoptosis and possibly other mechanisms .14 In the pediatric 
phase 1 study, the maximum tolerated dose (MTD) was determined to be 52 
mg/m2/day for 5 days. Of the 17 ALL patients enrolled, 4 achieved CR and one 
PR, resulting in an overall response rate of 29%.12 Dose limiting toxicities were 
reversible elevations in transaminases and skin rash. In the pediatric phase II 
study, 61 patients with ALL were enrolled and the overall response rate was  
ALLR18  
Page 4 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
30%.15 In vitro studies have demonstrated synergy between clofarabine and the 
alkylator cyclophosphamide .16 Cells treated with clofarabine impede repair of 
cyclophosphamide induced DNA damage. In the multicenter pedia tric phase I 
CLO -218 study, clofarabine was given in combination with cyclophosphamide 
and etoposide.17 Dose escalation was performed for all three drugs. An MTD was 
not reached, but the recommended phase II doses for the th ree agents were 40, 
440 and 100 mg/m2/day respectively for 5 consecutive days. The overall response 
rate for the 20 ALL patients enrolled was 55% (9 CR and 2 CRp). Treatment 
related toxicities were mainly infectious with documented infections in 72% of 
patients. Elevation in transaminases was commonly noted. This combination of 
agents has been subsequently used for patients with relapsed and refractory ALL 
by multiple centers. Three reports are available: a study of 25 patients from 
Italy18, a retrospective review of 18 patients from the UK19 and the St Jude 
experience of 11 patients with relapsed or refractory ALL.20 All three reports 
concluded that the regimen w as efficacious with an acceptable safety profile even 
in patients who had received a prior transplant and in infants. Supportive care, 
especially prophylaxis against infectious diseases was imperative. The St Jude 
frontline ALL study Total XVI incorporates  this regimen for high -risk patients 
and for infants. NKHEM is another ongoing St Jude study that utilizes the same 
combination followed by infusion of haploidentical natural killer cells. In 
ALLR18, we will add non - myelosuppressive agents such as vincris tine, 
dexamethasone and PEG -asparaginase in induction block I while awaiting count 
recovery. Prophylaxis against infectious agents (bacterial and fungal) will be 
required. Due to anticipated risk of increased hepatotoxicity, myelosuppression 
and infections  in patients with prior hematopoietic stem cell transplant, these 
patients will be evaluated in a separate stratum for toxicity.  
 
2.1.3 Rationale for the addition of NK  cells 
 
NK cells are normal lymphocytes that can kill target cells without the need for 
prior sensitization or activation. The ability of NK cells to perceive alterations in 
target cells is mediated by a balance of signals through many surface receptors 
including KIRs and activating receptors such as CD16a. CD16a is a low -affinity 
transmembrane Fragment c gamma receptor IIIA (FcγRIIIA) found predominantly 
in NK cells and is essential for ADCC .21 The FcγRIIIA binds clustered IgG 
molec ules bound to antigens on the cell surface of target cells and does not bind 
circulating monomeric IgG. Therefore, ADCC is highly specific and occurs only 
when the target cells are coated with antibody. The CD16b (FcγRIIIB) GPI -linked 
form on neutrophils b inds to IgG but is inefficient in inducing any signal or 
functional effect.21 Because one of the primary mechanisms of action of rituximab 
is primarily through ADCC, strategies to optimize NK cell mediated ADCC will 
be crucial to improve the outcomes of patients treated with rituximab.  
 
Four strategies may be used to optimize NK cel l therapy. First is to adoptively 
transfer normal NK cells from a healthy donor to the patients. This is particularly 
important in this protocol, as the patient’s NK cell number and function are  
ALLR18  
Page 5 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
expected to be low after chemotherapy. Using t he St. Jude NKCELL protocol, we 
performed 12 consecutive purifications of NK cells from 12 normal volunteers. The 
system uses a two -step procedure.22 First, mononuclear cells obtained by 
leukapheresis are depleted of T cells  by CD3+ cell depletion using the CliniMACS. 
Second, the CD3 -depleted product is enriched for CD56+ cells using the 
CliniMACS. The final products contained a median of 1.6 x 108 mononuclear cells 
and 91% CD3 -CD56+ cells. In addition, the final products had  minimal 
contamination with T cells (at or below the lower limit of detection in 10 of the 12 
products) or B cells (median 0.2%). Thus, recipients are expected to be at low risk 
for GVHD or EBV lymphoproliferative disease. We also found that the expression  
of KIRs, adhesion molecules, intracellular cytokines, perforin, and granzyme B in 
NK cells was not significantly different before and after cell purification. Extensive 
proliferative capacity and potent antitumor activity of the NK cells were 
demonstrated  by using an immunodeficient mouse model .23 In addition, GVHD 
developed in all mice transplanted with unpurified mononuclear cells, but in none 
of the 10 mice transplanted with purified NK cells.  
 
Based on these preclinical data, four clinical protocols have been opened at St. 
Jude to transplant normal NK cells from parents into leukemia patients. The data 
from the first cohort of 10 patients from the NKAML protocol (FDA IDE 11533) 
were published recently.24 This study demonstrated that haploidentical NK cell 
infusions were safe, feasible, and efficacious. The conditioning, IL -2, and NK cell 
transplantation were all well tolerated. The median NK cell dose was 27 x 106/kg 
(range, 5 to 80 x 106/kg). The average hospital stay was only 2 days. None of the 
patients have acute or chronic graft -versus -host disease. Correlative laboratory 
studies showed that all patients had transient donor NK cell engraftment for a 
median of 10 days. NK cell cytotoxicit y against K562 cells normalized in all 
patients by Day 7 after NK cell transplantation. Importantly, there was a 
significant expansion of KIR mismatched cells in the blood, from a median of 
only 210/ml on Day 2 to a median of 5,800/ml on day 14.  
 
The secon d strategy to optimize NK cell therapy in this protocol is the use of 
chemotherapy that is efficacious in ALL to induce cytopenia and to up -regulate 
stress ligand expression before rituximab and NK cell administration. We have 
shown that T cell activity ma y dominate NK cell activity; thus, T -cell 
lymphopenia may facilitate NK cell function .25,26 Furthermore, we have recently 
shown that blood DCs may suppress NK cell through IL -6 and IL -10.27 Taken 
together, these data suggest that giving chemotherapy before NK cell 
administration may augment NK cell function and expansion by induction of 
leukopenia. Furthermore, DNA damage is known to be able to trigger ATM and 
ATR pathways to up -regulate genotoxic stress ligands such as NKG2D ligand 
expression .28 NKG2D is a potent NK cell activating receptor and signals through 
DAP10 for degranulation and IF -γ production.  
 
The third approach to augm ent NK cell cytotoxicity towards ALL is to capitalize 
on the unique ability of St. Jude in selecting an optimal KIR mismatched donor .29 
ALLR18  
Page 6 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
The laboratory of Dr. Leung has set up comprehensive KIR typing assays fo r the 
highly polymorphic KIR genes.30 In humans, KIRs are encoded by a gene family 
on chromosome 19q13 and recognize specific HLA class I alleles in HLA -A, -B 
and -C. The receptors specific for MHC class I molecules on targe t cells inhibit 
NK effector functions such as cytotoxicity and cytokine production. Clinical data 
suggest that KIR2DL2 and KIR2DL3 that recognize an epitope shared by HLA -C 
group 1 allotypes, KIR2DL1 that recognizes an epitope shared by HLA -C group 2 
allotypes, and KIR3DL1 that recognizes an epitope shared by HLA -Bw4 
allotypes are important determinants of anti -tumor effect. In hematopoietic stem 
cell transplantation (SCT), the NK cells of the donor may exert potent anti - 
leukemia effects if the cognate MHC  class I epitope is absent on the patient’s 
leukemia cells for the donor’s inhibitory KIRs.31 This potency has been 
demonstrated in both mouse models and in clinical transplantation. In a study of 
51 patients at the St. Jude  Children’s Research Hospital with direct measurement 
of the donor KIR repertoire, patients with a KIR matched donor had a 4 -fold 
higher risk of relapse than those with a KIR mismatched  donor.29 
 
The fourth strategy to optimize NK cell therapy is the use of IL2. In the four 
clinical trials at St. Jude using haploidentical NK cell transplantation, all patients 
received low dose IL -2 (1 million units/m2/dose SQ) every other day starting the 
night bef ore NK cell transplantation. The purpose of the low dose IL -2 
administration is to expand NK cells in vivo and to augment their cytotoxicity.  
Correlative laboratory studies in the first cohort of participants showed that all 
patients had expansion of donor  NK cells with a median peak at Day 14 and 
normalization of NK cell cytotoxicity against K562 cells by Day 7 after NK cell 
transplantation .24 Importantly, there was a significant expansion of KIR 
mismatched cells in the bloo d in the first 2 weeks after transplantation. The IL2 
was well tolerated - there was no associated grade II -IV toxicity, no patients 
required hospitalization, and no patients required discontinuation of IL -2. 
 
2.1.4 Induction Block  II 
 
Two doses of HDMTX 5 g/m2 will be given a week apart together with 6MP. This 
regimen was used in Total XIV and will provide good CNS coverage. The second 
dose of methotrexate will be targeted to achieve a steady -state plasma 
concentration of 65 µM as has been done in our frontline studies since Total XV. 
Our goals are to continue to avoid unacceptably low concentrations (albeit in a 
small % of courses), minimize unacceptably high concentrations and avoid GI 
toxicity. Using this approach, we had only 5.1% of courses with grade 3 -4 
mucositis (compared to as high as 44% of courses with BFM’s administration of 5 
g/m2 without targeting). In patients who have experienced renal dysfunction, 
require concurrent drugs that might affect MTX clearance, or who are otherwise 
unstable, we will empl oy intra -course targeting of HDMTX.  
 
Rationale for change in administration of mercaptopurine (revision 2.1)  
ALLR18  
Page 7 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
Prior studies assessing the pharmacological and therapeutic impact of giving oral 
mercaptopurine (MP) with food or with dairy produc ts, or giving 6MP at different 
times of day have produced variable results. All of the early studies32-34 enrolled 
small numbers of patients and revealed trends in differences in peak plasma 
concentrations of parent drug or plasma area -under -the-concentration -time curve 
(AUC), but these results were not statistically significant. Other studies35,36 reported 
statistically significant differences in time of maximum  drug concentration in 
plasma (tmax) and AUC in the fasting state of parent drug35 or changes in ALL 
disease free survival36 associated with time of day of oral 6MP administration (with 
better  results reported for nighttime drug administration in that the risk of relapse 
was 4.6 times greater with the morning administration schedule).  
 
However, these older studies did not assess these variables in the context of 
treatment protocols that utilize  erythrocyte thioguanine nucleotides (TGN) levels 
to guide therapy adjustments, nor did they include thiopurine dosing as part of 
multivariate analyses for outcome predictors. A more recent study of 532 patients 
by Schmiegelow (2014) used a Cox multivariat e model to show that the circadian 
schedule (morning vs. evening vs. mixed) of MTX/6MP was not of prognostic 
significance for the risk of relapse, and the 10 -year cumulative relapse risk was 
below 20% in all groups.37 
 
A separate recent study assessed the effects of “pill -taking” habits on treatment 
adherence, erythrocyte TGN levels & relapse risk in 441 children enrolled on the 
COG AALL03N1 study.38 This study reported no association between relapse risk 
and whether 6MP was taken with food (p=0.5), with dairy (p=0.2), whether tablets 
were swallowed whole vs. crushing/chewing (p=0.7); IV), or time of day: 
evening/night vs. morning/mid -day (p=0.9), vary ing times vs. non -varying times 
(p=0.9). The 6MP taking habits were also not associated with DI - and age -adjusted 
TGN levels. The authors concluded that the commonly practiced restrictions 
concerning administration with food or at bedtime did not significa ntly influence 
outcome in their protocol and patient cohort.  
 
Based on these larger and newer studies, that include more careful attention to 
6MP dosing than was true in the earlier studies, and on the fact that 6MP dose is 
adjusted to desired blood counts , we propose to lift the restrictions concerning 
administering MP at bedtime and on an empty stomach to allow patients to take 
6MP at a time of day which is most likely to yield full adherence to the prescribed 
daily dosing of 6MP. As for any daily drug, w e recommend that parents 
administer and/or patients take 6MP at a consistent time every day. We also 
strongly recommend that erythrocyte TGN levels continue to be monitored to 
guide 6MP therapy (detect non -adherence and/or inappropriate dosing). Likewise, 
TPMT phenotype/genotype should continue to be assessed for each patient to 
guide the selection of optimal 6MP dosages for each patient. Finally, ALL 
continuation therapy should continue to be guided by measurement of WBC 
throughout therapy, with dosage adj usted made as stipulated in the primary ALL 
treatment protocol.32-40 
ALLR18  
Page 8 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
 
2.1.5 Induction Block  III 
 
High dose cytarabine and mitoxantrone will be used. This combination is well 
tolerated in multiple AML regimens.41,42 In the recent UK ALLR3 study for ALL 
in first relapse, mitoxantrone was shown to be beneficial .43 The estimated 3 -year 
overall survival was 69% in patients who received mitoxantrone in induction 
versus 45.2% in patients randomized to receive idarubicin. In addition, patients 
are not exposed to mitoxantrone in frontline studies for ALL and it is anticipated 
that the use of this agent will circumvent drug resistanc e. High dose cytarabine 
will provide good CNS coverage.  
 
2.2 Re-Induction  
 
A five day course of clofarabine, cyclophosphamide and etoposide along with 
non-myelosuppressive agents dexamethasone, vincristine and PEG -asparaginase, 
similar to Block I induction (wi thout rituximab and NK cells) will be used to 
consolidate remission.  
 
2.3 Continuation and Interim  Continuation  
 
These phases are similar to ALLR17 with the use of rapidly rotating drug pairs 
(modeled after Total XI and ALLR11). This continuation regimen is well 
tolerated in an outpatient setting. Four weeks of this regimen will be used as 
interim continuation betwee n the induction Block III and re -induction phases to 
allow time for recovery from intensive chemotherapy. During continuation 
cyclophosphamide and etoposide will be omitted as patients would have received 
these agents during the induction and re -induction blocks. We will use vinblastine 
in interim continuation and alternating with vincristine in weeks 4 and 8 of each 
cycle of continuation. There are in vitro data showing sensitivity of ALL to 
vinblastine .44 Considering the he matological toxicity of vinblastine, the dose will 
be adjusted according to the patient’s ANC.  
 
Additional interim continuation weeks of chemotherapy will also be given to the 
occasional patients who are deemed unable to tolerate intensive therapy as 
presc ribed by the study. Criteria include but are not limited to systemic fungal 
infection, severe thrombosis or grade 3 or 4 hepatic or renal dysfunction.  
 
2.4 MRD to Determine Indication and Timing of  HSCT  
 
Bone marrow MRD will be done at the end of each block of  induction therapy. 
Provisional standard -risk patients (i.e. late relapse) with positive MRD (≥0.01%) 
at the completion of Block II will be re -assigned to the high -risk group. Multiple 
studies in first relapse have demonstrated the prognostic implication o f positive 
MRD (≥ 0.01%) at the end of 4 -6 weeks of therapy.45 In the COG AALL01P2 
study, the 12 month EFS was 80% versus 48% in patients with positive versus  
ALLR18  
Page 9 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
negative MRD at the end of the first block of remission induction therapy.5 In the 
UKALLR3 study, patients with MR D ≥ 0.01% at week 5 were candidates for 
stem cell transplant.43 
 
MRD status immediately prior to HSCT is predictive of outcome in precursor B - 
cell ALL. In a report from the BFM group, the cumulative incidence of 
subsequent relapse was 57% in patients with ≥10-4 leukemic cells versus 13% in 
patients with ≤10-4 leukemic cells prior to HSCT .46 Thus, patients with positive 
MRD (≥0.01%) at the end of induction Block II will receive Block III (+/ - interim 
continuation) prior to HSCT. If MRD is still detectable or they are not candidates 
for HSCT, they may continue to re -induction therapy or be offered alternate 
studies. They will receive HSCT as soon as MRD is negative and a suitable donor 
is availab le. 
 
2.5 Background and Rationale for Biologic and Ancillary  Studies  
 
2.5.1 Minimal residual disease  (MRD)  
 
MRD is an excellent surrogate marker for response and survival in childhood 
ALL at initial diagnosis.4 At first relapse, studies at St Jude and other institutions 
have also demonstrated the prognostic implication of positive MRD (≥ 0.01%) at 
the end of 4 -6 weeks of therapy. In St Jude ALLR11 and ALLR15 studies, the 
cumulative incidence of second relapse was 70.2% for MRD positive patients (≥ 
0.01%) versus 28% for MRD negative patients (p=0.008) .45 In the COG 
AALL01P2 study, the 12 month EFS was 80% versus 48% in patients with 
positive versus negative MRD at the end of the first block of remission induction 
therapy.5 The proportion of patients who are MRD positive at  the end of re - 
induction therapy is relatively high: 68% in AALL01P2 and 71% in ALLR17.  
Thus, in ALLR18, we will attempt to decrease the rate of MRD positivity by 
utilizing a novel induction regimen. It remains unclear whether patients with 
insufficient r eduction of MRD can be salvaged by more intensive treatment.  
 
2.5.2 CD20  expression  
 
The CD20 antigen is expressed on the surface of peripheral blood B -lymphoblasts 
in approximately 50% of patients with precursor B -cell ALL.11 The 
administration of steroids increased this proportion to 75% by day 8 of  therapy.  
Up-regulation of CD20 expression sensitizes cells to the cytotoxic effects of 
rituximab .11 Post rituximab, the number of CD20 -positive cells is expected to 
diminish rapidly. Thus, we will measure CD20 expression by flow cytometry 
frequently during the first three weeks of induction Block I to study the kinetics of 
CD20 expression in relation to the various components of therapy.  
 
2.5.3 Donor NK cell KIR repertoire and NK cell infusions followed by  rituximab  
ALLR18  
Page 10 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
In humans, NK cells are regulated by KIRs that are encoded by a gene family on 
chromosome 19q13 and recognize specific HLA class I a lleles.47 KIRs includes 
receptors with activating as well as inhibitory potential, receptors that have no 
known ligand, and receptors with specificity for MHC class I such as HLA -A, -B 
and -C. The receptors specific for MHC class I molecules on target cells inhibit 
NK effector functions such as cytotoxicity and cytokine production. Each NK cell 
generally expresses at least one inhibitory receptor that recognizes a self HLA 
molecule, thus preventing autoimmunity. Fourteen memb ers of the KIR family 
have been identified on human NK cells thus far .48 The NK cells of the donor may 
exert potent anti -leukemia effects if the cognate MHC class I epitope is absent on 
the patient’s leukemia cells for the d onor’s inhibitory KIRs. In a landmark article 
evaluating NK cell alloreactivity in 57 adult patients with AML, none of the 34 
patients who received a KIR -ligand mismatched haploidentical HSCT had a 
disease relapse.49 In an analysis of 130 patients with hematologic malignancies 
undergoing unrelated donor SCT, those with KIR -ligand incompatibility (including 
patients with ALL, CML, and MDS) had higher probabilities of overall survival 
and disease free survival and lower rates o f transplant -related mortality and 
relapse.50 In an exclusively pediatric study, with 51 research participants at  St. 
Jude, the effect of KIR mismatch on myeloid leukemia was confirmed and a KIR 
mismatch effect was also noted in pediatric lymphoid leukemias .31 In this study, 
with direct measurement of the donor KIR repertoire, participants with a KIR 
matched donor had a 4 -fold higher risk of relapse than those with a KIR 
mismatched donor. In contrast to KIR mismatch, KIR -ligand mismatch was not a 
significant factor for the prediction of relapse. The absence of beneficial effects of 
KIR-ligan d mismatch has also been observed in additional studies .51 Taken 
together, these data underscore the importance of direct assessment of donor KIR 
repertoire rather than donor KIR -ligands. Peripheral blood will be obtained fr om 
the donor and the patient prior to Induction Block 1 and on Day 19 for 
immunophenotyping and genotyping for NK cell receptors as described 
previously.31 We will assess NK cell receptors including KIRs, NCRs, NKG2D, 
DNAM -1, 2B4, and NTBA.  
 
2.5.4 Asparaginase  antibodies  
 
Because patients have been treated previously with asparaginase, we expect there 
will be variability in both pre -existing asparaginase antibodies and in the 
development of antibodies on ALLR18. We will incorporate  single serum 
samples to measure antibodies to asparaginase as well as to measure asparaginase 
activity in serum (which may be affected by changes in immune response).  
Antibodies against native E. coli (Elspar), PEGylated E. coli (Oncaspar), and 
Erwinia asparaginase are measured by an ELISA. Those with possible allergic 
reactions will also have measurement of anti -asparaginase antibodies and 
asparaginase at the time of the reaction and, if re -challenged, after the next dose. 
Aspara ginase will be measured using a spectrophotometric assay based on 
conversion of asparagine to aspartic acid .52 These measures will be available to 
use as covariates in analyses of objectives 1.1.1 and 1.2.1.  
ALLR18  
Page 11 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
 
2.5.5 Surveillance for antibiotic resistance (completed with amendment  3.0) 
 
A COG study evaluating a 3 -block platform of intensive chemotherapy for 
children with first marrow relapse noted the rate of febrile neutropenia and 
clinically or microbiologically docu mented infections to be 59.7%, 39.6% and 
79.4% per block of therapy.5 Studies of the use of prophylactic antibiotics in 
neutropenic adult oncology patients conducted over the last 30 years have 
consistently shown efficacy in reducing the incidence of fever and 
microbiologically documented bacterial infections .53 What is less well documented 
is the evolution of antibiotic resistance in colonizing and invasive bacterial isolates 
in recipients of s uch antibiotic prophylaxis. Showing that antibiotic exposure can 
increase the rate of resistance among colonizing organisms is not an absolute 
confirmation that colonization by a resistant organism can result in  infection.  
There have, however, been a numbe r of studies in patients with acute leukemia and 
those receiving HSCT that illustrate that invasive infection is often linked to 
previously noted colonization by the same organism .54-56 Resistance not only to the 
antibiotic that a patient is being exposed to for antibiotic prophylaxis but cross - 
resistance to other antibiotic classes remains a major concern and needs to be 
systematically tracked. We will determine whether ciprofloxacin or cefepime 
prophylaxis will result in t he selective emergence of colonization with Gram 
negative organisms resistant to fluoroquinolones, higher generation of 
cephalosporins or other unrelated antimicrobial agents such as  carbapenems.  
Additionally, we will define whether fluoroquinolone or cefe pime prophylaxis will 
result in the emergence of colonization or invasive infections with S. mitis that are 
resistant to fluoroquinolones, higher generation cephalosporins or  penicillin.  
Finally, we will assess the impact of antibiotic prophylaxis on colonization with 
vancomycin resistant enterococci and incidence of C. difficle infections. Peri -rectal 
swabs will be collected pre and post antibiotic prophylaxis during inductions 
Blocks I, III and re -induction.  
 
2.5.6 Global gene expression and copy number  changes  
 
Matched diagnosis and relapse leukemic samples from the same patient offer an 
excellent resource to study the mechanisms of relapse and to identify potential new 
therapeutic targets. Gl obal changes in gene expression have been studied on 
Affymetrix microarrays and have demonstrated that pathways involved in cell 
cycle and DNA repair to be predominant in early relapse .57 Survivin, an anti - 
apoptotic gene wa s up-regulated at relapse and these findings have led to the 
initiation of a phase I study of survivin antagonists in relapsed ALL. Studies of 
DNA changes (copy number variations, loss of heterozygosity) at St Jude have 
provided insights into the clonal ev olution of relapse58 and a recent re -sequencing 
effort identified novel mutations including those in the CREBBP gene at relapse.59 
Another study of matched samples from the Children’s Oncology group identified 
deletions of the MSH6 gene in a subset of patients specifically at relapse.60 The 
studies mentioned above had a limited number of patient samples  and thus it was  
ALLR18  
Page 12 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
not possible to investigate changes specific to various ALL subtypes at relapse and 
correlate to multiple clinical features and response. In addition, recent discoveries 
of genomic aberrations (e.g. rearrangements of CRLF2, activating mutations of 
JAK2 ) in high risk ALL have not been studied in detail in relapsed ALL.61-64 In 
ALLR18, we will collect bone marrow samples at the time of relapse and retrieve 
cells from initial diagnosis from the ti ssue bank (if available). Consent for TBANK 
is required for participation in these studies.  
 
 
2.5.7 Drug sensitivity  studies  
 
In newly diagnosed ALL, ex vivo drug sensitivity predicts long -term relapse risk, 
is associated with drug -specific gene expression patte rns, and is being coupled 
with preclinical studies in cell lines and murine models to identify determinants of 
drug sensitivity.65-67 Not much data is available for in vitro drug resistance in 
relapsed ALL though it is well known clinically that relapsed blasts are relatively 
chemo -resistant. In 1995, Klumper et al68 demonstrated that relapsed blasts 
(N=137) were highly resistant to glucocorticoids, L -asparaginase, anthracyclines 
and thiopurine s, but not to other agents like vincristine, and epipodophyllotoxins 
when compared to samples from initial diagnosis (N=141). In this study, matched 
samples were only available for 16 patients which showed de novo as well as 
acquired drug resistance. At St  Jude, in vitro drug resistance profiles of leukemic 
blasts at diagnosis to a panel of chemotherapeutic agents have been performed in 
Studies Total XIII -XVI and have led to the identification of genes correlating with 
sensitivity to single agents as well a s combination chemotherapy.66,67 Findings also 
point to previously unrecognized potential targets for therapeutic  intervention.  
Profiles at relapse are available in a subset of patients too. I n ALLR18, we will 
continue to study ex vivo sensitivity of primary ALL blasts to multiple anti 
leukemic agents (e.g., mercaptopurine, thioguanine, prednisolone, dexamethasone, 
vincristine, L -asparaginase, cytarabine, and daunorubicin) and/or chemo - 
sensiti vity modulators (e.g., rolipram, a PDE4B inhibitor that improves sensitivity 
to glucocorticoids).  
 
2.5.8 Xenograft models of  ALL 
 
Establishing xenografts of primary human ALL samples has proven to be a 
powerful tool to establish bio -repositories of human leukemic cells to examine the 
genetic and biologic basis of treatment failure, to examine clonal heterogeneity and 
to use as a plat form for the testing of novel therapeutic agents ex vivo and in vivo . 
At St Jude, several investigators have performed xenotransplants of B -progenitor 
ALL, including CRLF2 -rearranged ALL, infant leukemia and hypodiploid ALL, 
and have achieved up to 80% eng raftment rates with remarkable reproducibility 
between the tempo of engraftment between replicate mice transplanted with the 
same tumor. Moreover, for CRLF2 rearranged and hypodiploid ALL downstream 
genomic assays demonstrated that the genomic alterations in the relapsed tumor  
ALLR18  
Page 13 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
recapitulate those present in the primary leukemia. The use of xenograft models 
has also proven valuable in determining the genetic basis of the aggressiveness of 
disease, and the basis of relapse.62,69,70 At St Jude, these studies have been 
performed with cryopreserved viable cells stored by the St Jude Biorepository.  
Cells harvested from patients in ALLR18 will be used for e ngraftment into murine 
models and will contribute to the ongoing efforts at SJCRH to establish a panel of 
xenografts of high risk acute leukemia samples to serve as a resource for a range of 
studies of the biologic basis of relapse in acute leukemia, as we ll as establishing a 
platform for the preclinical testing of novel therapeutics.  
 
 
2.5.9 Resistant clones during therapy for relapsed  ALL 
 
Recent genomic profiling studies from our group and others identified somatic 
mutation within the NT5C2 gene directly relat ed to drug resistance in relapsed ALL 
(~15 -20% in T and B -lineage ALL at relapse).71,72 Cells with NT5C2 gain-of- 
function mutation are extremely resistant to thiopurine therapy compared to th ose 
with wildtype NT5C2 , and we expect a substantial proportion of patients in this trial 
would be NT5C2 mutant. Therefore, this protocol offers a unique opportunity to 
examine the dynamics of NT5C2 mutation during therapy (e.g., the change of % 
mutant cel ls at a function of time), especially as patients progress through various 
blocks of therapy. Therefore, it is important to determine the feasibility of 
monitoring NT5C2 mutation during ALL therapy. Our ultimate goal is to examine 
the clinical value of pro spectively identifying NT5C2 mutant patients and possibility 
of implementing NT5C2 -guided treatment individualization. Bone marrow samples 
will be collected for this objective to coincide with the timing of MRD evaluations. 
Consent for TBANK is required fo r participation in these studies.  
 
3.0 ELIGIBILITY CRITERIA AND STUDY  ENROLLMENT  
 
According to institutional and NIH policy, the study will accession research 
participants regardless of gender and ethnic background. Institutional 
experience confirms broad representation in this regard.  
 
3.1 Inclusion Criteria for  Participant  
 
3.1.1 Must have relapsed or refractory precursor B -cell acute lymphoblastic 
leukemia or acute lymphoblastic  lymphoma.  
 
3.1.1.1  Participants with leukemia must meet one of the  following:  
 
1) In first hematologic relapse *, or 
 
2) Refractory  to one or two courses of frontline in duction therapy 
(≥ 5% blasts in the bone marrow or peripheral blood confirmed 
by flow cytometric  analysis).  
ALLR18  
Page 14 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
Note : see Exclusion Criterion 3.2.1. Participants aged 1 to 5 
years with induction failure and favorable cytogenetics (i.e., 
hyperdip loid or ETV6 -RUNX1) will not be eligible for this 
protocol. Other patients younger than 6 years will be eligible . 
 
3.1.1.2  Participant with lymphoma must meet one of the  following:  
 
1) In first relapse , or 
 
2) Refractory  to one or two courses of frontline induction therapy 
with measurable  disease  
*Relapse  in ALL is defined as the reappearance (in a patient who 
has previously achieved remission) of leukemic blasts in the bone 
marrow or peripheral blood.  
 
o Should flow cytometric analyses suggest relapse (by the 
reappearance of a similar immunophenotype to the original 
leukemia) in the presence of <5% blasts morphologically, a 
repeat bone marrow test is recommended to confirm  relapse.  
 
o Molecular or genetic re lapse is characterized by the 
reappearance of a cytogenetic or molecular  abnormality.  
 
o Early relapse is defined as relapse on therapy or < 6 months 
after completion of frontline therapy. Late relapse is defined 
as relapse occurring ≥ 6 months after complet ion of  frontline 
therapy.  
 
3.1.2 Participants age is < 22 years at time of enrollment (e.g., participant  is 
eligible until 22nd birthday).  
 
3.1.3 Prior  therapy  
 
3.1.3.1  There is no waiting period for participants who relapse while 
receiving frontline therapy and are free from acute side  effects 
attributable to such  therapy.  
 
3.1.3.2  Emergent radiation therapy, one dose of intrathecal  chemotherapy, 
and up to 7 days of steroids for  treatment of relapse are permitted 
before start of treatment in participants who relapse after 
completion of frontline  therapy.  
 
3.1.3.3  At least 90 days have elapsed since bone marrow transplant and 
participant is off immune suppression for > 2 weeks, if  applica ble. 
ALLR18  
Page 15 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
Participants with ALL or NHL who were transplanted in first 
remission are eligible for this study.  
 
3.1.4 Organ function  requirements  
 
3.1.4.1  Hepatic: Total bilirubin < ULN for age, or if total bilirubin  is 
>ULN, direct bilirubin is < 1.4 mg/dL.  
3.1.4.2  Cardiac: Shortening fraction > 28%.  
 
3.1.4.3  Renal: Glomerular filtration rate >50cc/min/1.73 m2, OR serum 
creatinine based on age as  follows:  
 
 
Age (years)  Maximum serum creatinine  (mg/dL)  
 Male  Female  
1 to 2 years  0.6 0.6 
2 to 6 years  0.8 0.8 
6 to 10 years  1 1 
10 to <13 years  1.2 1.2 
13 to 16 years  1.5 1.4 
> 16 years  1.7 1.4 
 
The threshold creatinine values in this Table were derived from the Schwartz formula for 
estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and  stature 
data published by the  CDC.  
 
3.2 Exclusion Criteria for  Participant  
 
3.2.1 Leukemia participants aged 1 to 5 years with induction failure and 
favorable cytogenetics (i.e., ETV6 -RUNX1 or hyperdiploidy defined  as 
DNA Index > 1.16 or modal chromosome number > 51). 
 
3.2.2 Hepatitis B or HIV  infection.  
 
3.2.3 Pregnant or  breast -feeding.  
 
3.2.4 Inability or unwillingness or research participant or legal 
guardian/representative to give written informed  consent.  
 
3.3 Screening criteria for NK cell  donors  
 
3.3.1 Donor is at least 18 years of  age. 
 
3.3.2 Donor is a family  member.  
ALLR18  
Page 16 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
Potential donor(s) will first be screened for eligibility and suitability (e.g., HIV 
testing, pregnancy, and blood samples to Pathology & BMT&CT to select the 
optimal donor(s). This will be accomplished using the donor eligibility checklist 
and donor conse nt. The BMT&CT and Oncology teams will then select the best 
donor(s) based on established institutional practice, among the screened donor(s) 
who meet the eligibility criteria listed in Section 3.3. Only the selected donor(s) 
will proceed to the donor proc edures. This will not require a re -consent or re - 
enrollment, although donors may withdraw consent at any time before the 
apheresis procedure is completed.  
 
3.4 Inclusion criteria for Selected  NK cell  donor  
 
3.4.1 Donor is not pregnant or  breast -feeding.  
 
3.4.2 Donor is HIV  negative.  
 
3.4.3 Donor does not have any other medical condition that, in the opinion of an 
independent physician, precludes performance of an apheresis  procedure.  
 
3.5 Research Participant Recruitment and  Screening  
 
Three institutions will collaborate in the proposed project: St. Jude Children's 
Research Hospital (SJCRH); Rady Children’s Hospital in San Diego, CA and 
Cook Children’s Medical Center in Fort Worth, TX. It is anticipated that 
additional sites will be added as new collaborat ions are established.  
 
3.6 Enrollment on Study at St.  Jude  
 
A member of the study team will confirm potential participant eligibility as 
defined in Section 3.1 -3.2, complete and sign the ‘Participant Eligibility 
Checklist’. The study team will enter the eligibility checklist information into the 
St. Jude Clinical T rials Management System (CTMS). Eligibility will be  reviewed, 
and a research participant -specific consent form and assent document (where 
applicable) will be generated. The complete signed consent / assent form(s) must 
be faxed or emailed to the  CPDMO  at to complete the enrollment 
process.  
 
The CPDMO is staffed 7:30 am -5:00 pm CST, Monday through Friday. A staff 
member from the St. Jude Cerner Millennium (MILLI) helpline is on call 
Saturday, Sunday, and holidays from 8:00 am to 6:00 pm. If you have a 
prosp ective research enrollment and need assistance releasing your consent,  please 
call the  MILLI  helpline  on call number.  
 
3.7 Enrollment on Study at Collaborating  Sites  
ALLR18  
Page 17 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
All participants must receive Block I therapy at St. Jude (includes NK cell 
infusions). Therefore, all participants will be consented and enrolled at St. Jude. 
Collaborating sites will assess preliminary eligibility on -site and will refer 
potentially eligible participants to St. Jude for final eligibility determination and 
work -up fo r NK cell infusions.  
 
4.0 RISK  ASSIGNMENT  
 
Provisional risk assignment will be based on timing of relapse. Final risk 
assignment will incorporate MRD measurements after Block II of remission 
induction therapy.  
 
4.1 Standard Risk  
 
1) Late relapse (≥ 6 months after completion of frontline therapy)  AND  
2) MRD < 0.01% at the end of Block II of remission induction  therapy.  
 
Provisional standard risk participants (i.e., late relapse) will be re -assigned 
to High risk if MRD > 0.01% at the end o f Block II.  
 
Participants with lymphoma must be in complete remission at the end of 
Block III.  
 
4.2 High Risk  
 
1) Early relapse (on therapy or < 6 months after completion of  frontline 
therapy),  OR 
2) Any relapse after hematopoietic stem cell transplant,  OR 
3) MRD ≥ 0.0 1% at the end of Block II of remission induction therapy,  OR 
4) Re-emergence of MRD at any time after attaining negative MRD  on 
ALLR18  
 
Biopsy of residual mass should be attempted (if feasible) for participants 
with lymphoma who are not in complete remission at the end of Block III.  
 
5.0 TREATMENT  PLAN  
 
5.1 General  Overview  
 
Refer also to Appendix V  
 
The general treatment plan will consist of chemotherapy for standard -risk patients 
and chemotherapy followed by HSCT for high risk patients. Remission induction 
for all patients comprises of three blocks of therapy wherein the first block is a 
novel immuno therapy regimen that includes cytotoxic chemotherapy, rituximab 
and infusion of haploidentical NK cells. Standard -risk patients will continue to  
ALLR18  
Page 18 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
receive chemotherapy for a total duration of approximately 2 years. High -risk 
patients will be candidates for HSCT and will proceed to transplant once a 
suitable donor is found and the patient achieves negative MRD.  
 
As the chemotherapy is intensive and pa rticipants with ALL will require 
supportive care measures and the majority of the participants will receive HSCT, 
placement of double -lumen Hickman line before starting the treatment is strongly 
recommended.  
 
All participants with ALL receive remission ind uction. All high -risk participants 
will be offered HSCT, which will be performed after a suitable donor is identified 
and preferably after MRD becomes negative (see section 5.5). Standard -risk 
participants continue chemotherapy if MRD is negative after Blo ck II of induction. 
If the assay is unsuccessful or the specimen is inadequate, the MRD will be 
assumed negative for purposes of treatment decisions and it will be handled as 
missing data for data analysis of MRD. Repeat MRD should be obtained as soon as 
possible.  
 
Interim continuation treatment will be given to the occasional participants who are 
deemed unable to tolerate dose intensive chemotherapy. Specific criteria to use 
interim continuation therapy include disseminated fungal infection, recent 
develop ment of cerebral thrombosis, or grade 3 or 4 renal or hepatic dysfunction. 
Interim treatment will consist of the plan for “interim continuation” as per section  
5.3. Protocol specified therapy will be resumed when the participant’s physical 
condition improves.  
 
5.1.1 General assumptions regarding chemotherapy administration for all  treatment 
phases:  
 
• The timing and duration for administration for all commercially availa ble 
agents are provided in the treatment phase sections as guidelines only. 
Variations in the timing and duration of chemotherapy infusions according to 
institutional practice or variations based on patient care needs are acceptable, 
as long as the treatin g investigator and/or PI determines that there was no 
impact on patient safety. These variations will not be considered protocol 
deviations, as long as the total dose is given within 10% of protocol specified 
dose.  
• The term “day” does not refer to an absol ute calendar day. It refers to  a 
general 24 -hour period as per St. Jude Nursing  P&P.  
• Medication dosing may be modified for research recipients based upon  actual 
body weight or adjusted ideal body weight when clinically indicated. Criteria 
for medication ca lculations based on body weight/body surface area can be 
found in any version of the St. Jude Formulary. Medication doses may be 
rounded to the nearest integer or to the nearest appropriate quantity when 
clinically or pharmaceutically indicated as per the M.D. and  Pharm.D.  
ALLR18  
Page 19 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
 
5.1.2 NK cell therapy for collaborating site  participants  
 
NK cell therapy for participants from collaborating sites will be done at St. Jude. The 
patient and donor will need to travel to Memphis and stay for about 3 weeks. St. Jude 
will cover travel costs for the patient, donor and one parent, housing for up to 4 
family members, and all medical costs during this time. St. Jude will also cover the 
travel costs for the NK cell donor.  
 
5.1.3 Guidance during times of drug shortages and  unavailability:  
 
Treating investigators are urged to consult with the PI and to use their best clinical 
judgment in optimizing therapeutic intent and ensuring patient safety in managing 
the protocol -specified the rapy. Although these decisions may constitute “Protocol 
Violations,” they are unavoidable and made in consideration of the best interest of 
an individual patient. These will not be considered monitoring/audit findings if 
appropriately documented. All proto col deviations must be noted in the research 
database and the alterations in therapy due to the agent shortage will be captured. 
This should be accomplished by entering “dose modified” and details noted in the 
comments field. These deviations will also be noted in the Deviation Log with the 
notation “Drug substitution/reduction due to unavoidable drug 
shortage/unavailability”.  
 
5.2 Remission Induction  
 
Required baseline evaluations : 
 
• History and physical  exam  
• CBC with  diff 
• CMP, LDH, uric  acid 
• Coagulation  screen  
• Urine  analysis  
• Hepatitis and HIV  screen  
• EBV, CMV. HSV, varicella, histoplasma and toxoplasma  titres  
• Bone marrow aspirate for MRD, mutant cells, cytogenetics, biology  and 
molecular  studies  
• Serum for asparaginase and anti -asparaginase  antibodies  
• CSF cell count, diff and  cytology  
• Chest X -ray 
• CT scan of involved areas (lymphoma participants  only)  
• ECHO and EKG (can be performed within 1 week of initiation of  therapy)  
• QCT for bone  density  
• Peri-rectal swab for infectious disease  research  
• HLA  typing  
• KIR genotyping and NK cell  phenotyping  
ALLR18  
Page 20 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
• VNTR or variable nucleotide tandem repeat (chimerism  studies)  
• Pregnancy test of female adolescent  patient  
ALLR18  
Page 21 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
5.2.1 Block I - (approximately 5 w eeks, until count recovery). Block I therapy 
must be administered at St.  Jude.  
Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  
VCR 
DEX 
ITMHA  DEX  DEX  RITUX  
DEX  DEX 
(ITMHA)  CLO 
CYCLO  
VP16 
DEX  CLO 
CYCLO  
VP16 
DEX  
Day 8  Day 9  Day 10  Day 11  Day 12  Day 13  Day 14  
CLO 
CYCLO 
VP16 
DEX  
ITMHA  CLO 
CYCLO 
VP16  CLO 
CYCLO 
VP16  IL-2 
(ITMHA) * NK cell 
infusion  RITUX  
IL-2  
Day 15  Day 16  Day 17  Day 18  Day 19  Day 20  Day 21  
IL-2  IL-2  IL-2 RITUX  PEG -ASP 
VCR 
DEX 
(ITMHA)  
Day 22  Day 23  Day 24  Day 25  Day 26  Day 27  Day 28  
DEX  DEX  DEX  DEX  DEX  RITUX  
DEX  VCR 
DEX 
ITMHA  
Day 29  Day 30  Day 31  Day 32  Day 33  Day 34  Day 35  
      PEG -ASP 
VCR**  
RITUX (rituximab) - 375 mg/m2/dose IV: Days 4, 13, 20, 27 
CLO (clofarabine) - 40 mg/m2/day IV: Days  6-10 
CYCLO (cyclophosphamide) - 300 mg/m2/day IV: Days  6-10 
VP16 (etoposide) - 100 mg/m2/day IV: Days  6-10 
DEX (dexamethasone) - 8 mg/m2/day divided TID PO or IV: Days 1 -8 and Days 21 -28 
(Avoid dexamethasone for at least 3 days prior to NK cell infusion)  
PEG -ASP (PEG -asparaginase) - 2500 units/m2/dose IV: Day 21 and 35  
VCR (vincristine) - 1.5 mg/m2/dose (max. 2 mg) IV: Day 1, 21, 28, 35 
IL-2 (interleukin -2) - 1 x 106 units/m2 SQ QOD for 5 doses (Day 11 -19) 
*ITMHA will be repeated on Day 11 if Day 8 CSF is not clear. Additional ITMHA on 
Days 5 and 21 for participants with CNS2, CNS3 or traumatic taps  with blasts. See 
Sections 5.2.1.2 and 5.10 for details of IT.  
**Day 35 PEG -ASP and VCR may be skipped if counts recover sooner than Day 35.  
ALLR18  
Page 22 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
See table 9 and appendix 5 for required research studies.  
ALLR18  
Page 23 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
5.2.1.1  Enrollment of initial 5  participants  
 
Enrollment of the initial participants will be done in a staggered fashion to ensure 
safety of the experimental treatment. For the first 5 enroll ments, participants must 
be enrolled one at a time and each participant must complete therapy through 
Block I with recovery of counts prior to the next enrollment. If the safety profile 
is acceptable for the first 5 participants, enrollment will proceed as  planned.  
 
Recovery of counts is defined as: WBC ≥ 1500/mm3, ANC ≥300/mm3 and 
platelet count ≥ 50 x 109/L 
 
5.2.1.2  Triple Intrathecal therapy (ITMHA) – Block  I 
 
• CNS1: Days 1, 8 and  28 
 
• CNS2 and CNS3 and traumatic tap with blasts: Days 1, 5, 8, 21 and  28. 
 
o If CNS blasts are not cleared by Day 8, additional ITMHA will 
be given on day 11.  
 
5.2.1.3  Bone marrow aspirate and MRD – Block  I 
 
Bone marrow aspirate/MRD will be performed after count recovery (WBC ≥ 
1500/mm3, ANC ≥ 300/mm3 and platelet count ≥ 50 x 109/L 
 
5.2.1.4  Participants who  do not receive NK cell therapy for any reason  (e.g., 
donor found to be ineligible after workup): IL -2 will NOT be given and 
chemotherapy Day 21 onwards may be moved up by a week to Day  14. 
 
5.2.1.5  NK cell therapy – Block  I 
 
Note: When scheduling needs warrant, Day 11 of therapy onwards may be 
delayed for 1 -3 days if necessary. Please contact PI or the transplant team for 
scheduling questions.  
 
Donor selection and testing  
 
1) HLA -typing in the HLA laboratory to confirm that the donor is  greater 
than o r equal to 3 of 6 HLA match to  recipient.  
 
2) KIR phenotyping and genotyping in Dr. Leung’s laboratory (Mnemonic: 
NK TYPING). The results of these assays will not be used for donor 
selection (i.e., KIR matched or mismatched donors will be able to  donate 
NK cells).  
ALLR18  
Page 24 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
3) Donors are required to  undergo screening, examination, and testing as 
described in 21 CFR 1271 and the Guidance "Eligibility Determination  for 
Donors of Human Cells, Tissues, and Cellular and Tissue -Based Products 
(HCT/Ps)" to determine eligibility. This includes the  following:  
 
a) Medically approved by a non -Department of Bone Marrow 
Transplantation and Cellular Therapy (St. Jude or non - St. Jude) to 
serve as an NK cell donor. Medical evaluation must be done  within 
60 days of NK cell collection (i.e. apheresis  procedure).  
b) Medicall y cleared by the Blood Donor Center physician or  designee 
to undergo apheresis within 7 days of apheresis  procedure.  
c) Infectious disease testing within 7 days of apheresis  procedure  
 
Participants with ALL will receive NK cell transplantation from an adult f amily 
member who shares at least one HLA -haplotype with the recipient if available. 
Specific exclusion criteria include pregnancy and any other medical condition 
that, in the opinion of an independent physician, precludes performance of an 
apheresis proced ure. If a suitable donor is not available, NK cell therapy as well 
as IL2 administration will be omitted. Subsequent chemotherapy can be initiated  a 
week earlier (i.e., chemotherapy planned day 20 onwards can begin on day  14). 
 
Histocompatibility testing is performed in a CLIA -certified, ASHI - and CAP - 
inspected laboratory of the Department of Pathology, SJCRH. Molecular techniques 
will be utilized to characterize donor and recipient HLA Class I gene content to the 
level sufficie nt to determine the ligand repertoire for KIR recognition.  
 
NK cell collection and selection  
 
On day 11 the donor will undergo apheresis once. The cells obtained will be 
purified for CD56+ cells by the two -step procedure described previously.22 The 
CliniMACS selection column will be operated using the Standard Operat ing 
Procedures of the Human Applications Laboratory. For this protocol, our goal is 
to infuse immediately after processing on Day 12 all the NK cells collected to 
give >2x106 CD56+ cells/kg of recipient body weight, but allowing for a 
CD3+CD56− cell dose o f no greater than 0.05x106 /kg. The maximum dose of 
cells that would be infused is 400 x 106 CD56+ cells/kg. The minimum dose that 
would be infused is 0.1 x 106 cells/kg . The NK cell product will undergo quality 
control testing that includes assays for via bility, sterility and purity before release 
for infusion following standard operating procedures of the Human Applications 
Laboratory.  
ALLR18  
Page 25 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
Quality assurance for cellular products  
 
The Department of Therapeutic Production and Quality has establis hed an 
independent division of Quality Assurance (QA). This group is responsible for  the 
management of Quality Control, Quality Assurance and Quality Improvement 
processes for the Human Applications Laboratory. Production and QA Systems 
that are in place  include:  
 
• Standard Operation Procedures (SOPs) for production and quality  processes  
• Documentation of Donor  Eligibility  
• Documentation of processes captured in Batch Records.  
• In-process quality control testing including  sterility  
• Release Specifications establ ished for all  products.  
• Out of Specification Reporting and Investigation  Process  
• Authorization by QA for the release of all products after review of  records 
and release specification test results.  
• Product labeling procedures with multiple person  review.  
• Variance Management  Process  
• Personnel Competence and Proficiency  Program  
• Inventory control and documentation of product history through  patient 
infusion.  
 
Test results that are out of specification for products that are needed on a clinically urgent 
basis will be evaluated by the laboratory medical director. The patient's physician or 
attending transplant physician will be informed of the test result prior t o infusion of the 
product. Notification regarding positive sterility results before or after infusion will be 
given to the primary attending physician and patient and/or parent/guardian. Notification 
to the FDA and St. Jude IRB will be given and will inclu de testing results or adverse 
events and any required intervention. An investigation following TPQ/HAL SOPs will be 
completed, reviewed by TPQ Quality Assurance and outcomes of the investigation 
reported.  
ALLR18  
Page 26 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
5.2.2 Induction Block II (duration 3  weeks ) 
 
Note: patients with high -risk relapse who will require cranial irradiation 
prior to transplant will NOT receive this block of therapy in order to prevent 
neurological toxicity.  
 
5.2.2.1  Drug dosages – Block II  
 
Agent  Dosage and route  # Doses  Schedule  
HDMTX  
(high dose methotrexate)  5 g/m2 IV or targeted 65 µM  2 Days 1 and 8  
6MP  
(mercaptopurine)  50 mg/m2/day PO  21 Days 1 to 21  
 
Block II will begin after count recovery from Block I (i.e., WBC ≥ 1500/mm3, 
ANC ≥ 300/mm3 and platelet count ≥ 50 x 109/L). 
 
5.2.2.2  Intrathecal therapy – Block  II 
 
• ITMHA on day  1 
 
5.2.2.3  Bone marrow aspirate/MRD – Block  II 
 
Bone marrow aspirate and MRD will be performed on Day 22, provided counts are 
satisfactory (WBC ≥ 1500/mm3, ANC ≥ 300/mm3 and platelet count ≥ 50 x 109/L. 
 
High -risk participants will proceed to BMT once MRD is negative. They may 
continue to receive protocol directed therapy while awaiting transplant workup. 
All participants with positive MRD will proceed to receive Block III.  
 
5.2.2.4  Mercaptopurine administration – Block  II 
 
Mercaptopurine should be given daily at a consistent time that maximizes 
adherence with the prescribed treatment. If a dose is inadvertently missed, then it 
should be given as soon as the omission is noted, as long as it is at least 6 hours 
prior to the next scheduled dose of MP.  
 
In participants for whom high dose methotrexate treatment is delayed, 
mercaptopurine may be continued until 7 days after the last course of high dose 
methotrexate. Mercaptopurine may be held in the presence of ANC < 300 /mm3, WBC  
< 1,500/mm3, platelet count < 50 x 109/L or grade 3 or 4 mucositis. Dosage of 
mercaptopurine may be reduced to 25 mg/m2/day in participants who have developed 
neutropenia after the first high dose methotrexate and mercaptopurine treatment. See 
section 6.13 for modifications of mercaptopurine based on TPMT status.  
ALLR18  
Page 27 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
 
5.2.2.5  HDMTX Administration – Block  II 
 
Patients will receive 5 gram/m2 (or a dose targeted to achieve a steady -state 
plasma concentration of 65 µM) administered over 24 hours in travenously. The 
subsequent dose of high dose methotrexate and mercaptopurine will be delayed if 
ANC <300/mm3, WBC < 1500/mm3, platelet count < 50 x 109/L, SGPT >500 
U/L, total bilirubin >2 mg/dl and direct bilirubin >1.4 mg/dl, or mucositis is 
present . For patients with Down syndrome, high dose methotrexate administration 
will be modified (see section 6.7.1)  
 
HDMTX pre -hydration  
 
At least two hours before high dose methotrexate, pre -hydration IV fluid (D5W + 
40 mEq NaHCO3/L + 20 mEq KCl/L) will be administered at the rate of 200 
ml/m2/hr. At start of pre -hydration, one IV dose of NaHCO3 (25 mEq/m2) diluted in 
50 ml D5W will be give n over 15 minutes. Pre -hydration fluid may also be given 
overnight at a rate of at least 125 ml/m2/hr. High dose methotrexate treatment will 
follow, provided that urinary pH is ≥ 6.5; exceptions must be cleared with the 
pharmacokinetics service and the att ending  physician.  
 
HDMTX infusion  
 
Methotrexate loading dose will be given over 1 hour, followed immediately by 
maintenance infusion over 23 hours. During the methotrexate infusion, 
participants should receive hydration fluid with D5W + 40 mEq/L NaHCO3 + 2 0 
mEq KCl/L at 125 -150 ml/m2/hr. Urine pH will be monitored with each void 
during infusion. An IV bolus of 12 mEq/m2 NaHCO3 will be given if urine pH is 
6.0; and 25 mEq/m2 will be given if urine pH is <6.0. Acetazolamide 500 mg/m2 
orally every 6 to 8 hours  may be used if systemic alkalosis limits the 
administration of bicarbonate for urinary alkalinization. Participants with 
evidence of renal dysfunction or delayed clearance during the methotrexate 
infusion may receive less than a 24 hour methotrexate infus ion. Blood samples  for 
methotrexate pharmacokinetics will be drawn as described  below.  
 
HDMTX leucovorin rescue  
 
Leucovorin, 15 mg/m2 (IV or PO) will be started at 42 hours after the start of 
methotrexate and repeated every 6 hours for a total of three to five doses, as 
determined by primary physician and Pharm D based on patient’s prior treatment 
history or present condition. The dosage of leucovorin will be increased in 
participants with high plasma methotrexate concentrations (>1.0 µM at 42 hours) 
and co ntinued until the methotrexate concentration is less than 0.10 µM. 
Additional measures, such as hydration, hemoperfusion, or carboxypeptidase will 
be considered in participants with 42 -hour methotrexate levels > 10µM. 
Participants with a history of delayed  Grade 3 or 4 gastrointestinal toxicity with  
ALLR18  
Page 28 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
prior methotrexate or a history of typhlitis with any chemotherapy should have 
leucovorin continue for 5 doses; those with early toxicity should have leucovorin 
begin at 36 hours with subsequent m ethotrexate; if toxicity recurs, the baseline 
leucovorin dosage should also be increased.  
 
See Appendix VIII, “HDMTX administration and monitoring guidelines, 
Induction Block II” for additional information.  
 
5.2.3 Induction Block III (approximately 3 weeks until count  recovery)  
 
Block III will begin when WBC ≥ 1500/mm3, ANC ≥ 300/mm3 and platelet count  
≥ 50 x 109/L. 
 
5.2.3.1  High dose mitoxantrone and cytarabine (MA) – Block III  
 
Agent  Dosage and route  # Doses  Schedule  
ARA -C 
(cytarabine)  1 g/m2 IV over 2 hours every 
12 hours  8 Days 1 -4 
MITO  
(mitoxantrone)  12 mg/m2 (0.4 mg/kg for 
participants < 10 kg) IV over 
1 hour  3 Days 3 -5 
 
5.2.3.2  Drug dosages, schedules and routes – Block  III 
 
ARA -C (cytarabine): 1 g/m2 IV over 2 hours every 12 hours on days 1 -4 (8 doses)  
 
MITO (mitoxantrone: 12 mg/m2 (0.4 mg/kg for participants less than 10 kg) IV 
over 1 hour on days 3 -5 (3 doses)  
 
5.2.3.3  Intrathecal treatment – Block  III 
 
• ITMHA on Day  7 
 
5.2.3.4  Conjunctivitis prophylaxis – Block  III 
 
Dexamethasone ophthalmic solution (0.1%), 2 drops to both eyes four times per day, or 
artificial tears (e.g., hydroxymethylcellulose, hypromellose, polyvinyl alcohol), 2 drops 
to both eyes every 2 -6 hours, may be use d during HDAC administration and for 24 hours 
after completion to prevent conjunctival irritation.  
 
5.2.3.5  Bone marrow aspirate/MRD – Block  III 
 
Bone marrow aspirate and MRD will be performed after count recovery (WBC ≥ 
1500/mm3, ANC ≥ 300/mm3 and platelet count ≥ 50 x 109/L. 
ALLR18  
Page 29 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
5.3 Interim Continuation (4  weeks)  
 
Interim continuation will begin when WBC ≥ 1500/mm3, ANC ≥ 300/mm3 and 
platelet count ≥ 50 x 109/L 
 
Week  Agent  Dosage and 
route  # Doses  Schedule  
1 VP16  
(etoposide)  300 mg/m2 IV 1 Day 1  
CYCLO  
(cyclophosphamide)  300 mg/m2 IV 1 Day 1  
2 MTX  
(methotrexate)  40 mg/m2 IV 1 Day 1  
6MP  
(mercaptopurine)  75 mg/m2 PO 7 Days 1 -7 
3 VM26  
(teniposide)  200 mg/m2 IV 1 Day 1  
ARA -C 
(cytarabine)  300 mg/m2 IV 1 Day 1  
4 DEX  
(dexamethasone)  12 mg/m2 PO 15 Days 1 -5 TID  
VINBLAST  
(vinblastine)  6 mg/m2 IV 1 Day 1  
 
5.3.1 Intrathecal therapy – Interim Continuation 
ITMHA on Day 1 of week  1. 
5.3.2 Mercaptopurine  administration  
 
Mercaptopurine should be given daily at a consistent time that maximizes 
adherence with the prescribed treatment. If a dose is inadvertently missed, then it 
should be given as soon as the omission is noted, as long as it is at least 6 hours 
prior to the ne xt scheduled dose of 6MP  
 
5.3.3 Dose modifications and delays – Interim  Continuation  
 
Chemotherapy except dexamethasone may be delayed or the dose will be reduced 
as follows:  
• WBC >1,500/mm3 and ANC >300/mm3; give full  dose 
• WBC > 1,000/mm3 but <1,500/mm3 and ANC >300/mm3; reduce dose by  50% 
• WBC < 1000/ mm3 or ANC <300/ mm3; hold  chemotherapy  
• Participants with a variant TPMT allele should receive no more than 60 
mg/m2 of 6MP  
ALLR18  
Page 30 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
5.3.3  Bone marrow/aspirate/MRD – Interim  Continuation  
 
Bone marrow aspirate and MRD will be performed at the end of week 4 provided 
counts are satisfactory (WBC ≥ 1500/mm3, ANC ≥ 300/mm3 and platelet count ≥ 
50 x 109/L). 
 
5.4 Re-Induction  Therapy  
 
Approximately 3 weeks until count recovery.  
 
5.4.1 Overview - Re-Induction treatment will begin when WBC ≥ 1500/mm3, 
ANC ≥ 300/mm3 and platelet count ≥ 50 X  109/L 
 
 
Day 1   
Day 2   
Day 3   
Day 4   
Day 5   
Day 6   
Day 7  
CLO 
CYCLO 
VP16 
DEX 
ITMHA   
CLO 
CYCLO 
VP16 
DEX   
CLO 
CYCLO 
VP16 
DEX   
CLO 
CYCLO 
VP16 
DEX   
CLO 
CYCLO 
VP16 
DEX   
 
PEG -ASP 
VCR 
DEX   
 
Day 8   
Day 9   
Day 10   
Day 11   
Day 12   
Day 13   
Day 14  
      
VCR   
 
Day 15   
Day 16   
Day 17   
Day 18   
Day 19   
Day 20   
Day 21  
 
(ITMHA)      PEG -ASP 
VCR   
 
5.4.2 Drug dosages, schedules and routes – Re-Induction  therapy  
 
CLO  (clofarabine)  40 mg/m2/day: IV Days 1 -5 
CYCLO  (cyclophosphamide)  300 mg/m2/day: IV Days 1-5 
VP16  (etoposide)  100 mg/m2/day: IV Days  1-5 
DEX  (dexamethasone)  8 mg/m2/day: PO Days  1-6 
PEG -ASP (PEG -asparaginase)  2500 units/m2/dose: IV Day 6 and 20 
VCR  (vincristine)  1.5 mg/m2/dose (max. 2  mg):  
IV push Day 6, 13, 20  
 
5.4.3 Intrathecal treatment – Re-Induction  therapy  
 
• CNS1: ITMHA on Day  1 
ALLR18  
Page 31 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
• CNS 2, 3 and traumatic tap with blasts: IT MHA on Days  1,15 
5.4.4 Bone marrow aspirate/MRD – Re-induction therapy  
 
Bone marrow aspirate and MRD will be performed after count recovery (WBC ≥ 
1500/mm3, ANC ≥ 300/mm3 and platelet count ≥ 50 x 109/L. 
 
5.5 Continuation Treatment  
 
5.5.1 Overview of Continuation  treatment  
 
Continuation treatment begins after completion of Re -Induction, provided that the 
ANC  300/mm3, WBC  1500/mm3 and platelet count  50 x 109/L as well as no 
evidence of grade 3 or 4 mucositis. Duration of continuation: 10 cycles of 8 -week 
rotations for a total of 80 weeks. Entire duration of treatment is approximately 2 
years.  
 
Week  Agents  
1 MTX + 6MP  
2 MTX + 6MP  
3 VM26 + ARA -C 
4 DEX + VCR  
5 MTX + 6MP  
6 MTX + 6MP  
7 VM26 + ARA -C 
8 DEX + VINBLAST  
 
5.5.2 Drug dosages, schedules and routes – Continuation  treatment  
 
MTX (methotrexate) 
6MP (mercaptopurine) 
VM26 (teniposide)  
VCR (vincristine)  40 mg/m2 
75 mg/m2 
200 mg/m2 
2 mg/m2 1 dose, IV* day 1 (weeks 1, 2, 5 & 6)  
days 1 -7, PO (weeks 1, 2, 5 & 6)  
1 dose, IV day 1 (weeks 3 & 7)  
(max 2 mg), 1 dose, IV push day 1 (week 4)  
ARA -C (cytarabine)  300 mg/m2 1 dose, IV day 1 (weeks 3 & 7)  
DEX (dexamethasone)  12 mg/m2 15 doses, PO day 1 -5 TID (weeks 4 & 8)  
VINBLAST (vinblastine)  6 mg/m2 1 dose, IV day 1 (week 8)  
 
*MTX should be given IM or as a 2 hour IV infusion if the participant has had 
previous cranial irradiation. Mercaptopurine should be given daily at a 
consistent time that maximizes adherence with the prescribed treatment. If a dose  
ALLR18  
Page 32 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
is inadvertently missed, then it should be given as soon as the omission is noted, 
as long as it is at least 6 hours prior to the next scheduled dose of MP  
ALLR18  
Page 33 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
5.5.3 Intrathecal therapy – Continuation  treatment  
 
• CNS1: ITMHA on Day 1 of week 1 of all  cycles  
• CNS2, 3 and traumatic tap with  blasts:  
o Cycles 1 -5: ITMHA on Day 1 of week 1 and Day 1 of week  5 
o Cycles 6 -10: ITMHA on Day 1 of week  1 
o Participants who are candidates for cranial irradiation will receive 4 -5 
ITMHAs during radiation therapy. These patients will not receive 
additional ITMHA following completion of radiation therapy. Lumbar 
puncture will be done every 16 weeks for surveillan ce only. See  section  
6.3.3.3 for details  
 
5.5.4 Dose modifications and delays – Continuation  treatment  
 
Dexamethasone and vincristine can be given regardless of counts. For all other 
drugs, dose will be reduced as follows:  
 
• WBC >1,500/mm3 and ANC >300 /mm3; give  full dose 
• WBC > 1,000/mm3 but <1,500/mm3 and ANC > 300 /mm3; reduce the 
dose by  50% 
• WBC < 1,000/mm3 or ANC <300/mm3; hold  chemotherapy  
• Participants with a variant TPMT allele should receive no more than 60 
mg/m2 of 6MP  
 
5.5.5 Bone marrow aspirate/MRD – Continuation treatment  
 
Bone marrow aspirate/MRD will be performed for all participants in week 1 of every 2 
cycles (i.e. every 16 weeks) and at  the end of therapy.  
 
5.5.6 End of therapy  evaluations  
 
• CBC with  diff 
• CMP, LDH, uric  acid 
• Bone marrow aspirate and  MRD  
• CSF cell count, differential and  cytology  
• ECHO/EKG  
 
5.6 Plan for  HSCT  
 
All high -risk participants are eligible for HSCT. HSCT will be performed as soon 
as MRD becomes negative (<0.01%). If MRD becomes negative and a donor has 
not been found, the patient will continue chemotherapy phases until a suitable 
donor is found. All at tempts will be made to attain a negative MRD prior to 
HSCT. If MRD is persistently positive, the plan will be discussed with the PI and 
the transplant team. Donor will be selected according to institutional practices and  
ALLR18  
Page 34 of 67 
Amendment 3.0, dated: 03 -19-2018  IRB Approval date: 06 -13-2018  St. Jude  
IRB NUMB ER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Protocol document date: 06 -12-2018   
  
transplant regimens will be used according to institutional HSCT protocols and 
guidelines.  
 
5.7 Prophylaxis and Treatment for CNS  Disease  
 
All participants will receive ITMHA. Irradiation will be given to some participants 
with CNS involvement at relapse, see section 6.3.  
 
5.7.1 Criteria for CNS  status  
 
• CNS -1: No blasts in  CSF 
• CNS -2: < 5 WBC/µL of CSF with  blasts  
• CNS -3: ≥ 5 WBC/µL of CSF with blasts or cranial nerve  palsy  
• Traumatic tap with blasts: > 10 RBC/µL of CSF with  blasts  
 
5.7.2 Dosage of  ITMHA  
 
Age < 1 year  1-2 years  2-3 years  > 3 years  
methotrexate  6 mg  8 mg  10 mg  12 mg  
hydrocortisone  12 mg  16 mg  20 mg  24 mg  
cytarabine  18 mg  24 mg  30 mg  36 mg  
total volume  6 ml 8 ml 10 ml  12 ml  
 
Leucovorin 5 mg/m2/dose, max 5 mg will be given PO or IV at 24 and 30 
hours after each intrathecal treatment during induction Block I, Block III 
and Re -induction. Leucovorin may be given during other phases of 
therapy if the patient has an adverse reaction with previous int rathecal 
treatments or methotrexate treatment or is neutropenic.  
 
5.8 Participation of St. Jude Collaborating Sites in the Treatment  Plan  
 
Block I Induction therapy will be administered at St. Jude. After 
completion of Block I Induction therapy, participants will return to 
collaborating site to complete the remainder of ALLR18 therapy.  
 
5.9 Participation of St. Jude Affiliates the Treatment  Plan 
 
St. Jude participants may return to affiliate to receive some parts of 
ALLR18. Blocks I, II, III of induction and Re -induction therapies, and 
HSCT must be given at St. Jude. Participants may return to affiliates to 
receive interim continuation and con tinuation treatments.  
St. Jude  
IRB NUMBER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018  IRB Approval date: 06 -13-2018   
 ALLR18  
Page 35 of  67 
 
 
5.10 Summary of Intrathecal Therapy on ALLR18  
 
CNS Status  Induction - 
Block I  Induction – 
Block II  Induction – 
Block III  Interim 
continuation  Re-induction  Continuation  All phases  
CNS -1 Days  Total  Day Total  Day Total  Day Total  Days  Total  Days  Total  Total –all 
phases  
1, 8, 
28 3 1 1 7 1 1 1 1 1 Cycles 1 -10: 
Day 1 of Week 1  10 17 
 
CNS -2, 1, 5, 8,  5 or 1 1 7 1 1 1 1, 15  2 Cycles 1 -5: 15 25 
(26 if 
given on 
Day 11 
Block I)  CNS -3, & (11*),  6*         Day 1, Week 1   
Traumatic tap  21, 28           & Day 1, week 5   
w/blasts              
           Cycles 6 -10:  
           Day 1, week 1   
*If CNS blasts are not cleared by Day 8, additional ITMHA will be given on Day 11  
 
Those patients receiving CNS irradiation should receive 4 -5 ITHMA during radiation. They will not receive subsequent ITMHA following 
radiation therapy. See section 6.3.3.3 - Concurrent chemotherapy with irradiation. Consult with PI and radiation oncologist.  
ALLR18  
Page 36 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 6.0 TREATMENT  MODIFICATIONS  
 
6.1 Philadelphia Chromosome -Positive (Ph+)  ALL  
 
The use of tyrosine kinase inhibitors has improved the outcome of children with Ph - 
positive ALL73. Imatinib and dasatinib are the agents used most frequently in 
frontline therapy. Unfortunately, resistance develops commonly  due to point 
mutations within the kinase binding domain of BCR -ABL. By using sensitive 
detection methods such as denaturing high -performance liquid chromatography, 
these mutations can be detected in a small sub -clone of leukemic cells in 40% of 
newly diag nosed patients, but in the dominant clone in 90% at relapse, thus 
implying selective pressure of the resistant clone after treatment with tyrosine 
kinase  inhibitors.74 
 
Ph-like ALL is a high -risk subtype of ALL with a gene e xpression profile similar to 
Ph-positive ALL, but lacking the Philadelphia chromosome.75 Recent studies have 
demonstrated that a subset of these cases harbor a diverse range of genomic 
alterations that activate tyrosine kina ses such as ABL1, ABL2, CSF1R and 
PDGFR.76,77 In preclinical studies, Ph -like leukemic cells with targetable lesions are 
highly sensitive to tyrosine kinase inhibitors.76,77 Various case reports also 
demonstrate that patients with Ph -like ALL respond well to TKIs despite resistance 
to standard chemotherapeutic agents.78 In view of compelling preclinical data, TKIs 
will be added to frontline ther apy for patients with Ph -like ALL in Total XVII as 
well as ongoing COG studies.  
 
In addition to patients with Philadelphia chromosome (Ph) -positive ALL, patients 
with the Ph -like subtype of ALL and a targetable lesion will also receive a tyrosine 
kinase in hibitor. Testing for specific mutations will be done in a CLIA -approved 
laboratory and patients with fusions predicted to respond to ABL1 inhibitor will 
receive a TKI (ex. imatinib, dasatinib, nilotinib). Please discuss individual cases 
with the PI.  
 
The c hoice of tyrosine kinase inhibitor in ALLR18 will be at the discretion of the 
treating physician and principal investigator dependent on prior exposure and 
resistance patterns. Examples include imatinib, dasatinib and nilotinib.  
 
Tyrosine kinase inhibitors  should be introduced after Day 20 of Induction Block I 
therapy to avoid drug interactions and interference with NK cell function. Consider 
holding during HDMTX in induction Block II to avoid cumulative toxicity. Dose 
should be adjusted to avoid myelosuppr ession to enable administration of therapy 
without interruption. Please discuss with the PI.  
ALLR18  
Page 37 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 6.2 PEG -Asparaginase  Allergies/Hypersensitivity  
 
Participants with allergic reactions or intolerance to PEG -asparaginase will be given 
Erwinia L-asparaginase intramusc ularly or intravenously over 30 -60 minutes 
duration.79 Each dose of PEG -asparaginase will be replaced by Erwinia at 25,000 
units/m2/dose thrice weekly (2 to 3 days apart, e.g. Monday, Wednesday and Friday).  
 
Participants wit h possible allergic reactions should have measurements of anti - 
asparaginase antibodies and asparaginase at the time of the reaction and if re - 
challenged, after the next dose. Native E. coli L-asparaginase (L -asparaginase, 
Elspar®) may be given when clini cally indicated, but this should be discussed and 
approved by the PI.  
 
6.3 Irradiation for Participants with CNS  Disease  
 
6.3.1 Participants with CNS3  disease  
 
Craniospinal irradiation will be given for participants whose first CR was less  than 
18 months and only cranial irradiation will be given for those whose CR was more 
than 18 months. The doses are 18 Gy cranial and 12 Gy  spinal.  
 
6.3.2 Participants with CNS2  disease 
 
Not all participants with CNS2 disease will require irradiation. These cases will be 
discussed individually with the radiation oncologist and PI.  
 
6.3.3 Timing of cranial/craniospinal  irradiation  
 
6.3.3.1  Participants who will not undergo HSCT (i.e. standard -risk participants): 
After completion of the 3rd course of continuation therapy (i.e. approximately one 
year from diagnosis of relapse). These participants will resume the protocol at  cycle 
4 of continua tion after completion of irradiation but will not receive subsequent 
intrathecal chemotherapy. A lumbar puncture will be done every four months for 
surveillance  only.  
 
Methotrexate should be given IM or as a 2 hour IV infusion if the participant has 
had pr evious cranial irradiation.  
 
6.3.3.2  Participants who will undergo HSCT (i.e. high -risk participants): 
Participants who will receive total body irradiation (TBI) for pre -transplant 
conditioning will receive a cranial irradiation boost (6 Gy) just prior to the  TBI. 
Participants who will not re ceive TBI conditioning will receive cranial or 
craniospinal irradiation as per section 6.3.1 just prior to  HSCT.  
ALLR18  
Page 38 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 6.3.3.3  Concurrent chemotherapy with  irradiation  
 
Those participants receiving cranial irradiation should only receive 4 to 5 triple 
intrathecal therapy with leucovorin rescue during irradiation. Mercaptopurine and 
methotrexate will be withheld for at least one week prior to and during irradiation; 
systemic chemotherapy during irradiation will include dexamethasone and 
vincristine with or w ithout PEG -asparaginase.  
 
6.4 Treatment for Testicular  Involvement  
 
The plan for testicular irradiation for participants with testicular involvement will 
be discussed with the radiation oncologist and PI at the time of diagnosis of relapse 
and at the end of in duction therapy. The need for testicular radiation will be 
determined for individual participants based on response to therapy, ultrasound 
findings and possibly testicular biopsy.  
 
6.5 Obesity  
 
Actual body weight will be used to calculate body surface area in all participants 
and used for dosage calculations (with the exception that vincristine dosage is 
capped at 2 mg).  
 
6.6 Infants  
 
With the exception of vincristine and mitoxantrone, all dosages given to infants (<  1 
year) will be based on body surface area. For infants < 1 month of age, or for 
infants < 3 months of age born significantly prematurely (< 36 weeks gestation), a 
50% redu ction in dosages of asparaginase, etoposide, methotrexate, thiopurines, 
cyclophosphamide, clofarabine, and cytarabine should be made. The vincristine 
dosage for participants < 12 months of age or < 10 kg weight is 0.05  mg/kg/dose.  
The mitoxantrone dose for  participants less than 10 kg is 0.4 mg/kg/dose  
 
6.7 Down Syndrome Participants  
 
Participants with Down syndrome should be closely monitored. Doses should be 
reduced (30% to 50%) as clinically indicated (especially dexamethasone and high - 
dose cytarabine, and for those who have higher than expected toxicity in earlier 
phases).  
 
6.7.1 HD-MTX  
 
Dosages of HD -MTX will be modified because participants with Down syndrome 
have altered MTX pharmacokinetics and enhanced tissue sensitivity to the effects of 
MTX. The hydration and alkalinization regimen should be the same as outlined in 
section 5.1.2. However, the dose of HD -MTX should be 500 mg/m2 (50 mg/m2 over 
1 h and 450 mg/m2 given over 23 h). Baseline leucovorin rescue will begin early (at 
hour 30 at 30 mg/m2 IV q 6 h × 2 doses, followed by 10 mg/m2 IV q6 h × 6 doses).  
ALLR18  
Page 39 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 If MTX plasma levels are elevated, increased leucovorin rescue will be 
recommended by the Pharmacokinetics Service. Vigorous hydration should be 
ensured until the 42 -hr MTX level is known.  
 
6.7.2 Cont inuation low -dose MTX  
 
The low -dose weekly MTX (40 mg/m2) should be administered at full dosage if 
possible. If the patient has severe neutropenia or leucopenia (which delays 
subsequent therapy) or grade 4 mucositis (or mucositis which delays subsequent 
therapy) after being administered 40 mg/m2 low-dose MTX, t he dosage should be 
decreased to 30 mg/m2, and further to 20 mg/m2 and finally to 10 mg/m2 if 
necessary. If 10 mg/m2 is also not tolerated, then leucovorin should be added at 5 
mg/m2 every 6 h for 4 doses, starting 42 h from the MTX dosage, with titration to 
acceptable toxicity.  
 
6.8 Participants with Renal  Dysfunction  
 
Subclinical renal impairment (normal serum creatinine but decreased GFR) may  be 
present in participants receiving concurrent nephrotoxic drugs (e.g. IV acyclovir 
and vancomycin) which, if possib le, should be held during and for 20 hours after 
HDMTX infusions or until adequate MTX clearance has been  documented.  
Consideration to delaying MTX should be given if a patient's serum  creatinine 
indicates renal impairment (e.g., glomerular filtration rate  <50cc/min/1.73 m2, 
however this will be a clinical decision, please contact PI, and/or  PharmD).  
 
In the event of toxicity secondary to high dose methotrexate, consider 
carboxypeptidase (glucarpidase).  
 
6.9 Participants with Hepatic  Dysfunction  
 
6.9.1 Mitoxantrone, clofarabine, etoposide and  vincristine  
 
Dosages for mitoxantrone, clofarabine, etoposide and vincristine should be 
modified in participants with elevated direct bilirubin concentrations or other 
evidence of biliary obstruction.  
 
• Direct bilirubin 2 -4 mg/dl: 50% dosage  decrease  
• Direct bilirubin 4 -6 mg/dl: 75% dosage  decrease  
• Direct bilirubin >6 mg/dl: withhold  dose 
 
6.9.2 PEG -Asparaginase  
 
PEG -asparaginase may need to be withheld in participants with elevated direct 
bilirubin concentratio ns, especially if there is evidence of mucositis.  
ALLR18  
Page 40 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 6.9.3 HDMTX – High dose  methotrexate  
 
HDMTX should be withheld if there is evidence of existing mucositis or if total 
bilirubin >2 mg/dl and direct bilirubin >1.4 mg/dl.  
 
Subclinical hypertransaminasemia (SGPT >500 IU/L) is an indication to delay only 
high dose methotrexate but no other chemotherapy.  
 
6.10 Cardiotoxicity  
 
Hold mitoxantrone until fractional shortening is > 28%. Consultation with 
cardiologist is suggested if clinically  indicated.  
 
6.11 Vinca Alkaloid  Neurotoxicity  
 
Mild vinca alkaloid toxicities are anticipated. These include jaw pain, constipation, 
decreased deep tendon reflexes. If there is persistent severe ab dominal cramps, gait 
impairment, severe pain that requires narcotics or SIADH develops, the dose may 
be reduced to 50%. Motor paralysis or typhlitis will warrant temporary 
discontinuation of vinca alkaloids.  
 
6.12 Pancreatitis  
 
Acute hemorrhagic pancreatitis is  a contraindication to continue PEG -asparaginase 
treatment. In the case of mild to moderate pancreatitis, PEG -asparaginase should be 
held until symptoms and signs subside, and amylase and lipase levels return to 
normal and then resumed. Any participants wi th abdominal pain suspected of 
pancreatitis should have serum amylase and lipase measured as well as an 
abdominal sonogram or CT scan done. In the case of severe pancreatitis (i.e. 
abdominal pain of 72 hours or more, amylase and lipase level three times or  more 
of the upper limit of normal, and sonographic or CT scan evidence of pancreatitis), 
PEG -asparaginase may be discontinued permanently when the possibility of 
glucocorticoid - or mercaptopurine induced pancreatitis is excluded. In cases with 
mild to mod erate pancreatitis (abdominal pain less than 72 hours and amylase and 
lipase level less than three times the upper limit of normal), PEG -asparaginase 
should be held and resumed once symptoms and signs subsided. Call the PI to 
discuss the management if the patient is asymptomatic (without abdominal pain) 
and has only elevated amylase or lipase levels. Consideration should be given to  use 
native asparaginase (10,000 units/m2 thrice weekly for 3 doses) for participants who 
are re -challenged. Consideration shou ld also be given to dexamethasone - or 
mercaptopurine - related pancreatitis. Contact the PI to discuss the management if 
there is a possibility that the pancreatitis is due to either of these two  drugs.  
ALLR18  
Page 41 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 6.13 TPMT Status and Thiopurine  Dosage  
 
Parti cipants who have at least one mutant TPMT allele often require dosage 
decreases of 6MP to avoid severe myelosuppression .80,81 In a setting in which 6MP 
dosage was preferentially adjusted in ab out 1/3 of participants with TPMT defects, 
overall leukemia -free survival was outstanding among participants with TPMT 
defects.82 Thus, we recommend that participants with phenotype or genotype 
consistent with at least one v ariant allele start mercaptopurine at 60 mg/m2 and 
adjust the subsequent doses according to blood count and red blood cell 6 
thioguanine nucleotide level (in consultation with Pharm D). For the participants 
who did not have TPMT testing in the frontline pr otocol, a blood sample (5 -10 ml) 
will be drawn along with routine lab work at the start of induction Block B to allow 
for timely TPMT genotyping and/or phenotyping.83 In participants in whom TPMT 
genotype and phenotype are d iscordant, or in whom suspected noncompliance, 
problems with toxicities or high blood counts are present, samples for red blood 
6TGN and/or repeat TPMT activity may be measured. The dose of 6MP may be 
adjusted based on participants’ TPMT status, 6TGN level s and WBC in 
consultation with Pharmaceutical Sciences.  
 
7.0 SUPPORTIVE CARE GUIDELINES  
 
These guidelines are provided to help physicians caring for participants treated on 
this protocol. They are guidelines and not protocol requirements. Nothing in these 
guidelines is intended to supplant the judgment of the treating physician regarding 
patie nt management. Current institutional practice may dictate other approaches  to 
the management of the areas discussed in this  section.  
 
7.1 Management of Tumor Lysis Syndrome  
 
It is suggested that baseline serum chemistries (uric acid, urea, creatinine, 
electrol ytes, Ca, Mg, and PO 4) be obtained pre -treatment and frequently after 
therapy is started, and a central venous line (Double Lumen Hickman Catheter or 
DLHC) be inserted for fluid administration and monitoring.  
 
Preventative measures  
 
1. Give allopurinol 300 mg/m2 daily divided TID. Alternatively, rasburicase 
may be given daily until the lysis period is  over.  
2. Intravenous fluids should be started at least 12 hours before  chemotherapy, 
3000 mL/m2/day. NO ADDED  POTASSIUM.  
3. Phosphate binder for  hyperphosphatemia as per institution  guidelines  
 
Suggested monitoring during Induction chemotherapy  
 
1. Strict monitoring of fluid balance is  essential.  
2. Check blood pressure  frequently.  
3. Daily  weights.  
ALLR18  
Page 42 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 4. Frequent measurement of serum chemistries  
7.2 Management of  Hyperleukocytosis  
 
In participants with WBC > 400 x 109/L or symptoms of hyperviscosity, 
leukapheresis or exchange transfusion may be used according to local institutional 
guidelines.  
 
7.3 Prophylaxis for  Pneumocystis Jiroveci Pneumonia  (REQUIRED)  
 
All participants should receive TMP/SMZ (trimethoprim 150 mg/m2/day in 2 
divided doses on Monday, Tuesday, and Wednesday of each week). For those who 
cannot tolerate TMP/SMZ, monthly pentamidine may be substitut ed. Other options 
include atovoquone or dapsone. Please consult with clinical pharmacists and local 
institutional guidelines.  
 
7.4 Prophylaxis for Fungal Infections  (REQUIRED ) 
 
Participants with relapsed ALL are at especially increased risk for fungal infections, 
most commonly candidiasis and aspergillosis. Although there is no national 
standard for antifungal prophylaxis of these participants, effective regimens include 
voricona zole and posaconazole. Micafungin and caspofungin are acceptable 
alternatives, but fluconazole and itraconazole are not recommended because of lack 
of activity against Aspergillus. Antifungal prophylaxis should be initiated when 
ANC < 500 or <1000 and fall ing or predicted to fall in induction blocks I, III and  
re-induction and continue until count recovery (ANC >100 and rising).  
 
All participants on ALLR18 must receive prophylactic antifungal therapy , 
although the agent(s) used may be based on local institu tional guidelines.  
Acceptable antifungal prophylaxis options are listed below, in order of preference. 
Currently, we recommend voriconazole or posaconazole. Please consult with 
clinical pharmacists for therapeutic drug monitoring and refer to local institu tional 
guidelines for voriconazole and posaconazole. Consult with the PI if other 
antifungal agents other than one listed below will be used.  
Voriconazole and other azoles should be avoided during administration of vinca 
alkaloids and high dose methotrexat e. 
 
• Voriconazole  
≥ 1 – 11 years:  7 mg/kg/dose PO BID (rounded up to 50 mg or 
100 mg dose  increments)  
≥ 12 years, <  40 kg: 200 mg PO BID x 1 day then 100 mg PO  BID 
>12 years, ≥  40 kg: 400 mg PO BID x 1 day then 200 mg PO  BID 
• Posaconazole  
Oral suspension 40 mg/mL (recommend adequate oral intake or 
nutritional supplement with at least 14 g of fat and avoid H2 antagonist 
and proton pump inhibitors.  
ALLR18  
Page 43 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 o Participants > 13 years old: 200 mg PO 3 times a day with  meals  
o Participants < 13  years old: dose not established  
Delayed -release tablets (do not cut or crush tablets and may administer 
without regards to meals)  
o Participants ≥ 13 years old: 300 mg PO 2 times a day for 1  day, 
then 300 mg once  daily  
o Participants < 13 years old: dose not established  
 
• Micafungin:  
o < 40 kg: 1 mg/kg/day IV (max 50 mg/day) or per local 
institutional  guidelines  
o 40 kg: 50 mg/day  IV 
• Liposomal amphotericin B IV: 3 -5 mg/kg/day  
• Caspofungin: 1 mg/kg/day IV (max 50 mg/day)  
 
7.5 Prophylaxis for Bacterial Infections  (REQUIRED)  
 
Because patients with relapsed ALL are at high risk for bacterial sepsis, all 
participants on ALLR18 must receive prophylactic antibiotics. Prophylactic 
antibioti cs should be started in induction blocks I, III and re -induction when 
the ANC < 500 or < 1000 and falling or predicted to fall, and continue until 
the ANC > 100 and rising. Antibiotics may be given by the parents or other 
caregivers at home, according to l ocal institutional guidelines. Acceptable 
prophylactic regimens, in order of preference, include the following:  
 
• Levofloxacin 10 mg/kg PO/IV every 12 hours if < 5 years of  every 
24 hours if > 5 years (maximum 500 mg per  dose)  
 
• Vancomycin 400 mg/m2/dose IV every 12 hours (maximum 1 gram 
per dose) plus ciprofloxacin 250 -350 mg/m2/dose PO every 12 hours 
(maximum 500 mg per  dose)  
 
• Cefepime 1500 mg/m2/dose IV every 12 hours (maximum 2  gram 
per dose)  
 
• Vancomycin 400 mg/m2/dose IV every 12 hours (maximum 1  gram 
per dose) plus cefepime 1500 mg/m2/dose IV every 12 hours 
(maximum 2 gram per dose). Note that this regimen is not 
recommended by the PI, but is acceptable if preferred by the local 
institution or treating  physician.  
 
• Please consult with the PI if you wish to use a prophylactic regimen 
other than one listed above. Because local infection rates, organisms, 
and susceptibilities vary, other prophylactic regimens will be 
allowed. However, regimens should be uniform at eac h collaborating  
ALLR18  
Page 44 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 site and data on each regimen will be captured to explore the 
efficacy of each regimen.  
7.6 Management of Febrile  Neutropenia  
 
Episodes of fever and neutropenia should be managed according to institutional 
guidelines. Participants  with fever (defined as a single oral temperature  38.3 C 
(101F) or temperature of  38.0 C (100.4 F) sustained over a one hour period 
and neutropenia (defined as ANC  500 cells/ L) should be given IV antibiotics 
immediately. We recommend the followi ng guidelines:  
 
• Participants who develop fever while receiving prophylactic levofloxacin or 
vancomycin and ciprofloxacin:  
o Begin cefepime (1500 mg/m2/dose IV every 8  hours)  
o Add or increase vancomycin to 400 mg/m2/dose IV every 8  hours  
o Discontinue ciprofloxacin or  levofloxacin  
 
• Participants who develop fever while receiving prophylactic  cefepime:  
o Begin meropenem (20 mg/kg/dose IV every 8  hours)  
o Add vancomycin (400 mg/m2/dose IV every 8 hours) if recent 
history of receiving intensive chem otherapy that produces  substantial 
mucosal  damage  
o Discontinue  cefepime  
 
Participants who have suspected catheter -related infection, have evidence of sepsis 
(including shock, hypotension, rigors, septic emboli, unexplained respiratory 
distress or hypoxemia, or poor peripheral perfusion), or are known to be colonized 
by Pseudomo nas aeruginosa , should also receive tobramycin, 60 mg/m2/dose IV 
every 6 hours.  
 
Participants who have severe abdominal pain or radiographic findings suggesting 
typhlitis, severe abdominal pain with evidence of sepsis, focal findings suggestive 
of intra -abdominal infection on physical examination, or known or suspected 
infection with Bacillus cereus should receive meropenem, 20 mg/kg/dose IV every 
8 hours, instead of cefepime.  
 
7.7 Growth  Factors  
 
Prophylactic use of hematopoietic growth factors (GM -CSF or G -CSF) is not 
recommended. However, GM -CSF (250 µg/m2/day) or G -CSF (5 -10 µg/kg/day) 
may be considered for participants who have life threatening fungal infections or 
bacterial sepsis after discus sion with PI.  
 
7.8 Management of Capillary Leak Syndrome Related to  Clofarabine  
 
In pediatric studies, during or shortly after clofarabine administration a few 
participants developed signs and symptoms consistent with capillary leak  
ALLR18  
Page 45 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 syndrome. In these heavily pretreated participants, it has been difficult to separate 
potential drug -related cases of capillary leak syndrome from concurrent medical 
conditions such as infection/sepsis, progressive disease, or other underlying 
problems resulting from p rior anti -leukemic therapies. For these reasons, during and 
after each dose of clofarabine investigators are to assess participants for the onset of 
the following signs or symptoms  grade 2:  
 
• Tachypnea or other evidence of respiratory  distress;  
• Unexplaine d hypotension;  and/or  
• Unexplained  tachycardia.  
 
If one or more of these signs or symptoms occurs during study drug infusion, 
clofarabine administration is to be interrupted or held as clinically indicated. It is 
recognized that the total infusion time for this clofarabine dose in this circumstance 
may e xceed 1 hour. Thus, if the patient’s condition stabilizes or improves, 
clofarabine administration may resume. Supportive care, strict monitoring of intake 
and output and investigation for other etiologies of the signs and symptoms, such as 
infection/sepsis , must be pursued.  
 
7.9 Etoposide  Reactions  
 
7.9.1 Cardiovascular effects - Transient hypotension has occurred in about 1 to 2  % 
of participants following rapid IV administration of etoposide during clinical trials. 
However, hypotension has not been associated with cardiac toxicity or 
electrocardiogram changes. Blood pressure usually normalizes within a few hours 
after discontinuation of the infusion. To avoid this complication, etoposide should be 
infused over 30 – 60 minutes. If hypotension should occur, stop the i nfusion, and if 
necessary, give 10 mL/kg NS bolus over 15 minutes. Repeat as necessary. Once 
symptoms resolve, resume infusion at ½ the previous infusion rate until the full dose 
administered. If hypotension recurs, stop infusion and administer 10 mL/kg NS  bolus 
as indicated. Once hypotension resolves, resume infusion at ½ previous infusion rate 
until complete. Consider infusing NS at 1 – 1.5 x maintenance during remainder of 
infusion. For all subsequent doses, further dilute and infuse over 2  hours.  
 
7.9.2 Sensitivity reactions - Anaphylactoid reactions consisting principally of 
chills, rigors, diaphoresis, pruritis, loss of consciousness, nausea, vomiting, fever, 
bronchospasm, dyspnea, tachycardia, hypertension, and/or hypotension have 
occurred in 0.7 – 3% of patients receiving etoposide. Other manifestations include 
flushing, rash, substernal chest pain, lacrimations, sneezing, coryza, throat pain, 
back pain, abdominal cramps, and auditory impairment. Facial/lingual swelling, 
coughing, diaphoresis, cyanosis , tightness in the throat, and laryngospasm have  also 
occurred. If an anaphylactoid reaction should  occur:  
 
1. Stop the infusion immediately and notify H/O Fellow or Attending  MD 
2. Administer the following as  indicated:  
a) diphenhydramine 1mg/kg IV (max dose 50  mg) 
ALLR18  
Page 46 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 b) hydrocortisone 50 – 100 mg/m2 IV 
c) epinephrine to be administered according to institutional  policy  
d) fluid bolus 10 mL/kg NS infused over 15  minutes  
3. Once symptoms have resolved, resume infusion at ½ previous rate until 
infusion complete. Consider infusing NS at 1 – 1.5 x maintenance during 
remainder of  infusion.  
4. If anaphylaxis recurs, stop the infusion and re -treat as above. Do  not 
administer remainder  of dose. Consider substituting etoposide with 
etoposide phosphate (Etopophos®) for all subsequent  doses.  
5. If anaphylaxis does not recur, pre -medicate all subsequent doses with 
diphenhydramine 1mg/kg (max 50 mg) and hydrocortisone 50 – 100 mg/m2. 
Consider s lowing the loading dose to be administered over 1  hour.  
6. Have at bedside all of the following for all subsequent  infusions:  
a) Diphenhydramine 1mg/kg IV (max 50  mg) 
b) Hydrocortisone 50 – 100 mg/m2 IV 
c) epinephrine to be administered according to institutional  policy 
 
Please note: anaphylactoid reactions are still possible with etoposide phosphate. If 
the patient cannot tolerate the substitution, drug is contraindicated and must be 
discontinued.  
 
7.10 Drug  Interactions  
 
Because concurrent use of enzyme inducing anticonvulsants (e.g. phenytoin, 
phenobarbital, and carbamazepine) with anti -leukemic therapy has recently been 
associated with inferior EFS, every effort should be made to avoid these agents, as 
well as rifampin, which also induces many drug metabolizing enzymes. Gabapentin 
does not induce hepatic drug metabolizing enzymes and may be a suitable 
alternative anticonvulsant. Azole antifungals (fluconazole, itraconazole, 
voriconazole, and ketoconazole) and the macrolid e group of antibiotics (e.g. 
erythromycin, rifampin, and zithromax) may have potent inhibitory effects on drug - 
metabolizing enzymes, and the doses of some antileukemic drugs (e.g. vincristine, 
anthracyclines, steroids, etoposide) may need to be reduced in  some patients on 
chronic azole antifungals or antibiotics. Consult Pharmacokinetics if long -term use 
of these interacting drugs is unavoidable.  
 
Penicillins interfere with tubular excretion of methotrexate, and it is recommended 
that an alternative non -penicillin antibiotic be used.  
 
Ph+ participants receiving tyrosine kinase inhibitors (e.g. imatinib, dasatinib and 
nilotinib) should not receive drugs known prolong the QT interval and should avoid 
strong CYP3A4 inhibitors. Participants should also avoid fo od 2 hours before and 1 
hour after taking dose.  
 
7.11 Cytokine Release Syndrome Related to Administration of IL -2 and NK 
cells 
ALLR18  
Page 47 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 Cytokine release syndrome is a disorder characterized by nausea, headache, 
tachycardia, hypotension, rash and shortness of breath. It is caused by the release of 
cytokines from the cells. IL -2 will be discontinued for cytokine release syndrome > 
grade 2. Supportive care with IV fluids, correction of hypoalbuminemia with albumin 
infusions and close monitoring should be perfo rmed. In severe cases, corticosteroids 
may be required. Corticosteroids should be avoided (if possible) during the 3 days 
prior to NK cell infusion or during the first 7 days after the infusion.  
 
8.0 DRUG/DEVICE/BIOLOGIC AGENT  INFORMATION  
 
See Appendix III  for information on the individual drugs to be used in this protocol.  
ALLR18  
Page 48 of 67 
St. Jude  
IRB NUMBER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018  IRB Approval date: 06 -13-2018   
  
9.0 REQUIRED EVALUATIONS, TESTS, AND  OBSERVATIONS  
 
Baseline  Induction 
Block I  Induction 
Block II  Induction 
Block III  Interim 
continuation  Re-induction  Continuation  Off therapy  
H&P  X Q 3-7 days  Q 3-7 days  Q 3-7 days  Q week  Q 3-7 days  Q week  X 
CBC with diff  X Q 3-7 days  Q 3-7 days  Q 3-7 days  Q week  Q 3-7 days  Q week  X 
CMP  X Q 3-7 days  Q 3-7 days  Q 3-7 days  As indicated  Q 3-7 days  As indicated  X 
Coagulation screen  X        
Urine analysis  X        
Hepatitis, HIV screen  X        
EBV, CMV, HSV,  
varicella, histoplasma and 
toxoplasma titres   
X        
Bone marrow for 
MRD and mutant cells  X End of block  End of block  End of block  End of block  End of block  Every 16 
weeks  X 
Bone marrow for biology 
studies  X        
#Peripheral blood for 
MRD   Day 6        
#Peripheral blood for 
CD20  X Days 2, 4, 6,  
11, 14 and 21        
Serum for asparaginase 
and anti -asparaginase 
antibodies   
X Days 21 & 35 
(pre-PEG 
each day)    Day 1 of week 
1 Days 6 & 20 
(pre-PEG 
each day)    
*TPMT genotyping   Day 3        
Germline DNA   Day 3  Day 1       
CSF cell count, diff, 
cytology  with each IT  with each IT  with each IT  with each IT  with each IT  with each IT  with each IT  with each IT  
Chest X -ray X        
ECHO/EKG  X       X 
QCT for bone density  X       5 years after completion 
of therapy  
CT scan of involved areas 
(lymphoma pts. only)  X   X (end of 
Block III)     X 
ALLR18  
Page 49 of 67 
St. Jude  
IRB NUMBER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018  IRB Approval date: 06 -13-2018   
  
 Baseline  Induction 
Block I  Induction 
Block II  Induction 
Block III  Interim 
continuation  Re-induction  Continuation  Off therapy  
HLA typing of patient, 
parents and full siblings  X        
KIR genotyping (recipient 
and donor)  X        
NK cell phenotype 
(recipient)  X Day 19        
NK cell phenotype (donors)  X        
NK Chimerism (recipient)   Day 19        
Variable nucleotide tandem 
repeat (recipient and donor)  X        
Pregnancy test, if applicable          
Donor evaluations and 
services as per “NK Donor 
Pre-Evaluations and 
Scheduled Evaluations Prior 
to Cell Collection” standard  
order set   
 
X        
# Peripheral blood MRD and Peripheral blood CD20 evaluations will be discontinued for a patient following a negative MRD resu lt (i.e., less than 0.01%)  
 
*TPMT genotyping will be sent if previous results are not available from frontline therapy  
 
 
Participants with possible allergic reactions to peg -asparaginase should have measurements of anti -asparaginase antibodies and asparaginase at the time of the reaction, and 
again if re -challenged (see Section 6.2)  
 
See Appendix I for listing of standard of  care versus research studies  
ALLR18  
Page 50 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
9.1 Response  Evaluations  
 
Bone marrow aspiration for microscopic evaluation and MRD by flow cytometry 
will be performed at the following time points:  
 
• End of block I of  induction  
• End of block II of  induction  
• End of Block III of  induction  
• End of interim  continuation  
• End of  re-induction  
• Every 16 weeks during  continuation  
• End of  therapy  
• As clinically indicated to plan for transplant or for suspicion of  relapse  
 
9.2 Suggested Long -Term Follow -up Evaluations  
 
The following evaluations are recommended for participants who are off -treatment 
after completion of protocol specified therapy:  
 
• It is r ecommended that participants will be followed every 4 months for 1 year, 
every 6 months for 1 year and then yearly until the patient is in remission for 
10 years and is at least 18 years old. Thereafter, the patient will become alumni 
and will be followed according to the institution’s  policy.  
• During the St. Jude visit, CBC with differential and other laboratory  studies 
as clinically indicated will be  obtained.  
• It is recommended that QCT for bone density be performed at 5 years off - 
therapy.  
• Participants wi ll be considered off therapy 30 days after last treatment 
taken. Adverse events will not be reported while patient is off -therapy 
unless they are unanticipated problems (see Section 12.0) deemed related  to 
therapy by the site  PI. 
• After attaining continuous , complete remission for 5 years or more, SJCRH 
participants will be invited to participate in the long -term follow -up 
umbrella protocol and may be referred to the After Completion of Therapy 
Clinic (ACT). Collaborating sites will follow participants as pe r local 
guidelines.  
• When a SJCRH patient has been in remission for 10 years and is at least  18 
years of age, the patient will become SJCRH alumni and will be followed 
according to the SJCRH institutional  policy.  
 
Note: Participants removed from therapy for other reasons (i.e., relapse, toxicity, 
etc.) before treatment is completed will be followe d for survival only, and 
evaluations will be done as per treating physician’s/institution’s standard practice.  
ALLR18  
Page 51 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
10.0 EVALUATION  CRITERIA  
 
10.1 Response Criteria for  Leukemia  
 
The response after each course of chemotherapy will be determined by the 
examination of the bone marrow. For the purposes of this protocol, MRD -negative 
is defined as < 0.01% blasts with a leukemia associated phenotype detected by 
flow cytometry. Because m orphologic examination of the bone marrow during 
periods of hematopoietic recovery after intensive chemotherapy may be unreliable, 
response will be based on blast percentage by flow cytometry. Blast percentages 
determined by morphology will be used in case s that are not evaluable by flow 
cytometry. If the blast percentage is less than 5% in such cases, they will be 
classified as complete response, MRD not evaluable.  
 
10.1.1  Complete response (CR), MRD -negative  
< 0.01% blasts by flow cytometry  
 
10.1.2  Complete response (C RM), MRD -positive 0.01% to < 5% blasts by flow 
cytometry  
 
10.1.3  Partial response (PR) - A decrease of at least 50% in the percentage  of 
blasts and 5% to 25% blasts by flow  cytometry.  
 
10.1.4  No response (NR) - No change in clinical or laboratory  status.  
 
10.1.5  Progressive disease (PD): Deterioration of initial disease  status  
 
10.1.6  Relapse  
 
• Bone marrow relapse: Subsequent appearance, after achievement  of 
CR, of ≥ 5% blasts in the bone marrow with confirma tion by flow 
cytometry  
• CNS relapse: ≥ 5 WBC/µL of CSF with definite blasts on  cytospin  
• Other extra -medullary relapse: Development of extra -medullary disease 
after achievement of  CR. 
 
10.2 Response Criteria for Lymphoblastic  Lymphoma  
 
10.2.1  Complete response (CR) - No clinical or radiographic evidence of disease 
with M1 marrow (<5% blasts) status and with normal CSF and  hemogram.  
 
10.2.2  Partial response (PR) - defined as >50% but <100% decrease in the sum  of 
the product of the maximum perpendicular  diameter of all lesions and 
decrease in bone marrow involvement by tumor cells by at least  50% 
 
10.2.3  No response (NR) - No change in clinical or laboratory status, response not 
qualifying for PR or Progressive  disease  
ALLR18  
Page 52 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
10.2.4  Progressive Disease (PD) - Worsening of disease, evidenced by >25% 
increase in the size of any lesion, increased organomegaly or appearance  of 
new disease.  
 
10.3 Toxicity Evaluation  Criteria  
 
Common Terminology Criteria for Adverse Events v4 (CTCAE): This study  will 
utilize the CTCAE of the National Cancer Institute (NCI) for toxicity and 
performance reporting. A copy of the current version of the CTCAE can be 
downloaded from the Cancer Therapy Evaluation Program (CTEP) home page 
(http://ctep.info.nih.gov ). Addi tionally, toxicities are to be reported on the 
appropriate data collection screens/forms.  
 
10.4 Acceptable Percentage of Missed Doses for Commercially  Available 
Drugs  
 
It is understood that deviations from the protocol should be avoided, except when 
necessary to eliminate an immediate hazard to a research participant. In such case, 
the deviation must be reported to the IRB. However, it is expected that participants 
will occasionally miss some doses or receive the wrong dose of oral chemotherapy. 
Compliance with oral medication will be captured in the CRIS database and 
appropriately documented in the participants’ medical records. Appropriately 
documented doses of missed o r wrong doses of chemotherapy will not constitute a 
deviation unless the amount in question is over 10% of the expected total dose due 
in the respective protocol cycles (these are specified in the CRIS ALLR18 
database). Missed doses do not include doses he ld or reduced for medical reasons 
(toxicity, illness) and will not be considered protocol deviations or violations.  
 
11.0 OFF THERAPY AND OFF STUDY  CRITERIA  
 
11.1 Off-Study  Criteria  
 
• Death  
• Withdrawal of  consent  
• Found to be ineligible (e.g., incorrect  diagnosis)  
• For St. Jude participants: completion of protocol -required evaluations and 
follow -up period (10 years), then survival outcomes will be followed per 
SJLTFU. For participants from collaborating sites, participants will be 
followed for survival status and relapse  until one of the above criteria are 
met (e.g. death, withdrawal of consent, found to be  ineligible).  
• For donors: 8 days after apheresis, or sooner if he/she is deemed ineligible 
after donor workup.  
ALLR18  
Page 53 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
11.2 Off-Treatment  Criteria  
 
Off-treatment participants will continue to be followed for survival status until an 
off-study criterion is met. The first relapse/progression will be documented and 
grade 3 -4 adverse events will be followed until they have resolved to < grade 2, or 
until the participant receives other anti -leukemia/lymphoma therapy.  
 
• Research participants who fail to achieve complete remission  after 
induction block III of  treatment.  
• Relapse as defined in section  10.1.6.  
• Second malignancy  
• Development of unacceptable toxicity during treatment (with concurrence 
of the  PI) 
• Participant/family decision to withdraw from protocol treatment at any  time 
for any  reason  
• Discretion of the study PI, such as the  following:  
o The researcher decides that con tinuing in the study would be  harmful  
o A treatment is needed that is not allowed on this  study  
o The participant misses so many appointments that the data cannot  be 
used in the  study  
o The participant’s condition gets  worse  
o New information is learned that a better treatment is available, or  that 
the study is not in the participant’s best  interest  
• 30 days after completion of all protocol prescribed treatment, or if 
participant proceeds to transplant, off treatment date will be  defined as  the 
first day of conditioning  therapy.  
 
12.0 SAFETY AND ADVERSE EVENT REPORTING  REQUIREMENTS  
 
12.1 Reporting Adverse Experiences (AEs) and Deaths on Treatment  
 
Only “unanticipated problems involving risks to participants or others” referred to 
hereafter as “unanticipated problems” are required to be reported to the St. Jude 
IRB promptly, but in no event later than 10 working days after the investigator first 
learns of the unanticipated problem. Regardless of whether the event is internal or 
external (for example, an IND safety report by the sponsor pursuant to 21 CFR 
312.32), only adverse events that constitute unanticipated problems are reportable 
to the St. Jude IRB. As further described in the definition of unanticipated 
problem, this includes any event  that in the PI’s opinion  was: 
 
• Unexpected (in terms of nature, severity, or frequency) given (1) the 
research procedures that are described in the protocol -related  documents, 
such as the IRB -approved research protocol and informed consent 
document, as well as other relevant information available about the 
research; (2) the observed rate of occurrence (compared to a  credible  
ALLR18  
Page 54 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
baseline for comparison); an d (3) the characteristics of the subject 
population being studied; and  
• Related or possibly related to participation in the research;  and 
• Serious; or if not serious suggests that the research places subjects or  others 
at a greater risk of harm (including ph ysical, psychological, economic, or 
social harm) than was previously known or  recognized.  
 
Unrelated, expected deaths do not require reporting to the IRB . Though death is 
“serious”, the event must meet the other two requirements of “related or possibly 
related” and “unexpected/unanticipated” to be considered reportable.  
 
Deaths meeting reporting requirements are to be reported immediately to the St.  
Jude IRB, but in no event later than 48 hours after the investigator first learns of  
the death.  
 
The followin g definitions apply with respect to reporting adverse experiences:  
 
Serious Adverse Event : Any adverse event temporally associated with the 
subject’s participation in research that meets any of the following criteria:  
 
• results in  death;  
• is life -threatening (places the subject at immediate risk of death from  the 
event as it  occurred);  
• requires inpatient hospitalization or prolongation of  existing 
hospitalization;  
• results in a persistent or significant  disability/incapacity;  
• results in a co ngenital anomaly/birth defect;  or 
• any other adverse event that, based upon appropriate medical judgment, 
may jeopardize the subject’s health and may require medical or surgical 
intervention to prevent one of the other outcomes listed in this definition 
(examples of such events include: any substantial disruption of the ability 
to conduct normal life functions, allergic bronchospasm requiring  intensive 
treatment in the emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpatient  hospitalization, or the 
development of drug dependency or drug abuse), a congenital 
anomaly/birth defect, secondary or concurrent cancer, medication 
overdose, or is any medical event which requires treatment to prevent any 
of the medical outcomes previous ly listed.  
 
Unexpected Adverse Event : 
 
• Any adverse event for which the specificity or severity is not consistent 
with the protocol -related documents, including the applicable investigator 
brochure, IRB approved consent form, Investigational New Drug (IND) or 
Investigational Device Exemption (IDE) application, or other relevant 
sources of information, such as product labeling and package inserts; or if  it 
ALLR18  
Page 55 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
does appear in such documents, an event in which the specificity, severity 
or duration is not consistent with the risk information included therein; or  
• The observed rate of occurrence is a clinically significant increase in  the 
expected rate (based on a cr edible baseline rate for comparison);  or 
• The occurrence is not consistent with the expected natural progression of 
any underlying disease, disorder, or condition of the subject(s) 
experiencing the adverse event and the subject’s predisposing risk factor 
profile for the adverse  event.  
 
Internal Events : Events experienced by a research participant enrolled at a site 
under the jurisdiction of St. Jude IRB for either multicenter or single -center 
research projects.  
 
External Events : Events experienced by partici pants enrolled at a site external to 
the jurisdiction of the St. Jude Institutional Review Board (IRB) or in a study for 
which St. Jude is not the coordinating center or the IRB of record.  
 
Unanticipated Problem Involving Risks to Subjects or Others : An un anticipated 
problem involving risks to subjects or others is an event which was not expected to 
occur and which increases the degree of risk posed to research participants. Such 
events, in general, meet all of the following criteria:  
 
• unexpected;  
• related o r possibly related to participation in the research;  and 
• suggests that the research places subjects or others at a greater risk of  harm 
(including physical, psychological, economic, or social harm) than was 
previously known or recognized. An unanticipated problem involving risk 
to subjects or others may exist even when actual harm does not occur to 
any participant.  
 
Consistent with FDA and OHRP guidance on reporting unanticipated problems 
and adverse events to IRBs, the St. Jude IRB does not require the submission of  
external events , for example IND safety reports, nor is a summary of such 
events/reports required; how ever, if an event giving rise to an IND safety or other 
external event report constitutes an “unanticipated problem involving risks to 
subjects or others” it must be reported in accordance with this policy. In general, to 
be reportable external events need  to have implications for the conduct of the  study 
(for example, requiring a significant and usually safety -related change in the 
protocol and/or informed consent  form).  
 
Although some adverse events will qualify as unanticipated problems involving 
risks t o subjects or others, some will not; and there may be other unanticipated 
problems that go beyond the definitions of serious and/or unexpected adverse 
events. Examples of unanticipated problems involving risks to subjects or others 
include:  
ALLR18  
Page 56 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
• Improperly staging a participant’s tumor resulting in the participant  being 
assigned to an incorrect arm of the research  study;  
• The theft of a research computer containing confidential  subject 
information (breach of confidentiality);  and 
• The contamination of a study drug. Unanticipated problems generally  will 
warrant consideration of substantive changes in the research protocol or 
informed consent process/document or other corrective actions in order to 
protect the safety, welfare, or righ ts of subjects or  others  
 
12.2 Recording AEs and  SAEs  
 
Adverse events (AEs) will be evaluated and documented by the clinical staff and 
investigators throughout inpatient hospitalizations and each outpatient visit. CRAs 
are responsible for reviewing documentatio n related to AEs and entering directly 
into CRIS protocol -specific database. The data to be recorded are 1) the event 
description, 2) the NCI CTCAE v4.0 code and grade, 3) the onset date, 4) the 
resolution date (or ongoing), 4) action taken for event, 5) p atient outcome 6) 
relationship of AE to protocol treatment/interventions, 7) if AE was expected or 
unexpected, and 8) comments, if applicable. AEs that are classified as serious, 
unexpected, and at least possibly related will be notated as such in the data base as 
“SAEs”. These events will be reported expeditiously to the St. Jude IRB within the 
timeframes as described above.  
 
Cumulative summary of Grades 1 -5 events will be collected in Induction Block I; 
and Grade 3 -5 events will be reported throughout rest of the protocol therapy as 
part of the progress reports to IRB at the time of continuing review. Hematological 
adverse eve nts will not be collected in database. Specific data entry instructions for 
AEs and other protocol -related data will be documented in protocol -specific data 
entry guidelines, which will be developed and maintained by study team and 
clinical research inform atics.  
 
The study team will meet regularly to discuss AEs (and other study progress as 
required by institutional DSMP). The PI will review Adverse Event reports 
generated from the research database, and corrections will be made if applicable. 
Once the info rmation is final the PI will sign and date reports, to acknowledge 
his/her review and approval of the AE as entered in the research database.  
 
12.3 Reporting Requirements to the  FDA  
 
Any unexpected fatal or unexpected life -threatening event judged by the PI to 
possibly be due to the investigational agent, will be reported to the FDA by 
telephone or fax as soon as possible but no later than seven calendar days after 
notification of the event and followed by a written safety report as complete as 
possible within e ight additional calendar days (i.e. full report 15 calendar days 
total after notification of event).  
ALLR18  
Page 57 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
Unexpected, non -fatal and non -life-threatening SAEs, which occur in on -study 
participants during the time periods specified in Section 9.1 t hat are considered due 
to or possibly due to the investigational agent, will be reported to the FDA  
by written safety report as soon as possible but no later than 15 calendar days of 
the notification of the occurrence of the event. Expected SAEs, even unex pected 
fatal SAEs, considered by the PI to be not related to the study, will be reported to 
the FDA in the Annual Review Report along with non -serious AEs. All FDA 
correspondence and reporting will be conducted through the St. Jude Office of 
Regulatory Aff airs. 
 
12.4 Reporting to St. Jude Regulatory Affairs Office  (RAO)  
 
Copies of all correspondence to the St. Jude IRB, including SAE reports, are 
provided to the St. Jude Regulatory Affairs office by the St. Jude study team. 
FDA -related correspondence and reporti ng will be conducted through the 
Regulatory Affairs office.  
 
12.5 Reporting AEs to and from St. Jude and Collaborating  Sites/Affiliates  
 
Adverse events from collaborating sites will also be reviewed by the PI and 
discussed in study team meetings as described above. SAE report from 
collaborating sites for AEs that are serious, unexpected, and at least possibly 
related to protocol treatment o r interventions will be reported to site IRB and the 
St. Jude IRB within the reporting requirements described above. The PI will 
determine if this is an event that will need to be reported expeditiously to all 
participating sites, considering the following  criteria:  
 
• Is the AE serious, unexpected, and related or possibly related to 
participation in the  research?  
• Is the AE expected, but occurring at a significantly higher frequency  or 
severity than  expected?  
• Is this an AE that is unexpected (regardless of se verity that may alter the 
IRB’s analysis of the risk versus potential benefit of the research and, as a 
result, warrant consideration of substantive changes in the research 
protocol or informed consent process/document?  
 
With the submission of the “Reporta ble Event” in St. Jude TRACKS application, 
the PI will indicate if all sites should be notified to report to their IRBs, and if the 
protocol and/or consent should be amended (consent will be amended if event is 
information that should be communicated to cu rrently enrolled subjects).  
Generally, only events that warrant an amendment to the protocol and/or consent 
will be reported expeditiously to all sites. However, any event may be reported 
expeditiously to all sites at the discretion of the PI.  
 
A cumulativ e summary of Grades 1 -5 adverse events that occur during Block I, 
Grade 3 -5 AEs adverse events during remainder of protocol therapy, and 
expected/unrelated deaths that occur more than 30 days off last protocol treatment  
ALLR18  
Page 58 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
will be reported to all sites with study progress report at the time of continuing 
review.  
For collaborating sites : Serious AND unexpected events are to be reported to the 
St. Jude PI (Dr. Sima Jeha) within 48 -72 hours via fax or email.  
 
Unexpected deaths must be reported to the St. Jude PI via phone call or email 
within 24 hours of the event. A written report must fo llow.  
 
All correspondence and reports must also be sent by email to ALLR18 study team . 
 
Sima Jeha, MD 
Department of Oncology  
Leukemia/Lymphoma Division  
St. Jude Children’s Research Hospital 
262 Danny Thomas Place  
Memphis, TN 38105 
Phone:  
FAX:  
 
Email:  
Email: 
 
13.0 DATA COLLECTION, MONITORING AND  CONFIDENTIALITY  
 
13.1 Data  Collection  
 
Electronic case report forms (e -CRFs) will be completed by the SJCRH 
Leukemia/Lymphoma CRAs. Data will be entered from record directly into a 
secure CRIS database, developed and maintained by St. Jude Clinical Research 
Informatics.  
 
Data Management will be  supervised by the Director of Clinical Trials 
Management, and Manager of Clinical Research Operations for the 
Leukemia/Lymphoma Division, working with Dr. Jeha or her designee. All 
protocol -specific data and all grade 3 -5 adverse events will be recorded b y the 
clinical research associates into the CRIS database, ideally within 2 -4 weeks of 
completion of study phase. All questions will be directed to the attending physician 
and/or PI and reviewed at regularly -scheduled working meetings. The attending 
physic ians (or their designees) are responsible for keeping up -to-date roadmaps in 
the patient’s primary SJCRH medical chart.  
 
Regular (at least monthly) summaries of toxicity and protocol events will be 
generated for the PI and the department of Biostatistics t o review  
 
13.2 Data Collection Instructions for Collaborating  Sites  
ALLR18  
Page 59 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
Collaborating sites will collect abstract data from medical records and submit by 
using e -CRFs via remote electronic data entry. All protocol -specific data and all 
grade 3 -5 adve rse events will be recorded by the clinical research associates into 
the CRIS database, ideally within 2 -4 weeks of completion of study phase.  
13.3 Study Monitoring  
 
This study is considered high risk (HR -3) for monitoring purposes. Protocol and 
regulatory comp liance, including essential regulatory documentation, will be 
assessed as well as the accuracy and completeness of all data points relating to the 
primary and secondary objectives semi -annually. If the study design has strata, 
accrual will be tracked conti nuously. The first two enrollees will be monitored and 
15% of the study enrollees thereafter, semi -annually.  
 
The PI and study team are responsible for protocol and regulatory compliance, and 
for data accuracy and completeness. The study team will meet at appropriate 
intervals to review case histories or quality summaries on participants and retain 
copies of the m inutes that are signed by the PI.  
 
The Eligibility Coordinators in the Central Protocol and Data Monitoring Office 
(CPDMO) will verify informed consent documentation and eligibility status on 
100% of St. Jude participants within 5 working days of enrollmen t completion.  
 
The Clinical Research Monitor (CRM) will verify informed consent documentation 
and eligibility status of all non -St. Jude participants and perform a quality 
verification of select St. Jude participants during routine monitoring intervals (ev ery 
6 months). Overall study conduct, compliance with primary and secondary 
objectives, age of majority consenting, safety assessments and reporting, and the 
timeliness and accuracy of database entries are monitored routinely.  
 
Study documents routinely mo nitored on selected participants include medical 
records, database entries, study worksheets, and case report forms. Study 
documents are monitored for participant status, demographics, staging, subgroup 
assignment, treatments, investigational drug accounta bility, evaluations, responses, 
participant protocol status, off -study and off -therapy criteria, and for all other 
specifics as detailed in a separate study -specific monitoring plan. The study - 
specific monitoring plan may be revised over time, to adapt mo nitoring frequency 
and/ or intensity to a changing environment when appropriate (for example: new 
safety signals; positive history of compliance; all participants are in long term 
follow -up; or the enrollment period has ended).  
 
The recording and reporting  of Adverse Events, Serious Adverse Events (SAEs), 
and Unanticipated Problems (UPs) to include type, grade, attribution, duration, 
timeliness and appropriateness will be reviewed by the Monitor/ CRM. The CRM 
will generate a formal report which is shared wi th the Principal Investigator (PI), 
study team and the Internal Monitoring Committee (IMC).  
ALLR18  
Page 60 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
Continuing reviews by the Internal Review Board (IRB) and Clinical Trials - 
Scientific Review Committee (CT -SRC) will occur at least annually. In addition, 
unanticipated problems are reviewed in a timely manner by the IRB.  
 
St. Jude affiliates and domestic collaborating study sites will be monitored on -site 
by a representative of St. Jude as needed.  
13.4 Confidentiality  
 
Study numbers will be used in place of an identifier such as a medical record 
number. No research participant names will be recorded on the data collection 
forms. The list containing the study number and the medical record number will be 
maintained in a lo cked file and will be destroyed after all data have been analyzed. 
The medical records of study participants may be reviewed by the St. Jude IRB, 
FDA, and St. Jude clinical research monitors.  
 
14.0 STATISTICAL  CONSIDERATIONS  
 
14.1 Accrual  
 
The institutional trial A LLR17 has been activated for 7 years and enrolled 41 
participants thus far. The first 6 participants were considered not evaluable due to an 
amendment to ALLR17. The previous trial ALLR16 opened in January 1997 and 
closed to accrual in September 2003 with 40 evaluable participants enrolled. Thus 
historically there would be on average 5 to 6 participants enrolled per year in our 
institution. Thus, at the institution’s historical rate, we expect 7 to 8 years accrual 
time for the desired sample size of 40. The  ALLR18 trial will be a multi -institution 
study and it is predicted that the accrual rate will be higher, at approximately 10 
evaluable participants per year. Assuming this rate, we expect to accrue 40 evaluable 
participants in approximately 4 years for th e primary objective.  
 
Update amendment 2.0 : The first 5 patients were enrolled in a staggered manner 
(until completion of Block I) due to FDA stipulations to ensure safety of the 
experimental regimen. As a consequence, enrollment was slow for the first 2 y ears 
until the restricted enrollment period was completed on 7/28/14. Therefore, we will 
extend the accrual of the trial by 2 years (i.e., we expect to accrue 40 evaluable 
patients in approximately 6 years for the primary objective).  
 
14.2 Monitoring of Inducti on Toxicities and Short -Term  Efficacy  
 
The chemotherapy in the remission induction phase of this protocol is more 
intensive than the previous trials. We will closely monitor grade 4 or higher 
infections and toxic deaths during remission induction.  
 
Grade 4  infection or higher: The rate of grade 4 or higher infection during 
Induction of ALLR16 and R17 is 15% and 17.6% respectively. The following 
group sequential rule will be in place to monitor if there is sufficient evidence that 
the true probability of gra de 4 or higher infection is higher than 20%.  
ALLR18  
Page 61 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
Number of participants completing 
Induction  Suspend trial if # Gr 4 Infection >= 
or toxic death during Block I  
10 5 
20 8 
30 11 
Based on the Binomial distribution, the overall significance level is less than 0.091 
based on the inclusion -exclusion formula, and the statistical power to stop the trial at 
each look is 0.49, 0.74, and 0.86, respectively if the true probability is 45%.  
 
Toxic deaths during Induction Block I. All toxic deaths (not related to 
progressive disease) during Induction will be monitored closely. In ALLR16 and 
ALLR17, all disease -unrelated deaths were toxic deaths: 2/40 on ALLR16 and 
2/39 on ALLR17. Thus, on ALLR1 8, we will not tolerate more than 3 toxic deaths 
in the first block of induction therapy. If, at any time, the third toxic death occurs 
during the first block of induction, we will suspend the trial and re -evaluate the 
safety of the therapy.  
 
One-year even t-free survival: The 1 -year EFS rate of ALLR16 and R17 is about 
50%. For monitoring purpose failures we will exactly include death, failure to 
attain CR, relapse, second malignancy, excessive toxicity resulting in cessation of 
ALLR18 treatment, and lost to  follow -up (but we fully expect to follow every 
patient for at least one year). The following binomial based group sequential rule 
will be in place to monitor if there is sufficient evidence that the true 1 -year failure 
rate is higher than 55%.  
 
Number of participants completing 
one-year Tx  Suspend trial if # failures >=  
15 10 
30 20 
 
Based on the binomial distribution, only when the number of failures greater than 
or equal to 12 and 22 at each look respectively can the overall significance level be 
controlled below 0.075, but these numbers are too high to be clinically acceptable. 
We t hus set the boundary at 10 and 20. Based on the binomial distribution, if the 
probability of failure at one year is 0.7 (i.e. 0.2 higher than the historical 0.5 and  
0.15 higher than the monitoring target of 0.55), then the stopping boundary gives 
the proba bility to stop at the first look 0.73 and at the second look 0.72. [Note that 
based on the binomial distribution, only when the number of failures is greater 
than or equal to 12 and 22 at each look respectively can the overall type -I error 
(i.e., erroneous ly stop when the true 1 -year failure rate is in fact 0.5) probability be 
controlled below 0.075, but these numbers are too high to be clinically acceptable. 
We thus set the boundary at 10 and  20.] 
 
14.3 Primary  Objective  
ALLR18  
Page 62 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
To estimate the 3 -year su rvival rate of participants with 1st relapse or primary 
refractory precursor B -cell ALL treated with risk -directed therapy  
 
Analysis and power: This is a phase -II clinical trial. The outcome will be analyzed 
in terms of overall survival (OS) since diagnos is of first relapse. Only death will be 
considered a failure for OS. Event -free survival (EFS) will also be estimated. For 
EFS, relapse and second malignancies will be considered as failures in addition to 
death in complete remission. The time to EFS will be set to 0 for participants who 
fail to achieve complete remission. Kaplan -Meier estimates of the OS and EFS 
functions will be computed, along with estimates of standard errors by the method of 
Peto. Three -year OS and EFS rates, as well as longer term sur vival rates (5 year and 
10 year) will be estimated with 95% confidence intervals.  
 
Additionally, EFS and OS will be estimated separately in two strata: participants 
with prior bone marrow transplant (BMT) and those never had any BMT because it 
is expected  that participants with prior BMT may have worse survival. The follow - 
up time on each participant will be three years since enrollment.  
 
Kaplan -Meier estimates of EFS and OS in R16 and R17 are shown below:  
 

ALLR18  
Page 63 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
 
 
The objective here is estimation instead of comparison. Comparisons to historical 
controls are considered exploratory. With the sample size n=40, the statistical 
power will be limited. Analysis will begin after 3 years of follow -up since the on - 
study date  of the last enrolled patient.  
 
14.4 Secondary  Objectives  
 
1) To determine minimal residual disease (MRD) levels at the end of  remission 
induction therapy and compare with  ALLR17.  
 
Probability (proportion) of positive MRD will be compared with that from the 
ALLR17 trial using Fisher’s exact test. MRD will also be put into ordered 
categories such as negative (<0.01%), low (0.01% - 1%) and high (>=1%) and 
compared with those in ALLR17 using exact Chi -square test. We are aware that 
the power is limited given the small sample size, unless the true difference is 
unusually large. Analysis will begin no later than 1 year after the last enrollment.  
 
2) To estimate levels of CD20 expression at ba seline, during treatment with 
dexamethasone -containing chemotherapy and following rituximab treatment in week 
1 of Block I of remission induction therapy for relapsed precursor B -cell ALL 
 
Mean and median of CD20 expression levels will be computed at each time point 
along with 95% confidence intervals. Trajectory of CD20 levels as a function of 
time will be modeled and predicted using a longitudinal data model, with time (and 
possibly other clinical and demographic variables) and an intra -patient random 
effect as factors; this analysis is considered exploratory. Analysis will begin no 
later than 1 year after the last enrollment.  

ALLR18  
Page 64 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
14.5 Exploratory  Objectives  
 
1) To assess donor NK cell killer immunoglobulin -like receptor (KIR) repertoire 
and explore the efficacy of NK cell infusions followed by rituximab in relapsed  ALL.  
 
The donor KIR repertoire will be described by summary statistics (counts and 
proportions). Th ree and five year EFS of participants who received NK cell 
infusion will be estimated by the KM estimator along with 95% confidence 
intervals. Analysis will begin no later than 1 year after the last enrollment.  
 
2) To study whether pre -existing or emerging de velopment of serum antibodies  to 
asparaginase is related to hypersensitivity reactions or exposure to asparaginase 
or to anti -leukemic or adverse effects of therapy, in participants with relapsed 
ALL.  
 
Due to heterogeneity among participants and prior ther apy, we will use exploratory 
analytic tools to assess whether anti -asparaginase antibodies are related to clinical 
hypersensitivity reactions. Analysis will begin no later than 1 year after the last 
enrollment.  
 
3) To describe the effect of prophylactic antib iotics on the evolution of  antibiotic 
resistance in peri -rectal swab isolates of Escherichia coli, Klebsiella pneumonia, 
Pseudomonas aeruginosa, Streptococcus mitis and enterococci and resistance 
patterns of bacterial isolates from all sterile site culture s (completed with 
amendment  3.0) 
 
Resistance of selected colonizing and invasive organisms to representative 
antibiotics from various classes (ex. Cephalosporins, carbapenems, 
fluoroquinolones) will be described pre and post antibiotic prophylaxis at basel ine 
(pre-antibiotic prophylaxis) and post -antibiotic prophylaxis at any time point for 
the entire study population and separately based on type of antibiotic prophylaxis 
the patients received. All suspected or proven infections which occur while a 
patient is on antibiotic prophylaxis as well as C. difficle infections during and up to 
one month post antibiotic prophylaxis will be described.  
 
Analysis will begin no later than 1 year after the last enrollment.  
 
4) To characterize global gene expression and copy number changes in  leukemic 
cells at relapse and to compare to initial diagnosis (when available) to improve 
knowledge of mechanisms of  relapse  
 
The analyses will be performed using established methods.17-19 Analysis will begin 
no later than in 1 year after the last enrollment.  
 
5) To determine in vitro sensitivity of pretreatment relapsed leukemic cells  to 
anti-leukemic agents and compare to in vitro sensitivity at diagnosis (when 
available)  
ALLR18  
Page 65 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
Desc riptive statistics of sensitivity such as IC50 will be calculated. Analysis will 
begin no later than 1 year after the last enrollment.  
 
6) To engraft freshly harvested relapsed ALL cells into murine models of ALL  to 
gain insights into therapy  resistance  
After  engraftment, various downstream analyses will be done on the leukemic cells 
including immunophenotype, histologic and genomic studies. Analysis will begin 
no later than 1 year after the last enrollment.  
 
8) To study the development of resistant clones dur ing therapy for relapsed ALL.  
 
NT5C2 mutation detection will be performed by targeted re -sequencing using next 
generation platforms. We plan to sequence NT5C2 coding regions on the Mi -seq 
platform, but are mindful of continuing evolvement of sequencing technologies to 
adopt the most cost -effective and efficient platforms for this study, with the help 
from Hartwell Center and PCGP. Analysis will begin no later than 1 year after the 
last enrollment.  
 
15.0 OBTAINING INFORMED  CONSENT  
 
15.1 Consent/Assent at  Enrollment  
 
The process of informed consent for AL LR18 will follow institutional policy. The 
informed consent process is an ongoing one that begins at the time of diagnosis and 
ends after the completion of therapy. Informed consent should be obtained by the 
attending physician or his/her designee, in the presence of at least one non -physician 
witness. Initially, informed consent will be sought for the institutional banking 
protocol (research study), blood transfusion and other procedures as necessary. After 
the diagnosis of relapse ALL is established, we w ill invite the patient to participate 
in the ALLR18 protocol. Consent/assent for initial enrollments will be done at St.  
Jude for all participants (including NK cell donors).  
 
Throughout the entire treatment period, participants and their parents receive 
constant education from health professionals at SJCRH and collaborating sites, and 
are encouraged to ask questions regarding alternatives and therapy. All families 
have ready access to chaplains, psychologists, social workers, and the St. Jude 
ombudsperson for support, in addition to that provided by the primary physician 
and other clinicians involved in their care.  
 
We will also obtain verbal assent from children 7 to 14 years old and written assent 
for all participants >14 years of age. Participants who re ach the age of majority 
while on study will be re -consented for continued participation on ALLR18, 
according to Cancer Center and institutional policy.  
ALLR18  
Page 66 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
15.2 Consent at Age of  Majority  
 
The age of majority in the state of Tennessee is 18 years old. Research participants 
must be consented at the next clinic visit after their 18th birthday. If an affiliate or 
collaborating site is located in a country or state where a different age of major ity 
applies, that location must consent the participants according to their local laws.  
 
15.3 Consent When English is Not the Primary  Language  
 
When English is not the patient, parent, or legally authorized representative’s 
primary language, the Social Work department will determine the need for an 
interpreter. This information documented in the participant’s medical record. 
Either a certified int erpreter or the telephone interpreter’s service will be used to 
translate the consent information. The process for obtaining an interpreter and for 
the appropriate use of an interpreter is outlined on the Interpreter Services, OHSP, 
and CPDMO websites.  
 
Collaborating Sites will follow institutional policy for consenting non -English 
speaking participants (and will provide institutional policy to St. Jude).  
ALLR18  
Page 67 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
16.0 REFERENCES  
 
1. Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic  leukemia 
without cranial irradiation. N Engl J Med 360:2730 -41, 2009  
2. Bailey LC, Lange BJ, Rheingold SR, et al: Bone -marrow relapse in paediatric  acute 
lymphoblastic leukaemia. Lancet Oncol 9:873 -83, 2008  
3. Ko RH, Ji L, Barnette P, et al: Outcome of patients treated for relapsed or refractory 
acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia 
Consortium study. J Clin Oncol 28:648 -54, 2009  
4. Campana D: Minimal residual disease in acute lymphoblastic l eukemia. Hematology 
Am Soc Hematol Educ Program 2010:7 -12, 2010  
5. Raetz EA, Borowitz MJ, Devidas M, et al: Reinduction platform for children with  first 
marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group 
Study[corrected]. J Clin Oncol  26:3971 -8, 2008  
6. Giulino LB, Bussel JB, Neufeld EJ, et al: Treatment with rituximab in benign and 
malignant hematologic disorders in children. J Pediatr 150:338 -44, 344 e1,  2007  
7. Griffin TC, Weitzman S, Weinstein H, et al: A study of rituximab and ifosfamid e, 
carboplatin, and etoposide chemotherapy in children with recurrent/refractory B -cell 
(CD20+) non -Hodgkin lymphoma and mature B -cell acute lymphoblastic leukemia:  a 
report from the Children's Oncology Group. Pediatr Blood Cancer 52:177 -81, 2009  
8. Meinhardt  A, Burkhardt B, Zimmermann M, et al: Phase II window study on 
rituximab in newly diagnosed pediatric mature B -cell non -Hodgkin's lymphoma  and 
Burkitt leukemia. J Clin Oncol 28:3115 -21, 2010  
9. Weiner GJ: Rituximab: mechanism of action. Semin Hematol 47:115 -23, 2010  
10. Thomas DA, O'Brien S, Faderl S, et al: Chemoimmunotherapy with a modified hyper - 
CVAD and rituximab regimen improves outcome in de novo Philadelphia 
chromosome -negative precursor B -lineage acute lymphoblastic leukemia. J Clin  Oncol 
28:3880 -9, 2010  
11. Dworzak MN, Schumich A, Printz D, et al: CD20 up -regulation in pediatric B -cell 
precursor acute lymphoblastic leukemia during induction treatment: setting the  stage 
for anti -CD20 directed immunotherapy. Blood 112:3982 -8, 2008  
12. Jeha S, Gandhi V, Chan KW, et al: Clofarabine, a novel nucleoside analog, is active  in 
pediatric patients with advanced leukemia. Blood 103:784 -9, 2004  
13. Pui CH, Jeha S: Clofarabine. Nat Rev Drug Discov Suppl:S12 -3, 2005  
14. Genini D, Adachi S, Chao Q, et al: Deoxyadenosine analogs induce programmed  cell 
death in chronic lymphocytic leukemia cells by damaging the DNA and by directly 
affecting the mitochondria. Blood 96:3537 -43, 2000  
15. Jeha S, Gaynon PS, Razzouk BI, et al: Phase I I study of clofarabine in  pediatric 
patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 
24:1917 -23, 2006  
16. Yamauchi T, Nowak BJ, Keating MJ, et al: DNA repair initiated in chronic 
lymphocytic leukemia lymphocytes by 4 -hydroperoxyc yclophosphamide is inhibited 
by fludarabine and clofarabine. Clin Cancer Res 7:3580 -9, 2001  
17. Hijiya N, Gaynon P, Barry E, et al: A multi -center phase I study of clofarabine, 
etoposide and cyclophosphamide in combination in pediatric patients with  refractory  
or relapsed acute leukemia. Leukemia 23:2259 -64, 2009  
ALLR18  
Page 68 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
18. Locatelli F, Testi AM, Bernardo ME, et al: Clofarabine, cyclophosphamide and 
etoposide as single -course re -induction therapy for children with refractory/multiple 
relapsed acute lymphobl astic leukaemia. Br J Haematol 147:371 -8, 2009  
19. O'Connor D, Sibson K, Caswell M, et al: Early UK experience in the use of 
clofarabine in the treatment of relapsed and refractory paediatric acute  lymphoblastic 
leukaemia. Br J Haematol,  2011  
20. Inaba H, Bhojwani  D, Pauley JL, et al: Combination chemotherapy with clofarabine, 
cyclophosphamide, and etoposide in children with refractory or relapsed 
haematological malignancies. Br J Haematol, 2011  
21. Ravetch JV, Kinet JP: Fc receptors. Annu Rev Immunol 9:457 -92, 1991  
22. Iyengar R, Handgretinger R, Babarin -Dorner A, et al: Purification of human  natural 
killer cells using a clinical -scale immunomagnetic method. Cytotherapy 5:479 -84, 
2003  
23. Leung W, Iyengar R, Leimig T, et al: Phenotype and function of human natural  killer 
cells purified by using a clinical -scale immunomagnetic method. Cancer Immunol 
Immunother 54:389 -94, 2005  
24. Rubnitz JE, Inaba H, Ribeiro RC, et al: NKAML: a pilot study to determine the  safety 
and feasibility of haploidentical natural killer cell transplantation in childhood acute 
myeloid leukemia. J Clin Oncol 28:955 -9, 2010  
25. Leung W, Handgretinger R, Iyengar R, et al: Inhibitory KIR -HLA receptor -ligand 
mismatch in autologous haematopoiet ic stem cell transplantation for solid tumour  and 
lymphoma. Br J Cancer 97:539 -42, 2007  
26. Lowe EJ, Turner V, Handgretinger R, et al: T -cell alloreactivity dominates natural 
killer cell alloreactivity in minimally T -cell-depleted HLA -non-identical paediatric 
bone marrow transplantation. Br J Haematol 123:323 -6, 2003  
27. Perez -Martinez A, Iyengar R, Gan K, et al: Blood dendritic cells suppress NK  cell 
function and increase the risk of leukemia relapse after hematopoietic cell 
transplantation. Biol Blood Marrow Tran splant 17:598 -607, 2011  
28. Gasser S, Orsulic S, Brown EJ, et al: The DNA damage pathway regulates  innate 
immune system ligands of the NKG2D receptor. Nature 436:1186 -90, 2005  
29. Leung W, Iyengar R, Triplett B, et al: Comparison of killer Ig -like receptor 
genotyping and phenotyping for selection of allogeneic blood stem cell donors.  J 
Immunol 174:6540 -5, 2005  
30. Bari R, Bell T, Leung WH, et al: Significant functional heterogeneity amon g 
KIR2DL1 alleles and a pivotal role of arginine 245. Blood 114:5182 -90, 2009  
31. Leung W, Iyengar R, Turner V, et al: Determinants of antileukemia effects  of 
allogeneic NK cells. J Immunol 172:644 -50, 2004  
32. Burton NK, Barnett MJ, Aherne GW, et al: The effect o f food on the oral 
administration of 6 -mercaptopurine. Cancer Chemother Pharmacol 18:90 -1, 1986  
33. Lafolie P, Bjork O, Hayder S, et al: Variability of 6 -mercaptopurine  pharmacokinetics 
during oral maintenance therapy of children with acute leukemia. Med Oncol  Tumor 
Pharmacother 6:259 -65, 1989  
34. Lonnerholm G, Kreuger A, Lindstrom B, et al: Oral mercaptopurine in childhood 
leukemia: influence of food intake on bioavailability. Pediatr Hematol Oncol 6:105 - 
12, 1989  
ALLR18  
Page 69 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
35. Riccardi R, Balis FM, Ferrara P, et al: Influence of food intake on bioavailability of 
oral 6 -mercaptopurine in children with acute lymphoblastic leukemia. Pediatr  Hematol 
Oncol 3:319 -24, 1986  
36. Rivard GE, Infante -Rivard C, Hoyoux C, et al: Maintenance chemothe rapy for 
childhood acute lymphoblastic leukaemia: better in the evening. Lancet 2:1264 -6, 
1985  
37. Schmiegelow K, Glomstein A, Kristinsson J, et al: Impact of morning versus evening 
schedule for oral methotrexate and 6 -mercaptopurine on relapse risk for childr en with 
acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and  Oncology 
(NOPHO). J Pediatr Hematol Oncol 19:102 -9, 1997  
38. Lindsey Hageman WL YCHKK, N; Evans, WE; Bostrom, B; Casillas, J; Dickens,  D; 
Angiolillo, A; Lew, G; Maloney, K; Masca renhas, L; Ritchey, A; Termuhlen, A; 
Carroll, WL; Relling, MV; Wong, FL; Bhatia, S: 369 impact of 6 mercaptopurine 
(6MP) pill -taking habits on adherence, thioguanine nucleotide (TGN) levels and 
relapse risk in children with acute lymphoblastic leukemia (AL L): results from a 
Children's Oncology Group (COG) study (AALL03N1), ASH,  2014  
39. Arico M, Baruchel A, Bertrand Y, et al: The seventh international childhood  acute 
lymphoblastic leukemia workshop report: Palermo, Italy, January 29 --30, 2005. 
Leukemia 19:1145 -52, 2005  
40. Clemmensen KK, Christensen RH, Shabaneh DN, et al: The circadian schedule for 
childhood acute lymphoblastic leukemia maintenance therapy does not influence 
event -free survival in the NOPHO ALL92 protocol. Pediatr Blood Cancer 61:653 -8, 
2014  
41. Creutz ig U, Ritter J, Zimmermann M, et al: Improved treatment results in high -risk 
pediatric acute myeloid leukemia patients after intensification with high -dose 
cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia -Berlin - 
Frankfurt -Munster 93. J  Clin Oncol 19:2705 -13, 2001  
42. Wells RJ, Adams MT, Alonzo TA, et al: Mitoxantrone and cytarabine induction, high - 
dose cytarabine, and etoposide intensification for pediatric patients with relapsed or 
refractory acute myeloid leukemia: Children's Cancer Grou p Study 2951. J Clin Oncol 
21:2940 -7, 2003  
43. Parker C, Waters R, Leighton C, et al: Effect of mitoxantrone on outcome of  children 
with first relapse of acute lymphoblastic leukaemia (ALL R3): an open -label 
randomised trial. Lancet 376:2009 -17, 2010  
44. Hongo T, Yajima S, Sakurai M, et al: In vitro drug sensitivity testing can predict 
induction failure and early relapse of childhood acute lymphoblastic leukemia.  Blood 
89:2959 -65, 1997  
45. Coustan -Smith E, Gajjar A, Hijiya N, et al: Clinical significance of minim al residual 
disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 
18:499 -504, 2004  
46. Bader P, Kreyenberg H, Henze GH, et al: Prognostic value of minimal residual  disease 
quantification before allogeneic stem -cell transplantation in relapsed childhood acute 
lymphoblastic leukemia: the ALL -REZ BFM Study Group. J Clin Oncol 27:377 -84, 
2009  
47. Moretta A, Bottino C, Mingari MC, et al: What is a natural killer cell? Nat  Immunol 
3:6-8, 2002  
ALLR18  
Page 70 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
48. Long EO: Regulation of immune responses through inhibitory receptors. Annu  Rev 
Immunol 17:875 -904, 1999  
49. Ruggeri L, Capanni M, Casucci M, et al: Role  of natural killer cell alloreactivity  in 
HLA -mismatched hematopoietic stem cell transplantation. Blood 94:333 -9, 1999  
50. Giebel S, Locatelli F, Lamparelli T, et al: Survival advantage with KIR ligand 
incompatibility in hematopoietic stem cell transplantation  from unrelated  donors. 
Blood 102:814 -9, 2003  
51. Davies SM, Ruggieri L, DeFor T, et al: Evaluation of KIR ligand incompatibility  in 
mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin -like 
receptor. Blood 100:3825 -7, 2002  
52. Hak LJ, Relli ng MV, Cheng C, et al: Asparaginase pharmacodynamics differ by 
formulation among children with newly diagnosed acute lymphoblastic  leukemia. 
Leukemia 18:1072 -7, 2004  
53. Hammond SP, Baden LR: Antibiotic prophylaxis for patients with acute  leukemia. 
Leuk Lympho ma 49:183 -93, 2008  
54. Schimpff SC, Young VM, Greene WH, et al: Origin of infection in acute 
nonlymphocytic leukemia. Significance of hospital acquisition of potential  pathogens. 
Ann Intern Med 77:707 -14, 1972  
55. Tancrede CH, Andremont AO: Bacterial translocation  and gram -negative bacteremia 
in patients with hematological malignancies. J Infect Dis 152:99 -103, 1985  
56. Wingard JR, Dick J, Charache P, et al: Antibiotic -resistant bacteria in surveillance 
stool cultures of patients with prolonged neutropenia. Antimicrob Agents  Chemother 
30:435 -9, 1986  
57. Bhojwani D, Kang H, Moskowitz NP, et al: Biologic pathways associated wit h relapse 
in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.  Blood 
108:711 -7, 2006  
58. Mulli ghan CG, Phillips LA, Su X, et al: Genomic analysis of the clonal origins  of 
relapsed acute lymphoblastic leukemia. Science 322:1377 -80, 2008  
59. Mullighan CG, Zhang J, Kasper LH, et al: CREBBP mutations in relapsed  acute 
lymphoblastic leukaemia. Nature 471:23 5-9, 2011  
60. Yang JJ, Bhojwani D, Yang W, et al: Genome -wide copy number profiling  reveals 
molecular evolution from diagnosis to relapse in childhood acute lymphoblastic 
leukemia. Blood 112:4178 -83, 2008  
61. Harvey RC, Mullighan CG, Chen IM, et al: Rearrangement of CRLF2 is associated 
with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and  a 
poor outcome in pediatric B -progenitor acute lymphoblastic leukemia. Blood 
115:5312 -21, 2010  
62. Notta F, Mullighan CG, Wang JC, et al: Evolution of huma n BCR -ABL1 
lymphoblastic leukaemia -initiating cells. Nature 469:362 -7, 2011  
63. Mullighan CG, Collins -Underwood JR, Phillips LA, et al: Rearrangement of  CRLF2 
in B-progenitor - and Down syndrome -associated acute lymphoblastic leukemia. Nat 
Genet 41:1243 -6, 2009  
64. Mullighan CG, Zhang J, Harvey RC, et al: JAK mutations in high -risk childhood acute 
lymphoblastic leukemia. Proc Natl Acad Sci U S A 106:9414 -8, 2009  
65. Kaspers GJ, Veerman AJ, Pieters R, et al: In vitro cellular drug resistance and 
prognosis in newly diagno sed childhood acute lymphoblastic leukemia. Blood 
90:2723 -9, 1997  
ALLR18  
Page 71 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
66. Hollem an A, Cheok MH, den Boer ML, et al: Gene -expression patterns in drug - 
resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J  Med 
351:533 -42, 2004  
67. Lugthart S, Cheok MH, den Boer ML, et al: Identification of genes associated  with 
chemotherapy crossresistance and treatment response in childhood acute 
lymphoblastic leukemia. Cancer Cell 7:375 -86, 2005  
68. Klumper E, Pieters R, Veerman AJ, et al: In vitro cellular drug resistance in children 
with relapsed/refractory acute lymphoblastic leuk emia. Blood 86:3861 -8, 1995  
69. Clappier E, Gerby B, Sigaux F, et al: Clonal selection in xenografted human T cell 
acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp  Med 
208:653 -61, 2011  
70. Anderson K, Lutz C, van Delft FW, et al: Gen etic variegation of clonal  architecture 
and propagating cells in leukaemia. Nature 469:356 -61, 2011  
71. Meyer JA, Wang J, Hogan LE, et al: Relapse -specific mutations in NT5C2 in 
childhood acute lymphoblastic leukemia. Nat Genet 45:290 -4, 2013  
72. Tzoneva G, Perez -Garcia A, Carpenter Z, et al: Activating mutations in the NT5C2 
nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 19:368 - 
71, 2013  
73. Schultz KR, Bowman WP, Aledo A, et al: Improved early event -free survival with 
imatinib in Philadelphia chromosome -positive acute lymphoblastic leukemia: a 
children's oncology group study. J Clin Oncol 2 7:5175 -81, 2009  
74. Pfeifer H, Wassmann B, Pavlova A, et al: Kinase domain mutations of BCR -ABL 
frequently precede imatinib -based therapy and give rise to relapse in patients with de 
novo Philadelphia -positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110: 727- 
34, 2007  
75. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of childhood 
acute lymphoblastic leukaemia with poor treatment outcome: a genome -wide 
classification study. Lancet Oncol 10:125 -34, 2009  
76. Roberts KG, Morin RD, Zhang J, et al: Ge netic alterations activating kinase and 
cytokine receptor signaling in high -risk acute lymphoblastic leukemia. Cancer  Cell 
22:153 -66, 2012  
77. Roberts KG, Li Y, Payne -Turner D, et al: Targetable kinase -activating lesions in Ph - 
like acute lymphoblastic leukemia. N Engl J Med 371:1005 -15, 2014  
78. Weston BW, Hayden MA, Roberts KG, et al: Tyrosine kinase inhibitor therapy 
induces remission in a patient with refractor y EBF1 -PDGFRB -positive acute 
lymphoblastic leukemia. J Clin Oncol 31:e413 -6, 2013  
79. Pieters R, Hunger SP, Boos J, et al: L -asparaginase treatment in acute lymphoblastic 
leukemia: a focus on Erwinia asparaginase. Cancer 117:238 -49, 2011  
80. Evans WE, Horner M, Ch u YQ, et al: Altered mercaptopurine metabolism, toxic 
effects, and dosage requirement in a thiopurine methyltransferase -deficient child with 
acute lymphocytic leukemia. J Pediatr 119:985 -9, 1991  
81. Relling MV, Hancock ML, Rivera GK, et al: Mercaptopurine ther apy intolerance  and 
heterozygosity at the thiopurine S -methyltransferase gene locus. J Natl Cancer Inst 
91:2001 -8, 1999  
82. Relling MV, Hancock ML, Boyett JM, et al: Prognostic importance of 6 - 
mercaptopurine dose intensity in acute lymphoblastic leukemia. Blo od 93:2817 -23, 
1999  
ALLR18  
Page 72 of 67 
St. Jude  
IRB Approval daIRteB: 0N6U-1M3B-E20R1:8Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
83. Yates CR, Krynetski EY, Loennechen T, et al: Molecular diagnosis of thiopurine  S- 
methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine 
intolerance. Ann Intern Med 126:608 -14, 1997  
ALLR18  
Appendix  I 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
APPENDIX I: TESTS PERFORMED FOR GOOD CLINICAL CARE AND FOR RESEARCH  
 
The standard of care services in this study are as follows:  
 
• History & physical  exams  
• CBC with  diff 
• Coagulation  screen  
• Urine  analysis  
• Hepatitis, HIV  screen  
• NK cell recipient - EBV, CMV, HSV, varicella, histoplasma, and toxoplasma  titres  
• Bone marrow aspirate and biopsy procedure and  MRD  
• Peripheral blood for  MRD  
• TPMT  genotyping  
• CSF cell count,  diff 
• Chest x -ray 
• ECHO and  EKG  
• QCT for bone  density  
• HLA typing of pat ient and potential  donors  
• Pregnancy test for females of childbearing potential  (patient)  
• All agents used in this trial are commercially available. Rituximab and IL -2 use are 
experimental  
 
The research services are as follows:  
 
• CliniMACS system and NK cell  infusions  
• Bone marrow sample for biology studies (taken at same time bone marrow  procedure 
is done for routine care to confirm relapse – baseline)  
• Peripheral blood for  CD20  
• Bone marrow for mutant  cells 
• Serum for asparaginase and anti -asparaginase antibodies (at specified time points – 
baseline, Induction Block I - Days 21, 28, 35 (pre -PEG each day); Interim 
continuation - Day 1 of week 1; Re -Induction – Days 6, 13, 20 (pre -PEG); and at time 
of reaction ( if applicable); again if re -challenged with asparaginase (section  6.2) 
• Germline DNA sample Day 3 Induction Block I and Day 1 induction Block  II 
• NK PHENO (patient) – baseline and Day 19 of Induction Block  I 
• NK PHENO (donor) – baseline  
• Variable nucleotide ta ndem repeat (VNTR) and KIR typing for recipient  participant  
• Donor testing – KIR typing, VNTR, serologic infectious disease testing, CBC, 
pregnancy test, complete metabolic panel; see NK Cell Donor Power Plan order set for 
full details  
ALLR18  
Appendix  II 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
APPENDIX II: PEDIATRIC RITUXIMAB INFUSION GUIDELINES  
 
Dose = 375 mg/m2 
 
• Dilute in NS to final concentration 1 mg/ml for ease of  administration.  
• Administer intravenously through a dedicated line 
Pre-medicate  with:  
• Acetaminophen 15 mg/kg PO (max 650  mg) 
• Bena dryl 1 mg/kg IV or PO (max 50  mg) 
 
FIRST INFUSION : Participants treated at St. Jude will be as per current St. Jude formulary 
from Intranet (collaborating sites will follow institutional formulary/policy)  
 
SUBSEQUENT INFUSIONS : Participants treated at St. Jude will be as per current St. Jude 
formulary from Intranet (collaborating sites will follow institutional formulary/policy)  
 
GENERAL GUIDELINES : 
 
1. Monitor blood pressure, pulse, respiration and temperature every 15 minutes for the 
first hour or until the participant is stable, then hourly until the infusion is  complete.  
2. Have epinephrine and diphenhydramine available along with resuscitation  equipment  
for the emergency management of anaphylactic  reactions.  
3. If infusion related events occur, slow the infusion or stop the infusion until resolution, 
treating the participant if necessary. If it is determined that the participant can be 
safely re -challenged,  begin the infusion at 50% of the rate at which the infusion was 
running when  stopped.  
4. Verify that the participant has not taken antihypertensive medications within 12  hours 
of beginning the rituximab infusion. Hypotension may occur during the  infusion.  
5. Participants with a high number of circulating cancer cells (> 25,000/mm3) may be  at 
a higher risk for tumor lysis syndrome. These participants should receive allopurinol  
and intravenous hydration and should be  monitored.  
6. Participants who experience severe infusional symptoms may need to be  hospitalized 
for observation. Participants and families should be counseled to be seen in the 
emergency room if infusion -related sympt oms occur again after the infusion is 
complete (i.e. at home at a later  time).  
7. Monitor participants during and for a few weeks after receiving rituximab for the 
development of mucositis with a sore throat or mouth ulcers followed by a diffuse  skin 
rash whi ch can worsen rapidly and result in total body skin sloughing and can become 
life threatening.  
8. Carriers of hepatitis B should be closely monitored for clinical and laboratory signs  of 
active HBV infection and for signs of hepatitis throughout their study  participation.  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
APPENDIX III: DRUG/DEVICE/BIOLOGIC AGENT INFORMATION  
 
1. VINCRISTINE  (Oncovin ) 
 
Source and pharmacology : Vincristine is an alkaloid obtained from the periwinkle (Vinca 
rosea) plant. It reversibly binds to microtubule and spindle proteins to cause metaphase arrest. 
Vincristine has poor penetration into the CSF. It is extensively protein bound (~75%).  
Extensive metabolism occurs in the liver. Excretion is primarily in the bile. A  dosage decrease 
is recommended in participants with elevated bilirubin (see section 7.3).  
 
Formulation and stability : Vincristine is supplied in multiple -dose 1 mg/mL vials containing 1 
mL, 2 mL and 5 mL. The intact vials should be stored under refrigerat ion and protected from 
light.  
 
Supplier : The drug is commercially available.  
 
Toxicity : Dose -limiting toxicity is neurotoxicity, which is characterized by constipation 
and/or paralytic ileus, ptosis, vocal cord paralysis, weakness, jaw pain, abdominal pain , 
peripheral neuropathies, loss of deep tendon reflexes, and “foot drop.” Peripheral neuropathy 
is often the first sign of neurotoxicity and is initially reversible. Other toxicities reported 
include alopecia, mild nausea and vomiting, SIADH, myelosuppress ion, orthostatic 
hypotension, optic atrophy, transient cortical blindness, and auditory damage. Acute shortness 
of breath and severe bronchospasm have been reported after administration of vinca  alkaloids. 
Myelosuppression is rare at usual doses. Vincristine is a vesicant and may cause severe tissue 
damage if extravasation occurs. Note that dose reduction may be necessary in participants <1 
year of age or <10 kg in weight; dosing on a “per kg” (ra ther than per m2) basis has been 
advocated for infants in order to decrease  toxicity.  
 
Guidelines for administration : intravenous, see Treatment section 5.2.1 (Remission induction 
Block I), section 5.4 (Re -Induction) and section 5.5 (Continuation).  
 
 
2. DEXAM ETHASONE (Decadron®)  
 
Source and pharmacology : Dexamethasone is a synthetic congener of the natural adrenal 
hormone hydrocortisone. Dexamethasone is a white or yellowish crystalline powder. It binds 
with steroid receptors on nuclear membranes to impair cellular mitosis and inhibit protein 
synthesis. Dexamethasone also has potent anti -inflammatory effects and suppresses the 
immune system. Dexamethasone is absorbed well orally. It is metabolized in the liver, and the 
metabolites are excreted mainly in the urine.  
 
Formulation and stability : Dexamethasone  is available as tablets of various strengths and as 
an elixir. It is also available as a solution for parenteral use. All formulations of the drug can 
be stored at room temperature. The injectable form may be further diluted in 5% dextrose or 
0.9% NaCl -containing solutions and is stable for at least 24 h at room temperature.  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
Supplier : The drug is commercially available.  
Toxicity : The side effects of dexamethasone vary depending on the duration of its use. Side 
effects that can occur with sho rt-term use include peptic ulcers with possible perforation and 
hemorrhage, increased susceptibility to infections, emotional instability, insomnia, increased 
appetite, weight gain, acne, and hyperglycemia. Side effects more commonly associated with 
prolon ged use include cataracts, increased intraocular pressure and associated glaucoma, 
development of a “cushingoid” state, compression fractures, menstrual irregularities, 
suppression of growth in children, secondary adrenocortical and pituitary unresponsiven ess 
particularly in times of stress as in trauma, surgery or illness, osteoporosis and muscle wasting.  
 
Guidelines for administration : PO, see section 5.2.1 (Remission induction, Block I), section  
5.3 (Interim continuation), section 5.4 (Re -Induction), sec tion 5.5 (Continuation)  
 
 
3. HYDROCORTISONE, Intrathecal (Cortef,  Solu-Cortef)  
 
Source and pharmacology : Hydrocortisone is a synthetic steroid akin to the natural adrenal 
hormone cortisol. Hydrocortisone has phase -specific cytotoxicity, killing lymphoblasts 
primarily during S phase. It has catabolic effect on proteins and alters the kinetics of 
peripheral blood leukocytes. It is excreted in the urine and catabolized in the liver.  
 
Formulation and stability : Solu -Cortef sterile powder is supplied in the followi ng package: 
100 mg plain, and 100 mg, 250 mg, 500 mg, and 1000 mg ACT -O-VIAL (MIX -O-VIAL). 
Store unreconstituted product at controlled room temperature 15 -30C (59 -86F). Store 
reconstituted solution in the refrigerator and protect from light. Unused solut ion should be 
discarded after 3 days. Use Solu -Cortef (plain vial) for intrathecal use, and reconstitute with 
0.9% sodium chloride, USP for injection.  
 
Supplier : Commercially available  
 
Toxicity : If given intrathecally, sterile arachnoiditis may occur. Headache, seizures, unusual 
feelings or sensations, loss of feeling or ability to move arms or legs, and difficulty with 
urination or bowel movements may also occur.  
 
Guidelines for administration : Intrathecal, see section 5.2.1 (Remission induction Block I), 
section 5.2.2 (Remission induction Block II), 5.2.3 (Remission induction Block III), section  
5.3 (interim continuation), section 5.4 (Re -induction), section 5.5 (Continuation), and 
5.7 (prophyl axis and treatment for CNS disease), 5.10 (summary of IT therapy).  
 
 
4. METHOTREXATE  
 
Source and pharmacology : Methotrexate is a folate analogue that acts by inhibiting 
dihydrofolate reductase. Dihydrofolate reductase is an enzyme important in the conversion of 
folic acid to tetrahydrofolic acid, which is necessary in the synthesis of purine nucleotides and 
thymidylate. By inhibiting the production of tetrahydrofolic acid, methotrexate interferes with  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
DNA, RNA and protein synthesis. Methotrexate  is poorly and variably absorbed orally, with 
an average of  40% for doses of < 30 mg/m2. At higher dosages, the extent of absorption 
decreases. Methotrexate is approximately 50% protein bound. It distributes widely into body 
tissues and fluids with sustained concentrations in the kidney and the liver. Methotrexate 
undergoes metabolism by cytosolic aldehyde oxidase to hydroxy methotrexate. It is excreted 
mainly in the urine as unchanged drug with sm all amounts being excreted in the bile and 
feces. The percent recovered as unchanged drug in the urine is higher with short infusions 
than with prolonged infusions. Methotrexate has a biphasic elimination with an initial half -life 
of  2-3 hours and a term inal half -life of 10 -12 hours. Methotrexate may be “sequestered” in 
body fluid collections and eliminated slowly from these areas. Patients with effusions or GI 
obstruction should have plasma levels monitored closely for delayed excretion  following  
high-dose methotrexate.  
 
Formulation and stability : Methotrexate is supplied in single -dose vials containing 50mg, 
100mg, 200mg, and 250 mg of methotrexate as a 25 mg/ml preservative -free solution and in 
vials containing 20mg, 50 mg, 100mg, 250 mg and 1000mg of l yophilized drug. It is also 
available in 2.5 mg tablets. Methotrexate preservative -free solution and lyophilized drug 
should be stored at room temperature and protected from light. Methotrexate tablets can also 
be stored at room temperature. The vials cont aining 20, 50, 100 and 250 mg of lyophilized 
product can be reconstituted by adding sterile water, 0.9% NaCl or D5W to a final 
concentration not exceeding 25 mg/ml. The 1000mg vials containing lyophilized product are 
reconstituted to a final concentration of 50 mg/ml.  
 
Supplier : commercially available  
 
Toxicity : The dose limiting toxicities of methotrexate are generally bone marrow suppression, 
ulcerative stomatitis, severe diarrhea or acute nephrotoxicity. Toxicities reported frequently 
include nausea and vomiting, diarrhea, anorexia, alopecia, hepatic toxicity  and alopecia. Less 
common side effects include blurred vision, photosensitivity, anaphylaxis, headache, 
pneumonitis, skin depigmentation or hyperpigmentation, rash, vasculitis and encephalopathy. 
During high -dose methotrexate therapy, most patients experi ence a transient decrease in GFR, 
but renal failure can occur, particularly if the patient does not receive urinary alkalinization and 
aggressive hydration before, during and after receiving high dose methotrexate. Leucovorin 
rescue should be initiated wit hin 48 hours of starting high -dose methotrexate and adjusted based 
on MTX levels to prevent bone marrow toxicity and mucositis. Leucovorin may also be 
necessary after IT administration, especially if IT methotrexate therapy is given to patients with 
renal dysfunction. Patients with Down syndrome have a tendency to have delayed methotrexate 
clearance and a greater risk of toxicity, despite increased leucovorin rescue.  
 
Guidelines for administration : Intrathecal and intravenous, see section 5.2.1 (Remission 
induction Block I), section 5.2.2 (Remission induction Block II), 5.2.3 (Remission induction 
Block III), section 5.3 (interim continuation), section 5.4 (Re -induction), section 5.5 
(Continuation), and 5.7 (prophylaxis and treatment for CNS disease), 5.10 (s ummary of IT 
therapy).  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
5. CYTARABINE (Ara -C) (Cytosar -U) 
 
Source and pharmacology : Cytarabine is a deoxycytidine analogue. It must be tri - 
phosphorylated to its active form, ARA -CTP, by deoxycytidine kinase and other nucleotide 
kinases. Ara -CTP inhibits DNA polymerase. In addition, ara -CTP is incorporated into DNA 
as a false base, causing inhibition of DNA synthesis. It is cell cycle, S phase specific.  
Cytarabine does penetrate the blood brain barrier. It is converted to its inactive form, urac il 
arabinoside, by pyrimidine nucleoside deaminase. Approximately 80% of the dose is 
recovered in the urine, mostly as uracil arabinoside (ara -U). 
 
Formulation and stability : Cytarabine is available in multi -dose vials containing 100, 500, 
1000 and 2000mg of lyophilized drug. Intact vials can be stored at room temperature. For IV  
use, either sterile water for injection or bacteriostatic water for injection can be used to 
reconstitute the lyophilized drug. For intrathecal use , only sterile water for injectio n should be 
used for reconstitution. The 100 and 500 mg vials are reconstituted with 2 and 10 ml 
respectively resulting in a final concentration of 50mg/ml. The 1000 and 2000mg vials are 
reconstituted with 20ml and 40 ml respectively resulting in a final c oncentration of 50mg/ml. 
After reconstitution, the drug is stable for 8 days at room temperature.  
 
Supplier : commercially available  
 
Toxicity : Myelosuppression is the dose limiting adverse effect, with leukopenia and 
thrombocytopenia being predominant. Oth er adverse effects reported commonly include 
nausea and vomiting (may be severe at high doses), diarrhea, mucositis, anorexia, alopecia, 
skin rash and liver dysfunction. A flu -like syndrome characterized by fever, muscle and bone 
aches is common. Less comm on side effects include allergic reactions and cellulitis at the 
injection site. High doses of cytarabine can cause conjunctivitis, hepatitis, and a group of CNS 
symptoms including somnolence, peripheral neuropathy, ataxia and personality changes.  
CNS symptoms are usually reversible and are more common in patients who have received 
previous cranial irradiation. In addition, a syndrome of sudden respiratory distress progressing 
to pulmonary edema has occurred.  
 
Guidelines for administration : Intrathe cal and intravenous; see section 5.2.1 (Remission 
induction Block I), section 5.2.2 (Remission induction Block II), 5.2.3 (Remission induction 
Block III), section 5.3 (interim continuation), section 5.4 (Re -induction), section 5.5 
(Continuation), and 5.7 ( prophylaxis and treatment for CNS disease), 5.10 (summary of IT 
therapy).  
 
 
6. RITUXIMAB  (Rituxan®)  
 
Source and pharmacology : Rituximab is a murine /human chimeric monoclonal antibody. It is 
specific for the CD20 antigen located on B -cells. Rituximab has been shown to mediate 
complement -dependent tumor cell lysis and antibody -dependent cellular cytotoxicity. Direct 
binding to t he CD20 antigen is thought to play a role in inhibition of cell growth. Rituximab is  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
administered intravenously. The mean serum half -life after a single IV dose of 375 mg/m2 is 
59.8 hours (range 11.1 -104.6 hours).  
Formulation and stability : Rituximab is available as 100 mg/10 ml single -use and 500 mg/50 
ml single -use vials. Each vial also contains sodium chloride 9 mg/ml, sodium citrate 7.35 
mg/ml, polysorbate 80 0.7 mg/ml and water for injection. Rituximab for injection 
concentration must be  diluted with 5% Dextrose or 0.9% NaCl prior to administration. After 
dilution, unused drug is stable for 24 hours when refrigerated (2 -8 degrees Celsius) and 12 
hours at room temperature. Vials should be protected from direct sunlight.  
 
Supplier : commerci ally available  
 
Toxicity : Hypersensitivity reactions may occur; therefore, premedication with acetaminophen 
and diphenhydramine should be considered before each infusion. The most common toxicities 
are infusion related and may include chills, fever, headac he, nausea, vomiting, angioedema 
(13%), hypotension (10%), bronchospasm (8%), and arrhythmia. Other possible adverse 
reactions include thrombocytopenia, myalgias, arthralgias, asthenia, and throat irritation.  
 
Guidelines for administration : Do not administer as an intravenous push or bolus. Infusions 
should be initiated at 50 mg/hour for 30 minutes. If hypersensitivity or infusion -related events 
do not occur, subsequent infusions can be administered at an initia l rate of 100 mg/hour and 
increased by 100 mg/hour every 30 minutes as tolerated. Infuse at a maximum rate of 400 
mg/hour. See section 5.2 (Remission Induction, Block I and Appendix II).  
 
 
7. CLOFARABINE (Clolar™,  Clofarex)  
 
Source and pharmacology : Clofarabi ne is a purine nucleoside analog. It is intracellularly 
metabolized to the active metabolite clofarabine 5’ -triphosphate which competes with 
deoxyadenosine triphosphate for binding to ribonucleotide reductase and DNA polymerase. It 
inhibits DNA synthesis, terminates DNA chain elongation and inhibits DNA repair.  
Clofarabine also disrupts the mitochondrial membrane which results in the release of proteins, 
cytochrome C and apoptosis -inducing factor leading to cell death. It is mainly excreted in the 
urine as unchanged drug.  
 
Formulation and stability : Clofarabine is available in the parenteral form as a preservative - 
free solution that is 1 mg/mL. It is available in 20 mL vials. The undiluted drug should be 
stored at room temperature. The diluted solution is s table for 24 hours at room temperature. 
Clofarabine injection should be filtered through sterile 0.2 micrometer syringe filter and then 
further diluted with 5% dextrose or 0.9% NaCl containing solutions.  
 
Supplier : The injection is commercially available.  
 
Toxicity: The most common side effects are nausea, vomiting, diarrhea, headache, fever and 
pruritus. Also reported are pericardial effusion, tachycardia, hypotension, left ventricular 
systolic dysfunction, edema, flushing, hypertension, fatigue, anxiety, pain, dizziness,  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
depression, irritability. Patients who receive clofarabine are at risk for tumor lysis syndrome 
and need to be monitored closely.  
 
Patients may also experience a systemic inflammatory response syndrome (SIRS) or capillary 
leak syndrome. Patients should be monitored for this during the infusion.  
 
Dosage and route of administration : Intravenous, see section 5.2.1 (Remission induction, 
Block I) and section 5.4 (Re -induction)  
 
 
8. CYCLOPHOSPHAMIDE  (Cytoxan) 
 
Source and pharmacology : Cyclophosphamide is a nitrogen mustard derivative. It acts as an 
alkylating agent that causes cross -linking of DNA strands by binding with nucleic acids and 
other intracellular structures, thus interfering with the normal function of DNA. 
Cyclophosphamide is cell -cycle, phase non -specific. Cyclophosphamide is well absorbed 
from the GI tract with a bioavailability of > 75%. Cyclophosphamide is a prodrug that 
requir es activation. It is metabolized by mixed -function oxidases in the liver to 4 - 
hydroxycyclophosphamide, which is in equilibrium with aldofosfamide. Aldofosfamide 
spontaneously splits into cyclophosphamide mustard, which is considered to be the major 
active  metabolite, and acrolein. In addition, 4 -hydroxycyclophosphamide may be 
enzymatically metabolized to 4 -ketocyclophosphamide and aldofosfamide may be 
enzymatically metabolized to carboxyphosphamide which are generally considered to be 
inactive. Cyclophosph amide and its metabolites are excreted mainly in the urine. Dosage 
adjustments should be made in patients with a creatinine clearance of < 50 ml/min.  
 
Formulation and stability : Cyclophosphamide is available in 25 and 50 mg tablets. 
Cyclophosphamide is als o available in vials containing 100, 200, 500, 1000 and 2000mg of 
lyophilized drug and 75 mg mannitol per 100 mg of cyclophosphamide. Both forms of the 
drug can be stored at room temperature. The vials are reconstituted with 5, 10, 25, 50 or 100 
ml of ster ile water for injection respectively to yield a final concentration of 20 mg/ml.  
Reconstituted solutions may be further diluted in either 5% dextrose or 0.9% NaCl containing 
solutions. Diluted solutions are physically stable for 24 hours at room temperatur e and 6 days 
if refrigerated, but contain no preservative, so it is recommended that they be used within 24 
hours of preparation.  
 
Supplier : commercially available  
 
Toxicity : Dose limiting toxicities of cyclophosphamide are bone marrow suppression and 
cardiac toxicity. Cardiac toxicity is typically manifested as congestive heart failure, cardiac 
necrosis or hemorrhagic myocarditis and can be fatal. Hemorrhagic cystitis may oc cur and 
necessitates withholding therapy. The incidence of hemorrhagic cystitis is related to 
cyclophosphamide dose and duration of therapy. Forced fluid intake and/or the administration 
of MESNA decreases the incidence and severity of hemorrhagic cystitis . Other toxicities 
reported commonly include nausea and vomiting (may be mild to severe depending on  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
dosage), diarrhea, anorexia, alopecia, immunosuppression and sterility. Pulmonary fibrosis, 
SIADH, anaphylaxis and secondary neoplasms have been reported rarely.  
 
Dosage and route of administration : Intravenous, see section 5.2.1 (Remission induction, 
Bloc k I), section 5.3 (Interim continuation) and section 5.4 (Re -induction).  
9. ETOPOSIDE (VP -16) (Vepesid) 
 
Source and pharmacology : Etoposide is an epipodophyllotoxin derived from Podophyllum 
pelatatum. It is thought to act mainly by inhibiting topoisomerase I I, causing double and 
single strand DNA breaks. Etoposide is cell cycle, phase -specific, with activity in the G2 and 
S phases. Absorption of etoposide is approximately 30 -40% and is highly variable and 
somewhat dose -dependent. It is extensively bound to se rum proteins and is metabolized in the 
liver, including cytochrome P450 3A metabolism to several moieties that include a reactive 
oxidized species. Etoposide and its metabolites are excreted mainly in the urine with a smaller 
amount excreted in the feces. Dosage adjustments should be considered in patients with liver 
dysfunction, kidney dysfunction or hypoalbuminemia.  
 
Formulation and stability : Etoposide is available in multi -dose vials containing 100mg, 
150mg, 500mg and 1000mg of etoposide as a 20mg/ml so lution and 30% alcohol. Etoposide 
is also available as a 50 mg capsule. The intact vials of etoposide solution should be stored at 
room temperature. The capsules should be stored under refrigeration. Etoposide solution 
should be diluted in D5W or 0.9% NaCl  prior to administration. Solutions with a final 
concentration of 0.2 and 0.4 mg/ml are stable at room temperature for 96 hours and 24 hours 
respectively.  
 
Supplier : commercially available  
 
Toxicity : Dose limiting toxicity is myelosuppression. Nausea and v omiting (usually of low to 
moderate severity), diarrhea, mucositis (particularly with high doses), alopecia and anorexia 
are fairly common. Hypotension can occur with rapid infusions. Other side effects reported 
less commonly include hepatitis, fever and c hills, anaphylaxis and peripheral neuropathy.  
Secondary leukemia has been reported.  
 
Dosage and route of administration: Intravenous, see section 5.2.1 (Remission induction, 
Block I), section 5.3 (Interim continuation) and section 5.4 (Re -induction)  
 
 
10. ETOPOSIDE PHOSPHATE  (Etopophos®) - To be used in case of etoposide  reactions 
(see section  7.9). 
 
Source and pharmacology : Etoposide is an epipodophyllotoxin derived from Podophyllum 
pelatatum. It is thought to act mainly by inhibiting topoisomerase II, cau sing double and 
single strand DNA breaks. Etoposide is cell cycle, phase -specific, with activity in the G2 and 
S phases. Absorption of etoposide is approximately 30 -40% and is highly variable and 
somewhat dose -dependent. It is extensively bound to serum pr oteins and is metabolized in the 
liver, including cytochrome P450 3A metabolism to several moieties that include a reactive  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
oxidized species. Etoposide and its metabolites are excreted mainly in the urine with a smaller 
amount excreted in th e feces. Dosage adjustments should be considered in patients with liver 
dysfunction, kidney dysfunction or hypoalbuminemia.  
 
Formulation and stability : Etoposide phosphate is a water -soluble ester of etoposide. The 
higher water solubility of etoposide phos phate than that of etoposide lessens the potential for 
precipitation following dilution and during administration. Etoposide phosphate is available in 
single -dose vials containing etoposide phosphate equivalent to 100mg etoposide. The intact 
vials of etopo side solution should be stored at 2 to 8 degrees Celsius. Etoposide phosphate 
solution should be diluted in D5W or 0.9% NaCl prior to administration. Solution is stable at 
room temperature for 24 hours.  
 
Supplier : commercially available.  
 
Toxicity : Dose li miting toxicity is myelosuppression. Nausea and vomiting (usually of low to 
moderate severity), diarrhea, mucositis (particularly with high doses), alopecia and anorexia 
are fairly common. Hypotension can occur with rapid infusions. Other side effects repo rted 
less commonly include hepatitis, fever and chills, anaphylaxis and peripheral neuropathy.  
Secondary leukemia has been reported.  
 
Guidelines for administration : Intravenous, see section 5.2.1 (Remission induction, Block I), 
section 5.3 (Interim continuation) and section 5.4 (Re -induction).  
 
 
11. CliniMACSTM System  
 
This system is described fully in the Investigators Brochure and is briefly described here. The 
mechanism of action of the CliniMACS Cell Selection System is based on magnetic -activated 
cell sorting. The CliniMACS device is a powerful tool for the isolatio n of many cell types 
from heterogeneous cell mixtures. For example, apheresis products can be separated in a 
magnetic field using an immunomagnetic label specific for the cell type of interest, such as 
CD34+ human hematopoietic cells enrichment, CD3+ T cel l depletion, or CD56+ NK cell 
enrichment.  
 
The cells to be isolated or depleted are specifically labeled with super -paramagnetic particles 
by an antibody directed toward a cell surface antigen. After magnetic labeling, the cells are 
separated using a high -gradient magnetic separation column as described below. The 
magnetically labeled cells are retained in the magnetized column while the unlabeled cells 
flow through. The retained cells are eluted by removing the magnetic field from the column, 
washing the c ells out and collecting them.  
 
The super -paramagnetic particles are small in size (about 50 nm in diameter) and are 
composed of iron oxide/hydroxide and dextran conjugated to monoclonal antibodies. These 
magnetic particles form a stable colloidal solution and do not precipitate or aggregate in 
magnetic fields. The CliniMACS device incorporates a strong permanent magnet and a 
separation column with a ferromagnetic matrix to separate the cells labeled with the magnetic  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
particles. The high -gradi ent system allows the application of strong magnetic forces and a 
rapid demagnetization. Small ferromagnetic structures, such as the column matrix, placed in a 
magnetic field, concentrate this homogenous field and thereby produce high magnetic 
gradients. I n their immediate proximity, the ferromagnetic structures generate magnetic forces 
10,000 -fold greater than in the absence of those structures enabling the retention of 
magnetically labeled cells. After removing the column from the magnet, the rapid 
demagn etization of the column matrix allows the release of retained cells.  
The CliniMACS device is comprised of a computer controlled instrument incorporating a 
strong permanent magnet, a closed -system sterile tubing set containing columns with a coated 
ferromag netic matrix and a paramagnetic, cell specific, labeling reagent. The instrument will 
separate the cells in a fully automated process  
 
 
12. INTERLEUKIN -2 (IL-2, ALDESLEUKIN,  PROLEUKIN ) 
 
Source and pharmacology : Aldesleukin is a biosynthetic cytokine (a lympho kine) of 
recombinant DNA origin. It differs from human interleukin -2 by the absence of an N -terminal 
alanine, the replacement of cysteine with serine at position 125 of the sequence, and the 
absence of glycosylation. It is a biologic response modifier with  complex antineoplastic and 
immunomodulating activities.  
 
Formulation and stability : Aldesleukin vials contain 22 million units of lyophilized 
recombinant interleukin. Each single use vial is reconstituted with 1.2 ml of sterile water for 
injection to give 18 million units/ml. Aldesleukin should be admixed with D5W for infusion, 
with alb umin 0.1% added to decrease adsorption. Do not use an in -line filter. Do not mix in 
saline.  
 
Supplier : commercially available  
 
Toxicities : Aldesleukin is a highly toxic drug. Most adverse effects are dose related and 
schedule dependent, with fewer toxiciti es associated with low dose, subcutaneous or 
continuous IV infusions as compared to high dose, rapid IV infusions. Most adverse effects 
are self -limiting and reversible within 2 to 3 days of drug discontinuance. Many of the 
adverse effects of aldesleukin a re related to capillary leak syndrome, which has been 
associated with this drug. The most frequently reported serious adverse effects include 
hypotension, renal dysfunction with oliguria/anuria, dyspnea or pulmonary congestion, and  
mental status changes (l ethargy, somnolence, confusion, agitation). Additional serious adverse 
effects reported include myocardial ischemia, myocarditis, gangrene, respiratory failure 
leading to intubation, GI bleeding, intestinal perforation, ileus, coma, seizures, sepsis, and 
renal impairment requiring dialysis. Most patients receiving aldesleukin develop some degree 
of a flu -like syndrome that may include fever, chills, rigors, fatigue, weakness, malaise, 
arthralgia and myalgia.  
 
Guidelines for administration : Subcutaneous inje ction, for NK Cell transplant participants 
only, see section 5.2.1 (Remission induction, Block I).  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
13. PEG -L-ASPARAGINASE (Pegaspargase,  Oncaspar ) 
 
Source and pharmacology : PEG -asparaginase is a modified version of the enzyme, L - 
asparaginase. L -asparaginase is modified by covalently conjugating units of polyethylene glycol 
(PEG) to the enzyme. The asparaginase used in the manufacturing of PEG -asparaginase is 
derived from Escherichia coli. Asparaginase hydrolyzes serum asparagine (an amino acid 
required to synthesize proteins and DNA) to aspartic acid and ammonia, and is therefore lethal 
to cells that cannot synthesize asparagine. Asparaginase is active during all phases of the cell 
cycle. Asparaginase is not absorbed from the GI tract and must be given parenterally. PEG - 
asparaginase has a plasma half -life of approximately 6 days, but is measurable for at least 15 
days following the initial treatment. It cannot be detected i n the urine.  
 
Formulation and stability : PEG -asparaginase is available in single -use vials containing 5 ml 
of PEG -asparaginase as a clear solution. Each vial contains 3750 units of drug at a 
concentration of 750 units/ml. The intact vials should be stored under refrigeration. Freezing 
destroys its activity, which cannot be detected visually. It should not be used if it is cloudy or 
a precipitate is present.  
 
Supplier : commercially available  
 
Toxicity : Acute toxicity includes anaphylactic reactions which occur most commonly when 
the drug is given IV. These can be characterized by laryngeal constriction, hypotension, 
diaphoresis, fever, chills, edema and loss of consciousness. Allergic reactions at the site of IM 
injection include pain, swelling and erythema. The incidence of hypersensitivity reactions to 
PEG -asparaginase may be less than with conventional E. coli derived asparaginase although 
cross -sensitivity can occur. Other adverse effects include ne utropenia and associated 
immunosuppression, mild nausea and vomiting, malaise, anorexia, elevated LFT’s, 
pancreatitis and hyperglycemia. A decrease in protein synthesis including albumin, fibrinogen 
and other coagulation factors may occur which can result in thrombosis or pulmonary 
embolism. Less common side effects include renal dysfunction and CNS complications, 
including somnolence, weakness, lethargy, coma and seizures.  
 
Guidelines for administration : Intravenous or intramuscular injection, see section 5.2.1 
(Remission induction) and 5.4 (Re -induction).  
 
 
14. ERWINIA L -ASPARAGINASE  (Erwinase ) 
 
To be used in case of allergy or intolerance to PEG -Asparaginase.  
 
Source and pharmacology : Erwinia asparaginase is an enzyme. It is derived from Erwinia 
chrysanthemi  and may be useful in patients with an allergy to the E. coli derived product. 
Asparaginase hydrolyzes serum asparagine (an amino acid required to synthesize proteins) to 
aspartic acid and ammonia, and is therefore lethal to cells that cannot synthesize as paragine. 
Asparaginase is active during all phases of th cell cycle. Asparaginase is not absorbed from  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
the GI tract and must be given parenterally. Asparaginase does not cross into the CSF. The 
plasma half -life of Erwinia asparaginase when g iven IM is approximately 16 hours. Only 
minimal urinary and biliary excretion occurs. Clearance is unaffected by age, renal function 
or hepatic function.  
 
Formulation and stability : Erwinia asparaginase is available in vials containing 10,000 units 
of lyop hilized drug. Unused vials should be refrigerated. The contents of each vial should be 
diluted with 1 ml of preservative -free normal saline, giving a resultant solution of 10,000 
units/ml. Once in solution, it is recommended that it be used within 8 hours as no preservative 
is added. Occasionally a small number of gelatinous -like fibers may develop upon standing. If 
this occurs, the solution can be filtered through a 5 micron filter to remove the particles with 
no change in  potency.  
 
Supplier : Commercially available  
 
Toxicity : Acute toxicity includes anaphylactic reactions that occur most commonly when the 
drug is given IV. These can be characterized by laryngeal constriction, hypotension, 
diaphoresis, fever, chills, edema and loss of consciou sness. Allergic reactions at the site of IM 
injection include pain, swelling and erythema. Other adverse effects include neutropenia and 
associated immunosuppression, mild nausea and vomiting, malaise, anorexia, elevated LFTs, 
pancreatitis and hyperglycemi a. A decrease in protein synthesis including albumin, fibrinogen 
and other coagulation factors may occur which can result in hemorrhage. Thrombosis and/or 
pulmonary embolism can also occur. Less common side effects include renal dysfunction and 
CNS complic ations including somnolence, weakness, lethargy, coma and seizures.  
 
Guidelines for administration : Intravenous or intramuscular injection, see section 5.2.1 
(Remission induction) and 5.4 (Re -induction).  
 
For additional information about this drug, please see package insert.  
 
 
15. MERCAPTOPURINE (6 -MP) (Purinethol ) 
 
Source and pharmacology : Mercaptopurine is a purine antimetabolite. It must be converted 
intracellularly to 6 -thioguanine nucleotides (6 -TGNs), the active forms of the drug. The 6 - 
TGNs are then incorporated into DNA and RNA and cause inhibition of DNA and RNA 
synthesis. Mercapt opurine is cell cycle, S phase specific. Absorption is variable and 
incomplete (5 -37%) and is decreased by the presence of food in the gut. Mercaptopurine does 
distribute into the CSF, with CSF concentrations of  27% of plasma concentrations when 
given by  continuous infusion. Mercaptopurine undergoes first pass metabolism in the GI 
mucosa and the liver. It is metabolized in hematopoietic tissues by HPRT to the active 
nucleotide forms. It is inactivated to methylated metabolites by TPMT (thiopurine methyl 
transferase) and to 6 -thiouric acid by xanthine oxidase. TPMT is a genetically regulated, 
polymorphically distributed enzyme and is deficient in about 1 in 300 persons who cannot 
tolerate usual doses of 6 -MP. Mercaptopurine is eliminated through the urine a s both 
unchanged drug and metabolites.  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
Formulation and stability : Mercaptopurine is commercially available as a 50 mg tablet and 20 
mg/mL oral suspension; store at room temperature and protect from light.  
 
Supplier : Tablets are commercially  available.  
 
Toxicity : The dose -limiting toxicity of mercaptopurine is myelosuppression. Mercaptopurine 
can cause intrahepatic cholestasis and focal centralobular necrosis and is usually manifested 
by hyperbilirubinemia and increased liver function tests. Other toxicities incl ude mild nausea 
and vomiting, skin rash, hyperuricemia, and mild diarrhea.  
Guidelines for administration : oral tablets or suspension, see section 5.2.2 (Remission 
induction, Block II), section 5.3 (Interim continuation), section 5.5 (Continuation).  
 
 
16. LEUCO VORIN (Folinic Acid)  
 
Source and pharmacology : Leucovorin is a racemic mixture of tetrahydrofolic acid, which is 
involved as a cofactor for 1 -carbon transfer reactions in the synthesis of purines and 
pyrimidines. Leucovorin is a potent antidote for both th e hematopoietic and 
reticuloendothelial toxic effects of folic acid antagonists by replenishing reduced folate pools. 
It is postulated that in some cancers, leucovorin enters and “rescues” normal cells from the 
toxic effects of folic acid antagonists, in p reference to tumor cells, because of differences in 
membrane transport and affinity for polyglutamylation. Leucovorin is converted in the 
intestinal mucosa and the liver to 5 -methyl -tetrahydrofolate, which is also active as a reduced 
folate. It is excreted  primarily in the urine with minor excretion occurring in the feces.  
 
Formulation and stability : Leucovorin is supplied in 5, 15 and 25 mg tablets and vials 
containing 50, 100 or 350 mg of leucovorin as a lyophilized powder. The tablets and the 
lyophilized  powder can be stored at room temperature. The 50 mg and 100 vials can be 
reconstituted by adding 5 or 10 ml of sterile water or bacteriostatic water for injection 
respectively to yield a final concentration of 10 mg/ml. The 350 mg vials can be reconstitut ed 
with 17 ml of sterile water or bacteriostatic water for injection to yield a final concentration of 
20 mg/ml. The reconstituted solution is stable for at least 7 days at room temperature.  
Leucovorin may be further diluted in 5% dextrose or 0.9% NaCl con taining solutions. 
Leucovorin is also available as a 1 mg/ml oral solution.  
 
Supplier : commercially available  
 
Toxicity : Leucovorin is generally well tolerated. Toxicities that have been reported 
uncommonly include rash, mild nausea, headache, and wheezing  (possible allergic reaction). 
Intrathecal leucovorin is contraindicated and has caused neurotoxic deaths. There have been 
rare reports of leucovorin promoting seizures.  
 
Guidelines for administration : oral or intravenous, see section 5.2.2 (Remission indu ction 
Block II after HDMTX, and section 5.7 (after ITHMA), section 5.7.2 (Down syndrome 
participants), and section 6.3.3.3 (ITHMA with CNS irradiation).  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
 
17. MITOXANTRONE  (Novantrone ) 
 
Source and pharmacology : Mitoxantrone is an anthracenedione that is structurally similar to 
the anthracyclines. It is thought to act by intercalating into DNA, causing template disorder, 
steric obstruction and inhibition of DNA and RNA synthesis. In addition, mitoxantrone 
inhibi ts the action of topoisomerase II. Mitoxantrone is active throughout the cell cycle.  
Mitoxantrone is about 78% protein bound and does cross the blood brain barrier. 
Mitoxantrone is metabolized in the liver to inactive metabolites. The parent drug and 
metab olites are excreted primarily via hepatobiliary excretion with small amounts excreted in 
the urine. Dosage adjustment is recommended for patients with severe hepatic dysfunction 
(total bilirubin > 3.4 mg/dl).  
 
Formulation and stability : Mitoxantrone is ava ilable in multi -dose vials containing 20 mg, 25 
mg or 30 mg of mitoxantrone as a dark blue, aqueous solution at a concentration of 2 mg/ml. 
The intact vials should be stored at room temperature. Refrigeration may result in 
precipitation of mitoxantrone, wh ich will re -dissolve upon warming to room temperature. The 
drug should be further diluted to at least 50 ml in 5% dextrose or 0.9% NaCl prior to 
administration. These solutions are chemically stable for at least 7 days when stored at room 
temperature.  
 
Supplier: commercially available  
 
Toxicity : The major dose -limiting toxicity of mitoxantrone is leukopenia with 
thrombocytopenia and anemia occurring much less frequently. Nausea and vomiting are 
usually moderate in severity. Other side effects reported commo nly include alopecia,  diarrhea, 
headache, fever and stomatitis. Blue to green discoloration of urine and other body fluids 
occurs. Other side effects reported less commonly include elevated liver function tests, 
allergic reactions, seizures, jaundice and r enal failure. Congestive heart failure has been 
reported, but is much less common than with doxorubicin. CHF has been reported primarily 
in patients receiving prior therapy with anthracyclines. Patients with an increased risk of 
cardiotoxicity include thos e having received prior therapy with anthracyclines, those with 
previous mediastinal radiotherapy and those with pre -existing cardiac  conditions.  
 
Guidelines for administration: Intravenous, see section 5.2.3 (Remission induction, Block III).  
 
 
18. TENIPOSIDE (VM -26) (Vumon) 
 
Source and pharmacology : Teniposide is a semi -synthetic derivative of epipodophyllotoxin 
derived from Podophyllum peltatum . It is thought to act mainly by inhibiting topoisomerase II 
and thus causing double and single strand DNA breaks. Teniposide is cell cycle, phase - 
specific, w ith activity in the G2 and S phases. Teniposide is highly protein bound. It is 
extensively metabolized in the liver, including O -demethylation by cytochrome P450 3A4 to  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
reactive oxidative metabolites. It is excreted in the urine as parent dr ug and metabolite. Fecal 
excretion may account for a small amount of total excretion.  
 
Formulation and stability : Teniposide is available in clear glass ampules containing 50 mg of 
teniposide. Each ml of teniposide solution contains 10 mg of teniposide, 30  mg benzyl 
alcohol, 500 mg Cremophor EL and 43% dehydrated alcohol. Intact ampules should be 
stored under refrigeration and protected from light. Freezing does not adversely affect the 
product. Teniposide must be diluted in 5% dextrose or 0.9% NaCl contai ning solutions prior 
to administration to a final concentration between 0.1 -1mg/ml. At these concentrations, 
solutions are stable for up to 24 hours at room temperature. Solutions of 1mg/ml should be 
used within 4 hours of preparation. Refrigeration of dil uted solutions is not recommended.  
 
Supplier : Commercially available  
Toxicity : The major dose -limiting effect of teniposide is bone marrow suppression. Nausea 
and vomiting (moderate in severity), diarrhea, alopecia and mucositis are reported commonly. 
Hypo tension may occur if the drug is given too rapidly. Hypersensitivity reactions and 
secondary leukemias have been reported.  
 
Guidelines for administration : Intravenous, see section 5.3 (Interim continuation) and section  
5.5 (Continuation).  
 
 
19. VINBLASTINE  (Velban) 
 
Source and pharmacology : Vinblastine is an alkaloid extracted from the periwinkle plant 
(Vinca Rosea). It reversibly binds to microtubule and spindle proteins causing metaphase 
arrest. It may also block cellular utilization of glutamic acid, thereb y inhibiting purine 
synthesis and urea formation via the citric acid cycle. Vinblastine is highly protein bound and 
poorly penetrates the CSF. Metabolism in the liver is extensive with one metabolite, deacetyl 
vinblastine, being more active than the parent  drug. The major route of elimination is via the 
bile. Dosages should be adjusted for patients with impaired liver function (bilirubin > 3 
mg/dl).  
 
Formulation and stability : Vinblastine is available in 10 ml vials containing 1mg/ml of 
vinblastine in solution. Intact vials of vinblastine solution and lyophilized vinblastine should 
be stored under refrigeration.  
 
Supplier : Commercially available  
 
Toxicity : The dose limiting to xicity is myelosuppression. Other toxicities reported commonly 
include alopecia, mild nausea and vomiting and constipation. Vinblastine is a vesicant and 
may cause severe tissue damage if extravasation occurs. Vinblastine rarely produces 
neurotoxicity char acterized by peripheral neuropathy, loss of deep tendon reflexes, weakness, 
jaw pain and “foot drop”. This toxicity is much less common than with vincristine. Acute 
shortness of breath and severe bronchospasm have been reported following the administration  
of vinca alkaloids.  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
Guidelines for administration : Intravenous, see section 5.3 (Interim continuation) and section  
5.5 (Continuation).  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
The following tyrosine kinase inhibitors may be used for participants with Ph+ ALL and 
Ph-like ALL as part of standard clinical management, at the discretion of the treating 
investigator.  
 
20. IMATINIB (Gleevec®, imatinib mesylate)  
 
Source and pharmacology : imatinib mesylate is a phenylaminopyrimidine derivative and is a 
4-[(4-Methyl -1-piperazinyl)methyl -N-[4-methyl -3-[[4-(3-pyridinyl) -2-pyrimid -inyl]amino] - 
phenyl]benzamidemethanesulfonate. It is a protein -tyrosine kinase inhibitor that inhibits the 
Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia 
chromosome abnormality.  
 
Formulation and stability : Each film -coated tablet contains 100 mg or 400 mg of imatinib free 
base. The drug should be stored at 25 C (77F); excursions permitted to 15 C-30C (59F - 
86F). The tablets should be dispensed in a tight container, USP, and protected from moisture.  
 
The prescribed dose should be administered orally, with a meal and a large glass of water. In 
children, the daily dose may be split into two – once in the morning and once in the evening. 
For patients unable to swallow the film -coated tablets, the tablets m ay be dispersed in a glass 
of water or apple juice. The required number of tablets should be placed in the appropriate 
volume of beverage (approximately 50 mL for a 100 -mg tablet, and 200 mL for a 400 -mg 
tablet) and stirred with a spoon. The suspension sho uld be administered immediately after 
complete disintegration of the tablet.  
 
Supplier : Commercially available  
 
Toxicity : Common toxicities include dyspepsia/heartburn, nausea/vomiting, headache, 
myelosuppression, and fatigue. Occasional toxicities include  fever, edema in limbs, face, 
periorbital area, weight gain, increased SGOT/SGPT, alkaline phosphatase, bilirubin, 
abdominal pain and cramping, myalgia, arthralgia, decreased bone marrow cellularity, 
lymphopenia, eczema dermatitis, rash, muscle pain and cr amping, anorexia, and pigmentation 
changes (hypo -vitiligo). Rare toxicities include cerebral edema, melena/GI bleeding, anemia, 
diarrhea, dysphagia, esophagitis, odynophagia, hemorrhage/bleeding without grade 3 or 4 
thrombocytopenia, pneumonitis/pulmonary infiltrates, late hepatotoxicity and decrease in the 
heart’s ability to pump blood.  
 
 
21. DASATINIB (SPRYCEL®)  
 
Source and pharmacology:  Dasatinib (an aminothiazole analogue) is an inhibitor of multiple 
tyrosine kinases. It is approved for the treatment of chronic myelogenous leukemia (CML) and 
for the treatment of adults with Philadelphia chromosome -positive ALL with resistance or 
intolerance to prior therapy. It is being investigated as a broad -spectrum antitumor agent against 
solid tumors. Dasatinib is a pot ent, broad spectrum ATP -competitive inhibitor of 5 critical 
oncogenic tyrosine kinase families: BCR -ABL, SRC family kinases, c -KIT, ephrin (EP) 
receptor kinases, and PDGFβ receptor. Each of these protein kinases has been strongly linked  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
to multiple forms of human malignancies. In adults, the maximum plasma concentration of 
dasatinib after oral administration is observed between 0.5 and 6 hours. The observed effects 
from food were not clinically relevant. The overall terminal half -life is 3 -5 hours. The drug 
exhibits dose proportional increases in AUC and linear elimination characteristics over the 
dose range of 15 mg to 240 mg/day in adults. Dasatinib is primarily metabolized in the liver 
by the human CYP3A4 enzyme, is a significant inhibitor of CYP3A4. Dasatinib may decrease 
the metabolic clearance of drugs that are significantly metabolized by the CYP3A4 enzyme.  
Due to the potential of dasatinib to prolong the QT/QTc, caution must be used when 
administering it with other potential QTc prolong ing medications. Due to the possibility of 
gastrointestinal, cardiac, and cutaneous hemorrhage, avoid using medications that inhibit 
platelet function or anticoagulants in conjunction with Dasatinib. Dasatinib is not a p - 
glycoprotein inhibitor.  
 
Formulation and stability : Dasatinib is available as tablets of 20 mg, 50 mg, or 70 mg. The 
core tablet is surrounded by a film coating to prevent exposure to the active drug substance 
during handling. If tablets are cut or crushed, procedures to prevent e xposure to the active 
drug substance should be followed. Pregnant women or breastfeeding mothers should not 
handle crushed and/or broken dasatinib tablets.  
 
The intact dasatinib tablets can be placed (and allowed to dissolve) in 1 ounce of lemonade (a 
double strength juice is recommended to obscure the bitter taste), or 1 ounce of preservative -free 
apple juice, or 1 ounce of preservative -free orange juice.  
 
The following (i.e. steps 1 thru 7) is the procedure for the preparation of the lemon ade dosing 
solution. For preservative -free apple juice or preservative -free orange juice, steps 2 thru 7 
should be followed.  
 
1. Mix the contents of one 12 ounce can of Minute Maid Premium Frozen Concentrate 
with 2 cans (i.e. the emptied  lemonade  container)  of water.  This will produce  lemonade 
that is a little more than twice as concentrated as the instructions on the can with a 
sweeter  taste.  Please  keep  the lemonade  solution  refrigerated  when  not in use. 
2. Place  1 ounce  (30 mL) of this lemonade  solution  into a drinking  glass.  
3. Place  the proper  dose of intact  tablets  into the lemonade.  Please  be sure to always  wear 
protective gloves when handling the medication. A mask is not required when  handling 
the medication. Always use the 1 oz of lemonade. Do not increase the lemonade 
volume.  
4. Start timing  for 20 minutes.  At approximately  the 5 minute  mark,  swirl  the contents  of 
the glass well for about 3 seconds.  
5. At approximately  the 15 minute  mark,  swirl  the contents  of the glass  a second  time.  At 
the 20 minute mark, swirl the contents of the glass one last time. Immediately 
administer the entire contents of the  glass.  
6. In order to ensure administration of the entire medication dose, a rinsing step is 
necessary.  Add 0.5 ounce (15 mL) of lemonade into the same glass that has just been 
emptied.  Swirl  the contents  to remove  any remaining  signs  of tablets  from  the sides  or 
bottom of the  glass.  
7. Administer the washing lemonade to the  patient.  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
 
The intact bottles should be stored at controlled room temperature (15  - 25C (59 - 77F) 
and protected from light.  
 
Supplier : Commercially available  
 
Toxicity : The most frequently reported adverse events include fluid retention (pleural 
effusion), diarr hea, nausea, abdominal pain, rash, headache, fatigue, vomiting, bleeding 
events and myelosuppression. The most frequently reported serious adverse events include 
pyrexia, febrile neutropenia, gastrointestinal bleeding, pneumonia, thrombocytopenia, 
dyspnea,  anemia and cardiac failure (3%). Less commonly reported are anorexia,  dehydration, 
abdominal distension and flatulence, flushing, pruritis, elevated creatinine, and  neuropathy.  
Elevations in transaminases and bilirubin can usually be managed with dose red uctions or 
dose interruption. Hypocalcemia during dasatinib therapy can be managed with oral calcium 
supplementation.  
 
 
22. NILOTINIB (Tasigna™)  
 
Source and pharmacology : Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor that may 
be used in the treatm ent of chronic myeloid leukemia (CML) and Philadelphia chromosome 
acute lymphoblastic leukemia (Ph+ALL). Nilotinib binds to and stabilizes the inactive 
conformation of the kinase domain of Abl protein. It is considered to be a “second generation” 
tyrosine kinase inhibitor and may be efficacious in patients who have becomes resistant to 
“first generation” drugs such as imatinib. Nilotinib is an analog of imatinib and features a 
more energetically favorable binding mode that contributes to its enhanced potenc y (twenty 
times higher than imatinib). The increased potency is hoped to allow lower dosages, which 
may limit side effects that would otherwise make this medication intolerable.  
 
Formulation and stability : Tasigna (nilotinib) capsules, for oral use, contai n 150 mg or 200 
mg nilotinib base, anhydrous (as hydrochloride, monohydrate) with the following inactive 
ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate 
and polyoxamer 188. The capsules contain gelatin, iron oxide (red), iron oxide (yellow), iron 
oxide (black) and titanium dioxide. The capsules should be stored at 25°C, although 
excursions are permitted between 15 -30°C.  
 
Supplier : Commercially available  
 
Toxicity : Its most common side effects, occurring in over 10% of patients, include peripheral 
edema, headache, rash, pruritis, fatigue, GI upset, increased lipids, neutropenia (grades 3/4, 
median duration 15 days), thrombocytopenia (grades 3/4, median duration 22 da ys), 
neuralgias, musculoskeletal pain, and upper respiratory tract infections. Other serious side 
effects include QT prolongation, depression, insomnia, electrolyte disturbances, pancytopenia, 
and elevated LFTs. Reports of sudden deaths from QTc prolongati on has let the FDA to 
require a “Black Box” warning on Tasigna emphasizing the need to monitor electrolyte levels 
and co -administration of other medications in patients taking the drug. Nilotinib should not be  
ALLR18  
Appendix  III 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
  
taken with drugs that prolong t he QT interval or inhibitors or inducers of CYP3A4. It may 
induce other CYP enzymes, thus affecting the metabolism of other drugs. It also inhibits P - 
glycoprotein and is a substrate for its efflux transporter. The REMS (Risk Evaluation and 
Mitigation Stra tegy) approved in conjunction with the Black Box Warning requires that all 
patients receive specific oral and written counseling to take nilotinib on an empty stomach, 
time doses appropriately, get regular ECGs, avoid grapefruit products, and report all ot her 
medications to the prescribing physician. Nilotinib should be used with caution in patients 
with a history of pancreatitis or impaired hepatic function.  
 
Dosage and route of administration : Nilotinib is available as oral capsules in 150 mg and 200 
mg s trengths. Nilotinib capsules should be taken twice daily (about 12 hours apart) with 
water. It must not be taken with food as this can significantly change adsorption; patients 
should not eat 2 hours prior or 1 hour after taking nilotinib. For patients una ble to swallow 
capsules, the contents may be mixed with a small amount of pureed apple sauce and taken 
within 15 minutes.  
ALLR18  
Appendix  IV 
St. Jude  
IRB Approval dateI:R0B6-N1U3-M2B01E8R: Pro00002817  
IRB APPROVAL DATE: 03/18/2019  Amendment 3.0, dated: 03 -19-2018  
Protocol document date: 06 -12-2018   
 
 
 
 
ALLR18  
Appendix  V 
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 APPENDIX V: TREATMENT AND EVALUATION CALENDARS  
 
Pretreatment - See order sheets. Offer enrollment for institutional banking and pharmacogenetic protocols  
 
Block I – must be given at St. Jude (including collaborating site participants)  
1 
ITMHA* 
VCR 
DEX  
 
*CSF cell count, diff 
and cytology  2 
 
 
DEX  
 
 
#Peripheral blood 
CD20  3 
 
 
DEX  
TPMT genotyping (if 
not available from 
frontline therapy)  
 
Germline DNA  4 
 
RITUX  
DEX  
 
 
#Peripheral blood 
CD20  5 
(ITMHA*) 
DEX  
 
 
 
(*CSF cell count, 
diff and cytology)  6 
CLO 
CYCLO 
VP16 
DEX  
 
 
#Peripheral blood 
MRD and CD20  7 
CLO 
CYCLO 
VP16 
DEX  
8 
ITMHA* 
CLO 
CYCLO  
VP16 
DEX  9 
 
CLO 
CYCLO 
VP16  10 
 
CLO 
CYCLO 
VP16  11 
 
(ITMHA*) 
IL-2 12 
 
NK cell infusion  13 
 
RITUX  
IL-2 14 
 
*CSF cell count, diff 
and cytology    #Peripheral blood 
CD20  
 
(*CSF cell count, 
diff and cytology)     
#Peripheral blood 
CD20  
15 
IL-2 16 17 
IL-2 18 19 
IL-2 20 
RITUX  21 
PEG -ASP** 
VCR 
(ITMHA*) 
DEX  
       
(*CSF cell count, 
diff and cytology)  
      #Peripheral blood 
CD20  
      **Asp & antibodies  
    NK Pheno (patient)    
***TKI Ph+ ALL & 
Ph-like ALL  
22 
DEX  23 
 
DEX  24 
 
DEX  25 
 
DEX  26 
 
DEX  27 
RITUX  
DEX  28 
ITMHA* 
VCR 
DEX  
       
*CSF cell count, diff 
and cytology  
29 30 31 32 33 34 35 
PEG -ASP** 
VCR  
 
**Asp & antibodies  
 
BM/MRD and 
mutant cells after 
count recovery  
ALLR18  
Appendix  V 
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 Notes:  
1. #Peripheral blood MRD and CD20 evaluations – will be discontinued following a negative MRD result (less than  0.01%)  
2. *CNS1: ITMHA Days 1, 8,  28 
CNS2 and CNS3 and traumatic tap with blasts: Days 1, 5, 8, 21 and 28. If CNS blasts not cleared by Day 8, additio nal ITMHA on Day 11  
3. **Asparaginase and anti -asparaginase antibodies: additional samples at time of  reaction  
4. H&P, CBC diff, CMP every 3 -7 days 
5. ***For participants with Ph+ ALL and Ph -like ALL (see section 6.1), tyrosine kinase inhibitor (TKI) may be added at the discretion of  the 
treating physician and principal investigator (e.g., imatinib, dasatinib and nilotinib). TKI’s should be introduced af ter day 20 of Induction 
Block I therapy to avoid drug interactions and interference with NK cell function. Treatment with TKI will be as per SOC or 
manufacturer’s recommendation. See package insert for specific drug for  details.  
ALLR18  
Appendix  V 
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 Block II – HDMTX and 6MP  
 
1 
*ITMHA 
HDMTX 
6MP  2 
 
 
6MP  3 
 
 
6MP  4 
 
 
6MP  5 
 
 
6MP  6 
 
 
6MP  7 
 
 
6MP  
 
*CSF cell count, diff 
Germline DNA        
8 
HDMTX 
6MP  9 
 
6MP  10 
 
6MP  11 
 
6MP  12 
 
6MP  13 
 
6MP  14 
 
6MP  
15 
 
6MP  16 
 
6MP  17 
 
6MP  18 
 
6MP  19 
 
6MP  20 
 
6MP  21 
 
6MP  
22 
 
 
 
BMA/MRD/mutant 
cells day 21  23 24 25 26 27 28 
Notes:  
1. H&P, CBC diff, CMP every 3 -7 days 
ALLR18  
Appendix  V 
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 Block III – ARAC and MITO  
 
1 
ARA -C 
ARA -C 2 
ARA -C 
ARA -C 3 
ARA -C 
ARA -C 
MITO  4 
ARA -C 
ARA -C 
MITO  5 
 
 
MITO  6 7 
*ITMHA  
 
*CSF cell count, diff  
8 9 10 11 12 13 14 
15 16 17 18 19 20 21 
 
 
BMA/MRD/mutant 
after cell count 
recovery  
 
CT scan involved 
areas - lymphoma 
pts. 
 
Notes:  
 
1. H&P, CBC diff, CMP every 3 -7 days  
ALLR18  
Appendix  V 
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
  
Interim Continuation  
 
1 
ITMHA* 
VP16 
CYCLO  
 
*CSF cell count, diff 
Asp & antibodies  2 3 4 5 6 7 
8 
 
MTX 
6MP  9 
 
 
6MP  10 
 
 
6MP  11 
 
 
6MP  12 
 
 
6MP  13 
 
 
6MP  14 
 
 
6MP  
15 
VM26 
ARA -C 16 17 18 19 20 21 
22 
VINBLAST 
DEX  23 
 
DEX  24 
 
DEX  25 
 
DEX  26 
 
DEX  27 28 
      BMA/MRD/mutant  
cells upon count 
recovery  
 
Notes:  
 
1. H&P, CBC diff every week, CMP as clinically  indicated  
2. Serum for asparaginase and anti -asparaginase  antibodies  
ALLR18  
Appendix  V 
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 Re-Induction  
 
1 
ITMHA* 
CLO 
CYCLO 
VP16 
DEX  
*CSF cell count, diff, 
cytology  2 
 
CLO 
CYCLO 
VP16 
DEX  3 
 
CLO 
CYCLO  
VP16 
DEX  4 
 
CLO 
CYCLO  
VP16 
DEX  5 
 
CLO 
CYCLO 
VP16 
DEX  6 
 
 
PEG -ASP** 
VCR  
DEX  
 
**Asp & antibodies  7 
8 9 10 11 12 13 
VCR  14 
15 
(*ITMHA)  16 17 18 19 20 
PEG -ASP** 
VCR  21 
 
(*CSF cell count, 
diff, cytology)       
**Asp & antibodies   
BMA/MRD/mutant 
cells after count  
recovery  
 
Notes:  
 
1. *CNS1: ITMHA on Day  1 
CNS 2, 3 and traumatic tap with blasts: ITMHA on Days 1 and 15  
2. **Asp & antibodies: additional samples at time of  reaction  
3. H&P, CBC diff and CMP every 3 -7 days 
ALLR18  
Appendix  V 
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 CONTINUATION THERAPY  
Week  Treatment  Special Studies  
1 MTX + 6MP + ITMHA  CSF cell count, diff  
2 MTX + 6MP   
3 VM26 + ARA -C  
4 DEX + VCR   
5 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
6 MTX + 6MP   
7 VM26 + ARA -C  
8 DEX + VINBLAST   
9 MTX + 6MP + ITMHA)  CSF cell count, diff  
10 MTX + 6MP   
11 VM26 + ARA -C  
12 DEX + VCR   
13 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
14 MTX + 6MP   
15 VM26 + ARA -C  
16 DEX + VINBLAST   
17 MTX + 6MP + ITMHA  CSF cell count, diff  
18 MTX + 6MP   
19 VM26 + ARA -C  
20 DEX + VCR   
21 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
22 MTX + 6MP   
23 VM26 + ARA -C  
24 DEX + VINBLAST   
25 MTX + 6MP + ITMHA  CSF cell count, diff  
26 MTX + 6MP   
27 VM26 + ARA -C  
28 DEX + VCR   
29 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
30 MTX + 6MP   
31 VM26 + ARA -C  
32 DEX + VINBLAST   
33 MTX + 6MP + ITMHA  CSF cell count, diff  
34 MTX + 6MP   
35 VM26 + ARA -C  
36 DEX + VCR   
37 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
38 MTX + 6MP   
39 VM26 + ARA -C  
40 DEX + VINBLAST   
41 MTX + 6MP + ITMHA  CSF cell count, diff  
42 MTX + 6MP   
43 VM26 + ARA -C  
44 DEX + VCR   
45 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
46 MTX + 6MP   
47 VM26 + ARA -C  
48 DEX + VINBLAST   
49 MTX + 6MP + ITMHA  CSF cell count, diff  
50 MTX + 6MP   
51 VM26 + ARA -C  
52 DEX + VCR   
53 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
ALLR18  
Appendix  V 
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
 Week  Treatment  Special Studies  
54 MTX + 6MP   
55 VM26 + ARA -C  
56 DEX + VINBLAST   
57 MTX + 6MP + ITMHA  CSF cell count, diff  
58 MTX + 6MP   
59 VM26 + ARA -C  
60 DEX + VCR   
61 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
62 MTX + 6MP   
63 VM26 + ARA -C  
64 DEX + VINBLAST   
65 MTX + 6MP + ITMHA  CSF cell count, diff  
66 MTX + 6MP   
67 VM26 + ARA -C  
68 DEX + VCR   
69 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
70 MTX + 6MP   
71 VM26 + ARA -C  
72 DEX + VINBLAST   
73 MTX + 6MP + ITMHA  CSF cell count, diff  
74 MTX + 6MP   
75 VM26 + ARA -C  
76 DEX + VCR   
77 MTX + 6MP (+ ITMHA)  (CSF cell count, diff)  
78 MTX + 6MP   
79 VM26 + ARA -C  
80 DEX + VINBLAST  *off therapy  
 
Notes:  
 
1. BMA/MRD/mutant cells every 16  weeks  
2. CNS1: Cycles 1 -10, day 1 of week  1 
CNS2 and CNS3 and traumatic tap with blasts:  
a. Cycles 1 -5: day 1 of week 1 and day 1 of week  5 
b. Cycles 6 -10: day 1 of week  1 
3. H&P and CBC diff every week, CMP as clinically  indicated  
4. *Off therapy evaluations: H&P, CBC diff, CMP, BMA/MRD, ECHO/EKG, CT scan involved areas 
(lymphoma  pts.) 
ALLR18  
Appendix VI  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
  
APP ENDIX VI: DEFINITIONS RELATED TO INFECTIOUS DISEASES  
 
I. ASSESSMENTS  
 
A. Fever : A single temperature of > 38.3oC (101oF) or >38.0oC (100.4oF) on two 
occasions within 12 hours. The measurement must be oral with glass or IVAC7 
thermometers or at the tympanic membrane by infrared instruments (Thermoscan7). 
The same method should be used throughout the febrile episode for each  patient.  
B. Neutropenia : Neutrophil count < 500/mm3 or < 1,000/mm3 with predicted decline 
to <500/mm3. 
C. Duration of Fever (for episodes of fever with neutropenia ): The initial 
temperature  is the one immediately before the first dose of antibiotics and GCSF. 
This is des ignated as zero hour . The end of a febrile period  is at the time of the 
first temperature of 38.0oC or less which is sustained at this level over a period  of 
24 hours or longer without antipyretic intervention. The duration of fever  is the 
number of hours from zero hour to the end of the febrile  period.  
D. Antibiotic Therapy:  Any systemic antibacterial drug will be considered as 
antibiotic therapy whether given orally or parenterally. Topical antibiotics will not 
be included.  
E. Antifungal Therapy:  Any antifungal  drug administered orally or parenterally  will 
be considered antifungal therapy. Antifungal therapy will be categorized for 
analysis  as: 
1. Treatment for oral candidiasis  
Nystatin  
Clotrimazole troches 
Micafungin 
Fluconazole 
Voriconazole  
2. Treatment for systemic  mycoses (includes empirical  use) 
Systemic amphotericin B (standard and liposomal) 
Fluconazole  
Voriconazole 
Posiconazole 
Itraconazole 
Micafungin  
 
II. BACTERIAL  
 
1. Bacteremia only : Defined as a growth of an organism that is judged not to be a 
contaminant in a blood culture drawn during a febrile episode. Organisms are 
considered contaminants if they are part of skin flora (e.g., diphtheroids other  than 
Corynebacterium jeikeium , Bacillus spp. not B. cereus, Propionibacterium spp., 
coagulase -negative staphylococcus (CNS) or Micrococcus spp. ) and if they are 
isolated from only one culture receptacle. All other organisms are regarded as 
pathogens. (Specify catheter -related or  not.) 
ALLR18  
Appendix VI  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
  
2. Bacterial sepsis : positive blood culture for any bacterium plus clinical evidence  of 
infection (fever, chills, hypotension, etc.). (Specify catheter -related or  not.) 
3. Urinary tract infection : urine colony count of 100,000 or greater of a single 
organism plus symptoms, dysu ria, flank pain, etc. Asymptomatic bactiuria  is the 
same colony count without  symptoms.  
4. Pneumonia (bacterial ): radiographic discernible infiltrate plus isolation of 
potentially causative bacteria from bronchoalveolar lavage, blood or biopsy 
specimen. If po sitive blood culture, code as bacterial sepsis with  pneumonia.  
5. Meningitis : positive culture of causative bacteria from CSF plus symptoms 
compatible with  meningitis.  
6. Osteomyelitis : radiographic lesions plus positive blood or bone aspirate/biopsy 
cultures.  
7. Acute Otitis Media : physician diagnosis plus antibiotic  treatment.  
8. Pharyngitis : only if group A beta hemolytic streptococcus is isolated from throat 
culture in patient with symptoms. A positive rapid streptococcal test is acceptable 
in place of culture. Oth er types of pharyngitis will not be  considered.  
9. Cellulitis : erythema and induration plus isolation of bacteria from aspirate/  drainage.  
 
III. FUNGAL  INFECTIONS  
 
A. Candidiasis  
1. Oral: presence of typical whitish lesions on the mucosal surface with  yeast 
or pseudomycelia on gram stain or KOH preparation or isolation of 
Candida species in culture from the  mouth.  
2. Esophageal or urinary bladder : evidence of tissue involvement proven by 
endoscopy and biopsy plus isolation of fungus in  culture.  
 
B. Invasive fungal infections  
1. Proven invasive fungal infection (not endemic  mycosis)  
Analysis and specimen  Moldsa Yeastsa 
Microscopic analysis:  Histopathologic,  Histopathologic,  
sterile material  cytopathologic, or direct  cytopathologic, or direct  
 microscopic examinationb microscopic examinationb 
 of a specimen obtained by  of a specimen obtained by  
 needle aspiration or biopsy  needle aspiration or biopsy  
 in which hyphae or  from a normally sterile site  
 melanized yeast -like forms  (other than mucous  
 are seen accompanied by  membranes) showing yeast  
 evidence of associated  cells – for example,  
 tissue damage  Cryptococcus species  
  indicated by encapsulated  
  budding yeasts or Candida  
  species showing  
  pseudohyphae or true  
  hyphaec 
ALLR18  
Appendix VI  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
  
 
Culture  
Sterile material  Recovery of a mold or 
“black yeast” by culture of 
a specimen obtained by a 
sterile procedure from a 
normally sterile and 
clinically or 
radiographically abnormal 
site consistent with an 
infectious disease process, 
excluding bronchoalveolar 
lavage fluid, a c ranial  sinus  
cavity specimen, and  urine  Recovery of a yeast by 
culture of a sample 
obtained by a sterile 
procedure (including a 
freshly placed [<24 h ago] 
drain) from a normally 
sterile site showing a 
clinical or radiographical 
abnormality consistent with 
an infectious disease 
process  
Blood  Blood culture that yields a 
moldd (e.g. Fusarium 
species) in the context of a 
compatible infectious 
disease process  Blood culture that yields 
yeast (e.g. Cryptococcus or 
Candida species) or yeast - 
like fungi (e.g.  
Trichosporon species)  
Serological analysis:  CSF Not applicable  Cryptococcal antigen in  
CSF indicates disseminated 
cyroptococcosis  
a If culture is available, append the identification at the genus or species level from the culture results.  
b Tissue and cells submitted for histopathologic or cytopathologic studies should be stained by 
Grocott‐Gomorri methenamine silver stain or by period ic acid Schiff stain, to facilitate inspection of fungal 
structures. Whenever possible, wet mounts of specimens from foci related to invasive fungal disease should 
be stained with a fluorescent dye (e.g., calcofluor or blankophor).  
c Candida, Trichosporon,  and yeast‐like Geotrichum species and Blastoschizomyces capitatus may also  
form pseudohyphae or true hyphae.  
e Recovery of Aspergillus species from blood cultures invariably represents contamination  
2. Probable invasive fungal infection (not endemic  mycosis)  
Host  factorsa 
• Recent history of neutropenia (<0.5 x 109 neutropils/mm3) for > 10 days)  temporally  
related to the onset of fungal disease  
• Receipt of an allogeneic stem cell  transplant  
• Prolonged use of corticosteroids (excluding among patients with allergic 
bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/day  of 
prednisone equivalent f or > 3  weeks.  
• Treatment with other recognized T cell immunusuppressants, such as cyclosporine, TNF -α 
blockers, specific monoclonal antibodies (such as alemtuzumab), or neucleoside  analogues 
during the past 90  days.  
• Inherited severe immunodeficiency (such a s chronic granulomatous disease or severe  combined 
immunodeficiency)  
ALLR18  
Appendix VI  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
  
Clinical criteriab 
• Lower respiratory tract fungal  diseasec 
o The presence of 1 of the following 3 signs on  CT: 
▪ Dense, well -circumscribed lesion(s) with our without a halo  sign 
▪ Air-crescent  sign 
▪ Cavity  
• Tracheobronchitis  
o Tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen  on 
bronchoscopic analysis  
• Sinonasal  infection  
o Imaging showing sinusitis plus at least 1 of the following 3  signs:  
▪ Acute localized pain (including pain radiating to the  eye) 
▪ Nasal ulcer with black  eschar  
▪ Extension from the paranasal sinus across bony barriers, including into  the 
orbit  
• CNS  infection  
o 1 of the following 2  signs:  
▪ Focal lesions on  imaging  
▪ Meningeal enhancement on MRI or  CT 
• Disseminated candidiasisd 
o At least 2 of the following 2 entities after an episode of candidemia within  the 
previous 2  weeks:  
▪ Small, target -like abscesses (bull’s eye le sions) in liver or  spleen  
▪ Progressive retinal exudates on ophthalmologic  examination 
Mycological  criteria  
• Direct test (cytology, direct microscopy, or culture)  
o Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus  aspirate 
samples, indicated by 1 of the  following  
▪ Presence of fungal elements indicating a  mold  
▪ Recovery by culture of a mold (e.g. Aspergillus, Fusarium, Zygomycetes, or 
Scedosporium  species)  
• Indirect tests (detection of antigen or cell -wall constituents)e 
o Aspergillosis  
▪ Galactomannan antigen detected in plasma, serum, bronchoalveolar lavage, 
or CSF  
o Invasive fungal disease other than cryptococcosis and  zygomycoses  
▪ β-D-glucan detected in  serum  
 
NOTE: Probable IFD requires the presence of a host factor, a clinical criteriaon, and a mycological criterion. 
Cases that meet the criteria for a host factor and a clinical criterion but for which mycological criteria are 
absent are considered possible IFD.  
a Host factors are not synonymous with risk factors and are characteristics by which individuals predisposed to 
IFDs can be recognized. They are intended primarily to apply to patients given treatment for malignant disease 
and to recipients of allogeneic hematopoietic stemm cell and solid -organ transplants. These factors are also 
applicable to patients who receive corticosteroids and other T -cell suppressants as well as to patients with 
primary immunodeficiencies.  
b Must be consistent with the mycological findings, if any, and must be temporally related to current episode  
c Every reasonable attempt should be made to exclude an alternative etiology  
ALLR18  
Appendix VI  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
  
d The presence of signs and symptoms consistent with sepsis syndrome indicates acute disseminated disease, 
whereas their absence denotes chromic disseminated disease  
e These tests are primarily applicable to aspergillosis and candidiasis and are not useful i n diagnosing 
infections due to Cryptococcus species or Zygomycetes (e.g. Rhizopus, Mucor, or Absidia species). Detection of 
nucleic acid is not included, because there are as yet no validated or standardized methods.  
 
3. Possible invasive fungal infection (no t endemic  mycosis)  
In the table above, cases that meet the criteria for a host factor and a clinical criterion but 
for which mycological criteria are absent are considered possible IFD.  
 
C. Histoplasmosis : a diagnosis of disseminated disease may be established by a 
positive Histoplasma antigen test on CSF, urine or serum by EIA, or the  presence 
of characteristic intracellular yeast forms in a peripheral blood smear or in bone 
marrow.  
Criteria for the diagnosis of endemic mycoses  
Diagnosis and criteria  
Proven endemic mycosis  
In a host with an illness consistent with an endemic mycosis, 1 of the following  
• Recovery in culture from a specimen obtained from the affected site or  from 
blood  
• Histopathologic or direct microscopic demonstration of appropriate morphologic 
forms with a truly distinctive appearance characteristic of dimporphic fungi, such 
as Coccidiodes species spherules, Blastomyces dermatitis thick -walled broad - 
based budding yea sts, Paraccidioides brasilensis multiple budding yeast cells, 
and, in the case of histoplasmosis, the presence of characteristic intracellular  yeast 
forms in a phagocyte in a peripheral blood smear or in tissue  macrophages  
• For coccidioidomycosis, demonstra tion of coccidioidal antibody in CSF, or a 2 - 
dilution rise measured in 2 consecutive blood samples tested concurrently in the 
setting of an ongoing infectious disease  process.  
• For paracoccidioidomycosis, demonstration in 2 consecutive serum samples of  a 
precipitin band to paracoccidioidin concurrently in the setting of an  ongoing  
infectious disease process  
Probable endemic mycosis  
• Presence of a host factor, including but not limited to those specified in #2  Table 
above, plus a clinical picture consistent with endemic mycosis and mycological 
evidence, such as positive Histoplasma antigen test result from urine, blood,  or 
CSF 
Note: E ndemic mycosies includes histoplasmosis, blastomycosis, coccidioidomycosis, 
paracoccidioidomycosis, sporotrichosis, and infection due to Penicillium marneffei. Onset within 
3 months after presentation defines a primary pulmonary infection. There is no cate gory of 
possible endemic mycosis, as such, because neither host factors nor clinical features are 
sufficiently specific; such cases are considered to be of value too limited to include in clinical 
trials, epidemiological studies, or evaluations of diagnost ic tests.  
 
D. Others : the investigator may include certain other infectious diseases of unique 
nature. Acceptance requires decision before decoding occurs and with the 
agreement of the principal investigator and an attending from the Infectious 
Disease  Department.  
ALLR18  
Appendix VI  
St. Jude  
IRB NUMBER: Pro00002817  
IRB Approval date: 0IR6-B13A-P2P0R1O8 VAL DATE : 03/18/2019  Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018   
  
IV. PROTOZOAN  
 
A. Pneumocystis carinii Pneumonia: discernible radiographic lesion plus 
identification of P . carinii in bronchoalveolar lavage fluid, biopsy or  induced 
sputum.  
B. Cryptosporidiosis : C. parum identified in stool plus  diarrhea.  
C. Toxoplasmo sis: see ACTG protocol  254. 
 
V. TOPOGRAPHICAL  
 
A. The following diagnoses are acceptable for objectively identified  infections 
without confirmation of  etiology.  
1. Pneumonia : lesion on  radiograph  
2. Osteomyelitis : radiological  diagnosis  
3. Sinusitis : radiological diagnosis (x -ray, CT,  MRI)  
4. Cellulitis : physician  diagnosis  
 
VI. FEVER OF UNDETERMINED  ETIOLOGY  
 
B. Fever without any focus or etiology identified by clinical history,  physical 
examination, radiological or microbiologic finding. Identify  as: 
1. neutrop enic = ANC  <500/mm3 
2. non-neutropenic = ANC  >500/mm3 
 
VII. CULTURE NEGATIVE SEPSIS  
 
In the absence of a positive culture, a systemic response to a possible infection by 
hemodynamic instability, focal or multiple organ involvement such as poor skin 
perfusion, oliguria, hypoxemia, and/or altered mental status or lethargy  
ALLR18  
Appendix  VII 
IRB Approval date: 0S6t-.1J3u-2d0e18 Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018  IRB NUMBER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019   
  
APPE NDIX VII: COMMON SUBSTRATES, INHIBITORS AND INDUCERS OF 
CYP3A4/3A5  
 
The following lists describe medications which are common CYP3A4 substrates, inhibitors and 
inducers. This list should not be considered all inclusive. Consult Pharmaceutical Services for 
specific information on metabolism by CYP3A4/CYP3A5 and particularly  for Ph+ participants 
receiving tyrosine kinase inhibitor.  
 
substrates  
 
Macrolide antibiotics  clarithromycin 
erythromycin 
NOT  azithromycin   
Anti-arrhythmics  quinidine   
 
Benzodiazepines  alprazolam 
diazepam 
midazolam 
triazolam   
Immune modulators  cyclosporine 
tacrolimus (FK506)  sirolimus  
 
HIV antivirals  indinavir 
nelfinavir 
ritonavir 
saquinavir   
 
Antihistamines  astemizole 
chlorpheniramine 
terfenidine   
 
Calcium channel blockers  amlodipine 
diltiazem 
felodipine 
lercanidipine  nifedipine 
nisoldipine 
nitrendipine 
verapamil  
 
 
HMG CoA reductase inhibitors  atorvastatin 
cerivastatin 
lovastatin  
NOT pravastatin 
simvastatin   
 
 
Steroid 6beta -OH estradiol 
hydrocortisone 
progesterone 
testosterone   
ALLR18  
Appendix  VII 
IRB Approval date: 0S6t-.1J3u-2d0e18 Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018  IRB NUMBER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019   
  
Substrates - continued  
 
 
 
 
 
 
Other  alfentanyl 
buspirone 
cafergot 
caffeine=>TMU 
cocaine 
dapsone  
codeine -N-demethyl 
dextromethorphan 
eplerenone  
fentanyl 
finasteride 
imatinib  
haloperidol (in part) 
irinotecan  Lidocaine methadone  
 
ondansetron 
pimozide 
propranolol 
quinine 
salmetrerol 
sildenafil 
tamoxifen 
paclitaxel 
trazodone 
vincristine 
zaleplon 
zolpidem  
inhibitors  
 
 
HIV antivirals  delaviridine 
indinavir 
nelfinavir 
ritonavir 
saquinavir   
 
 
 
 
Other  amiodarone NOT azithromycin 
cimetidine  
ciprofloxacin 
clarithromycin  
diethyl -dithiocarbamate 
diltiazem  
erythromycin 
fluconazole 
fluvoxamine 
gestodene  grapefruit juice 
itraconazole 
ketoconazole 
mifepristone 
nefazodone 
norfloxacin 
norfluoxetine 
mibefradil 
verapamil 
voriconazole  
inducers  
 
HIV antivirals  efavirenz 
nevirapine   
 
 
Other  barbiturates 
carbamazepine 
glucocorticoids 
modafinil 
phenobarbital 
phenytoin   
ALLR18  
Appendix  VII 
IRB Approval date: 0S6t-.1J3u-2d0e18 Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018  IRB NUMBER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019   
  
APPENDIX VIII: HDMTX ADMINISTRATION AND MONITORING GUIDELINES 
INDUCTION BLOCK II  
 
High -dose MTX (HDMTX) will be given at a dose of 5 g/m2 over 24 hours or targeted to a Cpss 
of 65 µM.  
 
The physician or pharmacist should review the past and current medication list for the patient 
prior to administration of HDMTX. Every effort should be m ade to avoid nephrotoxins 
(amphotericin, acyclovir) and drug that could compete with MTX (penicillins and proton pump 
inhibitors) on the day of and the day after HDMTX begins; use of NSAIDs and salicylates of any 
kind is contraindicated. HDMTX should not b e given to patients with any residual mucositis 
without discussion with the PI of the protocol.  
 
Standing orders should be in place that includes twice daily BMP, magnesium, and phosphorus. 
In addition, orders should include specific instructions to notify  the physician of record or their 
designee. These include:  
 
• Notification if HDMTX stopped for a cumulative time of 60 minutes or  more  
• Any increase in serum creatinine by > 0.3 mg/dL or a doubling of creatinine from pre - 
HDMTX  value  
• 2 or more consecutive urine pH < 6.5 or 2 consecutive urine pH > 9 
• No urine output for 4  hours  
• > 2 episodes of diarrhea in a 24 hour period within first 48 hours after start of  HDMTX  
• > 2 episodes  of emesis in a 4 hour period within first 48 hours after start of  HDMTX  
• Any episode of hypotension or sepsis within first 48 hours after start of  HDMTX  
 
MTX plasma concentrations will be obtained at least 4 times with the HDMTX: prior to starting 
the infu sion and at hours 6, 23, and 42 from the start of the infusion. Patients with MTX 
concentrations at 42 hours above 0.5 µM will be assessed at least daily until the concentration is  
< 0.1 µM. After the patient has cleared MTX, please fax copies of the MTX concentrations  (from 
your lab system) to the SJ Pharmacokinetics  Lab at for inclusion into the SJ 
electronic medical  record.  
 
Ideally, each patient will receive IV hydration with Bicarb beginning the evening prior to 
scheduled admission for HDMTX with a ra te of at least 125 mL/m2/hr. Hydration should 
continue at this rate until the MTX concentration is < 0.5 µM or longer if the patient has a 
history of toxicity or delayed excretion. Patients with poor clearance are candidates for increased 
hydration and mor e aggressive alkalinization. Acetazolamide is an effective diuretic in patients 
with delayed MTX excretion. Patients with MTX concentrations > 1 µM benefit from increasing 
urine output.  
 
MTX dosing may be individualized to achieve a target Cpss of 65 µM. The physician or their 
designee at the collaborating site should contact a SJ clinical pharmacist to discuss targeting and 
leucovorin rescue. (Please use the  group email  ).SJ will also 
provide contact information for help during the infusion at that  time.  
ALLR18  
Appendix  VII 
IRB Approval date: 0S6t-.1J3u-2d0e18 Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018  IRB NUMBER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019   
  
Leucovorin rescue should begin at 42 hour from the start of HDMTX. The dose is 15 
mg/m2/dose po or IV q6h x 3 doses. Patients with a history of delayed Grade 3 or 4 GI toxic ity 
with prior HDMTX or a history of typhlitis with any chemotherapy should have leucovorin 
continue for 5 doses, rather than 3. Those with early toxicity should have leucovorin begin at 
hour 36. Patients with vomiting, poor oral intake, period (>4 hours) of no urine output should 
receive all leucovorin doses IV. All doses > 50 mg should be given IV.  
 
MTX  
Concentration  Threshold for 
Action  Recommended LV Rescue  
6 hr – 5 gm/m2 or 
targeted to 65 µM  95 – 150 µM  Check that hydration and alkalinization are adequate; 
check for nephrotoxic drugs; check creatinine; notify the 
house officer and floor nurse to be particularly vigilant 
with urine output  
> 150 µM  All of above plus obtain another blood sample between 12 
and 24 hrs for assay  
Extra sample 
between 12 and 24 
hr because of 
suspected delayed 
excretion - 5 gm/m2 
or targeted to 65 µM  95 - 150 µM  Check that hydration and alkalinization are adequate; 
check for nephrotoxic drugs; check creatinine; notify the 
house officer and floor nurse to be particularly vigilant  
with urine output  
> 150  µM All of above plus stop MTX, continue monitoring MTX to 
estimate half -life. 
23 hr - 5 gm/m2 or 
targeted to 65 µM  95 - 150 µM  Check that hydration and alkalinization are adequate; 
check for nephrotoxic drugs; check creatinine; notify the 
house officer and f loor nurse to be particularly vigilant 
with urine output  
> 150  µM All of above plus obtain another blood sample for assay; 
consider possible early LV rescue;* consider obtaining 
glucarpidase, etc.  
42 hr#  < 0.5 µM  Protocol rescue & no further concentrations indicated, 
unless clinically warranted  
0.5 – 1 µM  Protocol rescue, cont IVF with bicarb & check 66 hr conc  
1 – 2 µM  30 mg/m2/dose po/IV q6h  
2 – 5 µM  50 mg/m2/dose IV q6h  
5 – 10 µM  100 mg/m2/dose IV q6h  
10 – 20 µM*  200 mg/m2/dose IV q6h or continuous infusion  
>20 µM*  Individualized  
66 hr#  < 0.1 µM  Per protocol and stop checking unless clinically indicated  
0.1 – 0.2 µM  5 mg/m2-/dose po/IV q12h & continue checking until < 0.1  
0.2 – 0.5 µM  15 mg/m2/dose po /IV q12h & continue checking until < 
0.1 
0.5 – 1 µM  15 mg/m2/dose po/IV q6h & continue checking until < 0.1  
1 – 2 µM  30 mg/m2/dose po/IV q6h & continue checking until < 0.1  
2 – 5 µM  50 mg/m2/dose IV q6h & continue checking until < 0.1  
>5 µM  Individualized  
ALLR18  
Appendix  VII 
IRB Approval date: 0S6t-.1J3u-2d0e18 Amendment 3.0, dated: 03 -19-2018 
Protocol document date: 06 -12-2018  IRB NUMBER: Pro00002817  
IRB APPROVAL DATE: 03/18/2019   
  
 
MTX  
Concentration  Threshold for 
Action  Recommended LV Rescue  
90 hr and later#  < 0.1 µM  Stop LV & stop checking, unless clinically indicated  
0.1 – 0.2 µM  5 mg/m2/dose po/IV q12h & continue checking until < 0.1  
0.2 – 0.5 µM  15 mg/m2/dose po/IV q12h & continue checking until < 0.1  
0.5 – 1 µM  15 mg/m2/dose po/IV q6h & continue checking until < 0.1  
>1 µM  As above under hr 66  
*Early rescue should be initiated and glucarpidase availability should be checked whenever it is 
a possibility that the patient will have plasma MTX concentrations > 10 µM at 42 hours.  
 
#Higher doses of leucovorin may be indicated based on the clinical con dition of the patient. 
Patients with MTX concentrations > 1 µM benefit from increased urine output. Forced diuresis 
with acetazolamide, along with increased hydration may be necessary.  
 
NOTE : Glucarpidase would not need to start before hr. 42, but availabi lity should be checked 1 
day prior. Nephrology should be consulted and hemoperfusion should be anticipated if 
glucarpidase will not be available by 42 hours. Ideally, leucovorin should NOT be given within 2 
hours BEFORE or AFTER glucarpidase dosing because  leucovorin is also a substrate for 
glucarpidase and will interfere with methotrexate hydrolyzation.  
 
NOTE : Early leucovorin rescue should not need to start prior to 24 hours, regardless of the 
concentration. Although it is not likely to be very effective, early leucovorin should be instituted 
sometime between 24 and 42 hours at a dose of ~2000 – 2400 mg/m2/day if the 24 hour 
concentration is > 300 µM or it is above 200 µM and the half -life is > 8 hours. Continuous 
infusions of leucovorin are slightly preferred over bolus infusions, on the off chance that high 
leucovorin concentrations could either compete with  MTX for excretion or contribute to 
neurotoxicity, but doses as high as 500 mg/m2 can be given safely if necessary.  